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Ovarian cancer is the fifth leading cause of cancer-related death among women and the 
deadliest of all gynecological cancers. Treatment failure is a major contributing factor in ovarian 
cancer-related mortality. Advances in the development of new agents that target critical pathways 
in cancer may provide better options to overcome treatment failure. One of the molecular 
mechanisms that can be targeted for ovarian cancer therapy is the protein quality control. 
Components of the protein quality control, such as heat shock proteins, the ubiquitin-proteasome 
system, the unfolded protein response and autophagy, regulate protein homeostasis. Protein quality 
control also provides phenotypic stability by buffering cryptic genetic variations that could 
potentially reduce the fitness of cancer cells. This concept was best illustrated by studies that 
genetically or pharmacologically inhibited heat-shock protein 90, and reported variations in the 
phenotype following the disruption of heat shock protein 90.  
This dissertation investigates the therapeutic efficacy of targeting valosin-containing 
protein (VCP), an important component of the protein quality control, in ovarian cancer.  
VCP or p97, a member of the ATPase Associated with diverse cellular Activities-ATPase 
(AAA-ATPase) protein family, has been associated with various cellular functions including 
endoplasmic reticulum associated degradation, the ubiquitin proteasome system, golgi membrane 
reassembly, autophagy, DNA repair and cell division making it an important regulator of the 
protein quality control. Recent studies identified VCP and the ubiquitin proteasome system as 
synthetic lethal targets in ovarian cancer. This dissertation describes the preclinical activity of VCP 
inhibitors in ovarian cancer. Results presented in this dissertation show that quinazoline-based 
VCP inhibitors initiate Gap 1 (G1) cell cycle arrest, attenuate cap-dependent protein translation 
and induce programmed cell death via the intrinsic and the extrinsic modes of apoptosis. 
iv 
 
Mechanistic studies point to the unresolved unfolded protein response as a mechanism by which 
VCP inhibitors contribute to cytotoxicity. These results support an emerging concept that the 
unfolded protein response pathway may be targeted in ovarian cancer as a source of vulnerability. 
Since prolonged induction of the unfolded protein response results in CCAAT/enhancer binding 
protein homologous protein (CHOP) mediated cell death, we tested the hypothesis that VCP 
inhibitors act synergistically with compounds that enhance CHOP expression. Here, we show that 
VCP inhibitors act synergistically with salubrinal, an inhibitor of growth arrest and DNA-damage-
inducible 34 (GADD34), by enhancing CHOP expression in ovarian cancer cell lines. Our results 
provide a proof-of-concept that VCP inhibitors can be used as a single agent and can be synergized 
with compounds that enhance CHOP expression to induce cell death. 
While the synergistic effects observed between VCP inhibitors and GADD34 inhibitor 
provides an in vitro proof-of-concept, these results have little clinical relevance because salubrinal 
is not a clinical candidate. Therefore, we identified mifepristone, an FDA approved steroidal 
progesterone antagonist, to act synergistic with VCP inhibitors across several ovarian cancer cell 
lines. Combination treatment between clinically achievable doses of mifepristone and oral VCP 
inhibitor- CB-5083 show an atypical increase in the unfolded protein response, a significant 
decrease in colony formation as well as an increase in caspase activity.  Mechanistic studies upon 
mifepristone treatment point towards the inhibition of activating transcription factor 6 (ATF6) 
branch and the activation of heme- regulated inhibitor (HRI) kinase pathway as two plausible 
mechanisms contributing towards the synergistic effect.  
Oral VCP inhibitor- CB-5083 is currently in Phase I clinical trials because it shows 
therapeutic effects in multiple tumor xenograft models; however, the mechanism of resistance to 
CB-5083 is unknown. Here, we characterize the molecular mechanism of resistance to CB-5083. 
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Using incremental exposure to CB-5083, we established CB-5083- resistant ovarian cancer cells 
that show 5 to 6-fold resistance in vitro compared to parental cells. Genomic and complementary 
DNA sequencing of the VCP coding region revealed a pattern of co-selected mutations: (1) 
missense mutations at codon 470 in one copy resulting in increased ATPase activity; and (2) 
nonsense or frameshift mutations at codon 606 or codon 616 in another copy causing the loss of 
allele-specific expression. Unbiased molecular docking studies show codon 470 as a putative 
binding site for CB-5083. Furthermore, the analysis of somatic mutations in cancer genomes from 
the cancer genome atlas (TCGA) indicate that codon 616 is frequently mutated in human cancers. 
Thus, identification of these mutations associated with in vitro resistance to VCP inhibitors may 
be useful as potential theranostic markers while screening for patients to enroll in clinical trials. 
VCP has emerged as a viable therapeutic target for several cancer types, and therefore targeting 
such hyperactive VCP mutants should aid in improving the therapeutic outcome in cancer patients.    
Overall, this dissertation 1) provides a proof-of-concept that VCP can be targeted in 
ovarian cancer, 2) proves that VCP inhibitors can act synergistically with other compounds that 
modulate the protein quality control, 3) identified a clinically relevant drug combination (CB-5083 
and mifepristone) that should be investigated further, 4) unearths a novel mechanism of resistance 
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1.1 . Ovarian Cancer   
 
1.1.1 Ovarian Cancer incidence and subtypes 
Ovarian cancer is the most lethal gynecological malignancy responsible for 14,000 deaths 
per year in the United States. Currently, it accounts for 2.5% of all female cancer cases, but 5% of 
all female cancer deaths (Siegel et al., 2018). According to the National Cancer Institute, ovarian 
cancer is defined as the cancer that forms in the tissues of the ovary. Once seen as a single disease 
derived from the ovarian surface epithelium, it is now well recognized to be a heterogeneous 
disease with multiple origins (Levanon et al., 2008). Based on the cell types, ovarian cancer can 
be divided into three groups- epithelial, germ cell, and sex cord-stromal. Epithelial ovarian cancer 
accounts for more than 90% of all ovarian cancer cases, while germ cell and sex cord-stromal 
ovarian cancer account for 3% and 2% of cases, respectively (Figure 1.1) (Siegel et al., 2018). 
Germ cell ovarian cancers originate from the germ cells of the ovary, whereas the sex cord-stromal 
ovarian cancers originate from the other supportive cells in the ovarian follicles. While the origins 
of germ cell and sex cord-stromal ovarian cancer are well understood, the origins of epithelial 
ovarian cancer have been long debated. 
Recent advances in the understanding of epithelial ovarian cancer suggest it can be 
categorized into four distinct diseases that originate outside the ovary. Epithelial ovarian cancer 
can be subdivided into serous (52%), endometrioid (10%), mucinous (6%) and clear cell tumors 
(6%) (Figure 1.1). Growing evidence suggests that serous carcinomas originate from the epithelial 
cells of the fallopian tube and subsequently spread to the ovaries. Similarly, endometrioid and clear 
cell tumors may originate in the endometrium (lining of the uterus), while mucinous tumors may 
originate in the ovaries or fallopian tube-peritoneal junction. Endometrioid, mucinous and clear 




than 90% of all serous tumors are classified as Type II carcinomas. Type II carcinomas are 
considered high-grade and defined by the frequent involvement of both ovaries, aggressive 





Figure 1.1. The distribution of ovarian cancer by subtypes. The pie chart represents the 
distribution of ovarian cancer cases by subtypes in the United States. Serous, endometrioid, 
mucinous and clear cells can be grouped under the epithelial ovarian cancer. Other or unspecified 
subtype include very low occurring ovarian tumors as well as undifferentiated tumors that are hard 
to categorize based on the histological phenotype. Source: North American Association of Central 







1.1.2 Symptoms and screening modalities in ovarian cancer 
The majority of ovarian cancer cases are diagnosed at an advanced stage because of the 
lack of specific symptoms and reliable screening tests. Common symptoms of ovarian cancer 
include abdominal bloating, indigestion, nausea, loss of appetite, increased abdominal girth and 
tiredness. Such non-specific symptoms have made the diagnosis of ovarian cancer quite 
challenging. 
The two most commonly used screening modalities in ovarian cancer are the transvaginal 
ultrasound and the cancer antigen 125 blood test. The transvaginal ultrasound is performed by 
placing an ultrasound wand into the vagina. It uses sound waves to detect tumors in the uterus, 
fallopian tubes, and ovaries. The sound waves can detect tumor mass; however, it cannot determine 
if a mass is malignant or benign. Cancer antigen 125 is a protein marker that can be detected in the 
blood sample. Patients with ovarian cancer usually have elevated levels of cancer antigen 125 in 
their bloodstream. Since cancer antigen 125 levels often drop with decreased ovarian tumor mass, 
this biomarker has been used to monitor the effects of treatment. Although both these tests are 
extensively used in clinics, results from randomized clinical trials accessing the efficacy of cancer 
antigen 125 and transvaginal ultrasound on ovarian cancer mortality have been mixed (Buys et al., 
2011; Jacobs et al., 2016).  
1.1.3 Staging ovarian cancer 
International Federation of Gynecology and Obstetrics (FIGO) staging system is the most 
accepted system used to stage the ovarian tumors upon diagnosis. Updated in 2014, this system 
now includes four stages (Prat and Oncology, 2015) which are as follow:   




2) Stage II- Tumor involves one or both ovaries with pelvic extension or primary peritoneal 
cancer.  
3) Stage III- Tumor involves one or both ovaries with cytologically or histologically 
confirmed spread to the peritoneum outside the pelvis and metastasis to the retroperitoneal 
lymph nodes. 
4) Stage IV- Distant metastases excluding peritoneal metastases.   
1.1.4 Treating ovarian cancer 
Ovarian cancer is a highly heterogeneous disease even though the treatment regimen 
remains fairly homogenous. The main treatment modalities for ovarian cancer include debulking 
surgery followed by chemotherapy. Recently, a few targeted therapies have been approved by the 
Food and Drug Administration (FDA) for ovarian cancer.  
1) Optimal debulking surgery: This surgery technique includes removing all tumors larger 
than 1 cm (Altman et al., 2012). This often includes removing the uterus (hysterectomy) or 
both ovaries and fallopian tubes (bilateral salpingo-oophorectomy).  
2) Adjuvant chemotherapy: Chemotherapy for ovarian cancer generally includes a 
combination of two drugs given intravenously 3-6 times at an interval of 3-4 weeks 
between treatments. Currently, the standard chemotherapy regimen includes a combination 
of a platinum compound such as cisplatin or carboplatin and a taxane agent such as 
paclitaxel or docetaxel (Akin et al., 2014; Sharma et al., 2009).    
3) Targeted therapy: Targeted therapies are drugs or other agents that are developed to target 
specific molecules in cancer cells. Molecularly targeted therapies attack cancer cells while 
doing little or no damage to normal cells. In recent years, multiple targeted therapies were 




angiogenesis inhibitor bevacizumab (McClung and Wenham, 2016; Pujade-Lauraine et al., 
2014) and PARP inhibitors olaparib, rucaparib, and niraparib (Bamford and Webster, 
2017). Clinical trials are on the way to investigate the effectiveness of these agents in 
combination with standard chemotherapy.  
1.1.5 Survival rates for ovarian cancer 
Survival of patients with ovarian cancer is largely dependent on the stage at which the 
tumor is first diagnosed. Although the overall 5-year survival rate for ovarian cancer is 45%, it 
jumps up to 92% for cases that are diagnosed at Stage I. Unfortunately, approximately 70% of 
ovarian cancer cases are diagnosed at Stage III and IV, where the 5-year survival rate drastically 
drops to 39% and 17%, respectively. These statistics highlight the importance of early detection 
in improving patient outcome. Similarly, newer therapeutic agents for the advanced disease may 
improve the overall survival rate.   
1.1.6 Challenges in improving patient outcome 
One of the challenges in improving the outcome of patients with ovarian cancer is the lack 
of early screening. Several high-profile early screening trials have investigated the feasibility and 
efficacy of using cancer antigen 125 and transvaginal ultrasound for the early detection of ovarian 
cancer. The Prostate, Lung, Colorectal, and Ovarian (PLCO) trial investigated the potential benefit 
of using cancer antigen 125 and transvaginal ultrasound in improving the outcome of patients with 
ovarian cancer. The trial enrolled 78,216 healthy women aged 55 to 74 years between 1993 and 
2001. From the original enrollment, 39,105 women were placed in the intervention group, while 
39,111 women were placed in the usual care group. In the intervention group, annual screening 
with cancer antigen 125 was performed for 6 years and transvaginal ultrasound was performed for 




screening with the cancer antigen 125 and the transvaginal ultrasound did not reduce overall 
ovarian cancer mortality (Buys et al., 2011).  
Similarly, UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) performed a 
large-scale randomized controlled trial to investigate the efficacy of cancer antigen 125 or 
transvaginal ultrasound on ovarian cancer mortality. The study enrolled 202,638 healthy women 
between 50 to 74 years among 13 National Health Service Trust centers in the United Kingdom. 
Participants were randomly stratified into three groups: the multimodal screening group, the 
transvaginal ultrasound group and the no-screening group, in a 1:1:2 ratio. The multimodal 
screening participants received an annual screening for cancer antigen 125, while the transvaginal 
ultrasound screening participants received the annual transvaginal ultrasound. Participants in the 
no-screening group did not receive these tests. After a median follow-up of 11.1 years, the trial 
reported similar ovarian cancer incidence as well as similar overall ovarian cancer mortality rates 
among all three groups. However, when ovarian cancer mortality rates were analyzed for subjects 
who were in the trial for a longer period of 7-14 years, the study reported 23% reduction in 
mortality for the multimodal screening group and 21% reduction in mortality for the transvaginal 
ultrasound group compared to the no-screening group (Jacobs et al., 2016). These results indicate 
that early detection screens that employed the cancer antigen 125 and the transvaginal ultrasound 
can reduce ovarian cancer-related mortality in a long-term setting. 
Additional challenges in improving the outcome of patients with ovarian cancer are tumor 
recurrence after chemotherapy (relapse) and acquired resistance to existing chemotherapy. 
Although 60-70% of ovarian cancer cases are diagnosed at Stage III and Stage IV, the cancer is 
responsive to the standard platinum-based chemotherapy in 70%-80% of cases. Unfortunately, 




al., 1999). Relapsed patients can often be subjected to the same treatment. However, after multiple 
rounds of chemotherapy, the tumor can acquire resistance to conventional chemotherapies. This 
clinical fact outlines the rationale for developing novel therapeutics for treating ovarian cancer in 
relapse and resistant settings. In the subsequent sections, I will discuss molecular characteristics 
of high-grade serous ovarian cancer, which constitutes 70% of all ovarian cancer cases, and I will 
present a molecular basis for targeting protein homeostasis to develop new targeted agents that 
exploit vulnerabilities in this disease. 
1.1.7 Molecular characteristics of high-grade ovarian tumors 
Although high-grade serous ovarian cancer displays a heterogeneous phenotype, there are 
some common features observed in this disease. Missense or nonsense mutations in the tumor 
suppressor gene TP53 is observed in nearly all ovarian serous carcinomas (Table 1.1) (TCGA, 
2011). These mutations result in the loss of functional p53 (protein product of TP53), which is 
now well accepted as an early driver mutation in Type II ovarian carcinomas, including high-grade 
serous ovarian cancer. This observation makes restoring the function of wild-type p53 one of the 
therapeutic strategies (Muller and Vousden, 2014). Furthermore, studies have now indicated that 
certain missense mutations in TP53 can yield variants of p53 protein with novel functions that can 
promote tumorigenesis (Dittmer et al., 1993; Oren and Rotter, 2010). These reports indicate some 
hotspot missense mutations in TP53 to be oncogenic (Oren and Rotter, 2010; Parrales et al., 2016); 
therefore, inhibiting p53 in such scenarios could be effective. Several small-molecule inhibitors 
have been shown to selectively either reactivate the loss-of-function p53 (p53 activating 
compounds) or degrade gain-of-function p53 (p53 deactivating compounds). p53 activating 
compounds include CP-31398, STIMA-1, and PRIMA-1, while p53 deactivating compounds 




Parrales et al. (2016) reported the degradation of tumor-promoting mutant p53 by statins. The 
treatment with statins resulted in a reduction of growth in tumors displaying the gain-of-function 
p53 mutations (Parrales et al., 2016). These compounds might be effective in improving the 
therapeutic outcome of patients with high-grade serous ovarian cancer.   
Next, germline mutations in tumor suppressor genes Breast Cancer 1, Early Onset (BRCA1) 
and Breast Cancer 2, Early Onset (BRCA2) are observed in 7.77% and  7.13% of ovarian serous 
carcinomas cases, respectively (Table 1.1) with up to 50% of patients displaying defects in the 
homologous recombination (HR) repair pathway (Konstantinopoulos et al., 2015; TCGA, 2011). 
Poly (ADP-ribose) polymerase (PARP) inhibitors, which target the homologous recombination 
repair pathway, have also emerged as effective agents for targeting breast and ovarian cancer that 
harbor mutations in BRCA1 or BRCA2. Other frequently reported alterations in high-grade serous 
ovarian cancer include upregulation of oncogenic pathways driven by NOTCH, PI3K, RAS/MEK 
and FOXM1 (Mukhopadhyay et al., 2010; TCGA, 2011). A few studies have reported the 
therapeutic efficacies of targeting the altered oncogenic pathways in high-grade serous ovarian 










Most mutated genes in ovarian serous carcinomas 
Gene Number of mutations Frequency 
TP53 585 91.76% 
TTN 126 17.43% 
BRCA1 49 7.77% 
BRCA2 47 7.13% 
USH2A 40 6.34% 
CSMD3 37 5.86% 
FAT3 39 5.86% 
MUC16 40 5.71% 
LRP2 33 4.75% 
HMCN1 31 4.60% 
 
Table 1.1. Top 10 mutated genes in ovarian serous carcinomas. Data Source: cBioPortal Cancer 
Genomics. Datasets: Ovarian Serous Cystadenocarcinoma (TCGA, Nature 2011) & Ovarian 
Serous Cystadenocarcinoma (TCGA, Provisional). Total samples analyzed = 631. 
 
Additionally, defects in the retinoblastoma (RB) pathway, either due to the amplification 
of cyclin E1 (CCNE1) or the loss of retinoblastoma, are observed in 30% of high-grade serous 
ovarian cancer cases (Etemadmoghadam et al., 2013). In cyclin E1-amplified ovarian cancer cells, 
knocking down cyclin E1 caused cell cycle arrest and cell death  (Etemadmoghadam et al., 2010), 
further highlighting the significance of targeting the amplified cyclin E1. Although cyclin E1-
amplified high-grade serous ovarian cancer cell lines are resistant to cisplatin, they are sensitive to 
proteasome inhibitor bortezomib (Etemadmoghadam et al., 2013). These results indicate that 
cyclin E1 amplification presents a vulnerability in a subset of high-grade serous ovarian cancer.   
Copy number alterations (CNA) are observed in almost all high-grade serous ovarian 
carcinomas. Copy number alterations result in the abundance or reduction of transcripts within the 
affected regions and cause genomic instability (TCGA, 2011). To better understand the genomic 
landscapes of cancer, Ciriello et al. (2013) initiated a study to look for genetic and epigenetic 




was geared towards identifying unique signatures in these tumors based on their genetic and 
epigenetic profiles from the Cancer Genome Atlas (TCGA) datasets. The study divided these 12 
cancer types into two mutually exclusive classes: mutation class (M class) and copy number class 
(C class). Cancer driven by point mutations (M class) included kidney clear-cell carcinomas 
(KIRC), glioblastoma (GBM), colorectal carcinoma and uterine carcinomas. In contrast, almost 
all high-grade serous ovarian cancer and breast cancer samples were classified in the copy number 
class (C class) because their genomic signature is predominated by copy number alterations.  
Several other studies have also concluded that copy number alterations are a hallmark of the high-
grade serous ovarian cancer (Kuo et al., 2009; TCGA, 2011). 
Copy number alterations observed in the high-grade serous ovarian cancer can be viewed 
as a vulnerability. The increase or the decrease in transcripts from the copy number-affected 
regions can place a severe strain on the biological processes, such as transcription, translation, 
post-translation modifications, and degradation of proteins etc. The increase in RNA transcripts 
resulting from copy number alterations can cause transcriptomic stress, and the resulting increase 
in protein load can cause proteotoxic stress (Deshaies, 2014). Similarly, a decrease in RNA 
transcripts can also result in alterations in the steady state of the proteome by disrupting the overall 
protein homeostasis. Therefore, copy number alterations present a vulnerability which can be 
targeted by modulating protein quality control mechanisms in high-grade serous ovarian cancer. 
In the subsequent sections, I will discuss the phenomenon of protein homeostasis, describe protein 
quality control pathways, and identify specific targets in these pathways that are currently being 





1.2 . Protein homeostasis 
 Inside a cell, proteins are responsible for carrying out biochemical and cellular functions that 
are essential for sustaining a cellular life. Normal cellular functions are highly reliant on the steady 
state of the proteome maintained through dynamic regulation between protein synthesis and 
degradation, a process known as protein homeostasis or proteostasis. Dysregulation of protein 
homeostasis is the basis of most prominent disorders, including cancer. In their seminal reviews, 
Hanahan & Weinberg outlined hallmarks that allow non-malignant cells to acquire a neoplastic 
state ultimately resulting in cancer (Hanahan and Weinberg, 2000; Hanahan and Weinberg, 2011). 
It is now well accepted that these hallmarks are manifested through dysregulation in the protein 
dynamics pre-dominantly via overexpression of oncoproteins and/or downregulation of tumor 
suppressor proteins caused by epigenetic alterations. Furthermore, in copy number-driven cancer, 
such as the high-grade serous ovarian cancer, cancer cells possess additional alterations such as 
chromosomal duplications, aneuploidy and copy number alterations, which can further create an 
imbalance in protein homeostasis.  The resulting stress manifested by the imbalances in protein 
homeostasis is called proteotoxic stress.  
1.3 . Protein quality control 
Protein quality control includes pathways that ensure protein homeostasis either by facilitating 
the proper folding of misfolded or unfolded proteins or by targeting such proteins for degradation. 
Components of the protein quality control include 1) the unfolded protein response pathway, 2) 
the adaptive chaperone pathway regulated through heat shock proteins (HSPs), 3) ubiquitin 
proteasome system and 4) autophagy.  The unfolded protein response and heat shock proteins are 
primarily responsible for the proper folding of unfolded or misfolded proteins (Figure 1.2). The 




these pathways can also trigger the degradation of misfolded or unfolded proteins through the 
ubiquitin proteasome system and autophagy (Figure 1.2). 
 
Figure 1.2. Fate of the unfolded/misfolded protein. Misfolded or unfolded protein can be refolded 
into its proper configuration through chaperone-mediated heat shock proteins (HSPs) or the 
unfolded protein response (UPR) pathway. Failure to properly fold the protein can trigger the 
degradation of this protein either by the ubiquitin proteasome system (UPS) or autophagy.  
 
The unfolded protein response is a physiological response observed through the 
phosphorylation of two endoplasmic reticulum transmembrane proteins inositol requiring enzyme 
1 (IRE1) and protein kinase R-like endoplasmic reticulum kinase (PERK), as well as through the 
cleavage of endoplasmic reticulum transmembrane protein activating transcription factor 6 (ATF6) 
(Walter and Ron, 2011). Several studies have now confirmed that cancer cells have elevated levels 
of unfolded protein response due to hypoxia, nutrient deprivation, copy number alterations, and 
mutations (Wang et al., 2010a). The unfolded protein response induces the expression of 
endoplasmic reticulum resident chaperones such as the glucose-regulated protein 78 (GRP78) and 
the glucose-regulated protein 94 (GRP94), as well as reduces protein translation. These events aid 




Another prominent protein quality control mechanism includes the chaperone network 
regulated mediated by the heat-shock proteins. By masking the effects of cryptic genetic variation, 
heat-shock protein 90 (Hsp90) serves as a capacitor of genetic variation while allowing phenotypic 
stability (Queitsch 2002; Rutherford 1998). This property of Hsp90 determines the adaptive value 
of genetic variations and influences the evolution of genomes (Jarosz and Lindquist, 2010). The 
Hsp90 complex has been shown to be upregulated in several tumor types (Barrott and Haystead, 
2013; Zagouri et al., 2012). In cancer, Hsp90 allows for the proper functioning of essential 
oncoproteins and tumor suppressor proteins. Cancer is a heterogeneous disease, and 
overexpression of Hsp90 masks the defective and deleterious phenotype ultimately increasing 
cancer fitness.   
Additionally, protein quality control mechanisms include prominent protein degradation 
pathways such as the ubiquitin proteasome system and autophagy, which can reduce protein load 
by degrading misfolded and unfolded proteins into small peptides or individual amino acids 
(Figure 1.2). Cancer cells display increase proteotoxic stress which makes them heavily reliant on 
the protein quality control mechanisms for survival and proliferation: a phenomenon known as 
non-oncogenic addiction. This addictive phenotype provides the rationale for targeting 
components of the protein quality control in cancer (Figure 1.3). In the subsequent sections, I will 









Figure 1.3. Rational for targeting protein quality control in cancer. Non-malignant cells are at 
protein homeostasis with basal activity of the unfolded protein response (UPR). Cellular stressors 
such as the reactive oxygen species (ROS), calcium dysregulation, glucose imbalance, nutrient 
deprivation and increased misfolded or unfolded proteins can increase proteotoxic stress. 
Similarly, pharmacological agents, such as proteasome inhibitors, VCP inhibitors, and other 
inhibitors targeting the protein quality control mechanisms, enhance the proteotoxic stress. Non-
malignant cells cope with these stresses by inducing the unfolded protein response, as well as other 
quality control pathways such as the heat-shock protein 90 (Hsp90) network, the ubiquitin 
proteasome system and autophagy, which are predominantly adaptive (State 2). Activation of 
protein quality control mechanisms allows the restoration of protein homeostasis in non-malignant 
cells. (State 1). In contrast, poor vascularization combined with genomic insults means that 
malignant cells already have a higher level of the unfolded protein response as well as the 
activation of protein quality control pathways (State 2); therefore, further cellular or 
pharmacological stress in malignant cells triggers cell death (State 3).   
 
 
1.4 . Emerging therapeutic targets in the protein quality control 
pathways 
Several targets in the protein quality control pathways have been actively pursued in cancer 
therapeutics. In this chapter, I will discuss the prominent components of the protein quality control 
pathway, primarily focusing on the targets of emerging therapeutics for cancer treatment.  
1.4.1.  The unfolded protein response 
Folding and maturation of secretory and membrane proteins takes place in the endoplasmic 
reticulum. A series of physiologically conserved signaling pathways, commonly referred to as the 
unfolded protein response monitor the condition of the endoplasmic reticulum and fine tunes its 
performance to match the protein folding capacity. The activation of the unfolded protein response 
increases endoplasmic reticulum space to match the increase in workload, increases the expression 
of endoplasmic reticulum-resident chaperones and transiently decreases protein synthesis. The 
unfolded protein response is triggered by changes in three transmembrane endoplasmic reticulum 
proteins that mediate the three branches of the unfolded protein response. These three branches 




endoplasmic reticulum kinase (PERK) branch, and the activating transcription factor 6 (ATF6) 
branch. In the subsequent subsections, I will briefly discuss all three branches of the unfolded 
protein response. 
1.4.1.1. Inositol-requiring enzyme 1 alpha (IRE1α) branch 
IRE1 was first identified through inositol auxotroph selection where mutant IRE1 yeast strains 
required a high concentration of inositol for growth (Nikawa and Yamashita, 1992). Subsequent 
studies identified IRE1 as a transmembrane endoplasmic reticulum kinase, which was activated 
upon the induction of the unfolded protein response (Shamu and Walter, 1996). In mammalian 
cells, glucose-regulated protein 78 (GRP78/BiP), an endoplasmic reticulum-resident chaperone, 
binds and inactivates IRE1α (the IRE1 homolog implicated in unfolded protein response) under 
normal conditions. The unfolded proteins in the endoplasmic reticulum recruit GRP78 away from 
IRE1α, which allows for the activation of IRE1α through oligomerization and 
autophosphorylation. Activated IRE1α is a bifunctional endoribonuclease and kinase (Walter and 
Ron, 2011). The endoribonuclease activity of IRE1α includes the splicing of X-box binding 
protein-1 (XBP1) messenger RNA (Figure 1.4). Spliced XBP1 messenger RNA is translated into 
XBP1 transcription factor, which upregulates the expression of endoplasmic reticulum chaperones 
and other unfolded protein response target genes (Figure 1.4) (Oslowski and Urano, 2011; Walter 
and Ron, 2011).   
Activation of IRE1α can attenuate protein translation through the RNAse activity known as 
regulated IRE1-dependent decay (RIDD) (Maurel et al., 2014), which is largely considered to be 
pro-survival. Paradoxically, the RIDD-dominant pathway promotes cell death in diabetes. How 




cell types remains to be elucidated. Early evidence showed that perturbation of the unfolded 
protein response sensitized multiple myeloma towards proteasome inhibitors providing a rationale 
to identify inhibitors against specific branches of the unfolded protein response, including IRE1α. 
Several compounds have been shown to inhibit IRE1α. These include 1) STF-083010, 2) 
salicylaldehydes [3-Ethoxy-5,6-dibromosalicylaldedyde (3ETH)  and 3-methoxy-6-
bromosalicyaldehyde], 3) MKC-3946  and 4) toyocamycin (Chien et al., 2014; Mimura et al., 
2012; Papandreou et al., 2011; Ri et al., 2012). STF-083010 was identified by screening 
compounds using a reporter gene assay in cells that blocked bortezomib-induced X-box binding 
protein-1 (XBP1) splicing. Subsequent in vivo studies showed that once-weekly intraperitoneal 
treatment of STF-083010 (30mg/kg) for two weeks significantly reduced subcutaneous multiple 
myeloma tumor xenografts in NOD/SCID/IL2Ry null mice (Papandreou et al., 2011). Mouse 
studies with another IRE1α inhibitor, 3ETH showed that intraperitoneal injection of 3ETH 
(20mg/kg) given three times a week for four weeks reduced human pancreatic cancer xenografts 
in NOD/SCID mice (Chien et al., 2014). Similarly, intraperitoneal treatment of MKC-3946 
(100mg/kg) inhibited tumor burden in vivo in a multiple myeloma mouse xenograft model 
(Volkmann et al., 2011). Likewise, in SCID mice, the intraperitoneal injection of 3-methoxy-6-
bromosalicyaldehyde (50mg/kg) prevented tunicamycin-induced XBP1 splicing in the liver, 
kidney, and spleen (Mimura et al., 2012). Lastly, intraperitoneal injection of toyocamycin 
(0.5mg/kg) showed a reduction in multiple myeloma xenograft with further reduction in the 
combination with 1mg/kg bortezomib (Ri et al., 2012). These results provide a rationale for the 






Figure 1.4. Schematic diagram representing the Inositol-requiring enzyme 1 alpha (IRE1α) 
branch of the unfolded protein response pathway. Increased unfolded/misfolded proteins in the 
endoplasmic reticulum recruit Bip (Grp78) away from IRE1α, allowing the oligomerization and 
autophosphorylation of IRE1α. Activated IRE1α acts as an endoribonuclease splicing X-box 
binding protein-1 (XBP1). Spliced XBP1 can then be translated into XBP1 protein, which is an 
active transcription factor responsible for inducing a subset of unfolded protein response genes 
mediating endoplasmic reticulum-associated degradation (ERAD) and endoplasmic reticulum 
biogenesis.   
 
1.4.1.2. Protein kinase R-like endoplasmic reticulum kinase (PERK) branch 
Similar to the IRE1, PERK is also an endoplasmic reticulum-resident transmembrane 
kinase, which can dimerize and trans-autophosphorylate upon the induction of the unfolded protein 
response. Activated PERK phosphorylates downstream eukaryotic initiation factor 2α (eIF2α) 




expression of activating transcription factor 4 (ATF4) and CCAAT/enhancer binding protein 
homologous protein (CHOP) (Figure 1.5). ATF4 and CHOP are transcription factors that primarily 
induce expression of pro-survival genes aiding to resolve the unfolded protein response. However, 
a prolonged activation of the PERK branch induce cell death. Therefore PERK branch can 
modulate the pro-survival and pro-apoptotic response in cells based on the level of the unfolded 
protein response. This feature has allowed several groups to target different components of the 
PERK branch.  
 
Figure 1.5. Schematic diagram representing the Protein kinase R-like endoplasmic reticulum 
kinase (PERK) branch of the unfolded protein response pathway. Increased unfolded/misfolded 
proteins in the endoplasmic reticulum recruit Bip (Grp78) away from PERK allowing the 
oligomerization and autophosphorylation of PERK. Activated PERK phosphorylates eukaryotic 




transcription factor 4 (ATF4), while lowering global protein synthesis. ATF4 is a transcription 
factor that can upregulate the expression of another transcription factor CCAAT/Enhancer-binding 
protein homologous protein (CHOP). Both ATF4 and CHOP together can upregulated growth 
arrest and DNA damage-inducible protein-34 (GADD34), which can dephosphorylate phospho-
eIF2α. Other outputs of the PERK branch include genes involved in antioxidant response and cell 
death. 
 
Two PERK inhibitors, GSK2656157 and GSK2606414, have been shown to reduce tumor 
growth in several pancreatic and multiple myeloma mouse models (Atkins et al., 2013; Axten et 
al., 2012). Unfortunately, administration of GSK2656157 caused pancreatic toxicity. Furthermore, 
both PERK inhibitors were later described as potent receptor-interacting protein kinase 1 (RIPK1) 
inhibitors, raising questions on the conclusions of previously published studies using these 
compounds (Rojas-Rivera et al., 2017). Another compound, integrated stress response inhibitor 
(ISRIB) has been shown to modulate eIF2α phosphorylation (Sidrauski et al., 2015). ISRIB has 
been investigated as a potential candidate for enhancing memory retention in neurodegenerative 
diseases (Halliday et al., 2015). Salubrinal, an inhibitor of growth arrest and DNA damage-
inducible protein 34 (GADD34), prolongs the phosphorylation of eIF2α. Salubrinal has been 
shown to prevent cartilage degradation in osteoarthritis (He et al., 2013) as well as provide a 
neuroprotective role in cerebral ischemia (Anuncibay-Soto et al., 2016). The modulation of the 
pro-survival and pro-apoptotic responses through the PERK branch presents an exciting 
opportunity to develop therapeutic agents for several human disorders including cancer.  
1.4.1.3. Activating transcription factor 6 (ATF6) branch 
 ATF6, an endoplasmic reticulum-localized transmembrane protein, is translocated to the 
Golgi upon induction of the unfolded protein response (Figure 1.6). Golgi contains two specific 
proteases: Site-1 Protease (S1P) and Site-2 Protease (S2P) that sequentially cleave ATF6 to release 




nucleus, where it induces the expression of proteins that resolve the unfolded protein response 
(Figure 1.6). ATF6 is the least studied branch of the unfolded protein response, due to the lack of 
reliable antibodies and compounds pertaining to the ATF6 branch. Recently, two back-to-back 
publications have independently identified several activators and an inhibitor of ATF6.  Plate et 
al. (2016) employed a three-tiered screening strategy to identify several compounds from a 
644,951 small molecule library that could specifically activate ATF6. The study showed that 
treatment with compounds 132 and 263 induced ATF6 processing and its nuclear localization 
(Plate et al., 2016). In an independent screening study, Gallagher et al. (2016) used a cell line 
stably expressing the endoplasmic reticulum stress response element (ERSE) luciferase reporter to 
screen 106,281 compounds that could inhibit thapsigargin-induced activation of ATF6α, the 
isoform associated with the unfolded protein response. The study identified Ceapins as specific 
inhibitors of ATF6α as well as showed that treatment with Ceapin A7 sensitized cells towards 
unfolded protein response-mediated cytotoxicity in vitro (Gallagher et al., 2016). Further studies 









Figure 1.6. Schematic diagram representing the Activating transcription factor 6 (ATF6) 
branch of the unfolded protein response pathway. Activating transcription factor 6 (ATF6) is a 
transmembrane protein. Induction of the unfolded protein response results in the translocation of 
ATF6 to the Golgi where it is cleaved first by the luminal Site 1 Protease (S1P) and then the intra-
membrane Site 2 Protease (S2P) releasing the cytoplasmic portion of ATF6 (ATF6-N). Activated 
ATF6 upregulates a subset of unfolded protein response genes associated with chaperone activity, 










1.4.2. Heat-shock proteins (HSPs) 
Heat-shock proteins (HSPs) are an ancient defense system that acts through molecular 
chaperones allowing for the proper folding of misfolded proteins as well as targeting the damaged 
proteins for degradation. In mammalian cells, heat-shock proteins are important contributors in the 
protein quality control. Heat-shock proteins belong to six highly conserved classes: 1) heat-shock 
protein 33 (Hsp33), 2) heat-shock protein 60 (Hsp60), 3) heat-shock protein 70 (Hsp70), 4) heat-
shock protein 90 (Hsp90), 5) heat-shock protein 100 (Hsp100) and the class of small heat-shock 
proteins (sHSPs). Cancer cells are more dependent on heat-shock proteins (HSPs) for survival, 
which has led to the development of several inhibitors targeting different heat-shock proteins. 
Next, I will discuss the molecular chaperone HSP90, which has been extensively studies in cancer 
therapeutics.  
1.4.2.1. Heat-shock protein 90 (Hsp90) 
Hsp90 is a molecular chaperone that is essential for the proper folding of several client proteins, 
allowing these proteins to acquire a functionally active form. Hsp90 aids in maintaining 
proteostasis by buffering its protein substrates from several stressors such as heat shock (sudden 
change in temperature), oxidative stress, and proteotoxic stress. Seminal studies performed in the 
Lindquist laboratory have established Hsp90 as a capacitor for phenotypic variation and 
morphological evolution (Queitsch et al., 2002; Rutherford and Lindquist, 1998). The studies 
showed that robust Hsp90 activity allows for the proper functioning of metastable proteins 
ensuring normal growth and development (canalization). Furthermore, they showed that 
pharmacological inhibition of Hsp90 released these genetic variations (Rutherford and Lindquist, 
1998), which manifested through defects in the phenotype (Queitsch et al., 2002). These findings 




been shown to stabilize key oncoproteins. In tumor cells, Hsp90 acts as a buffering system against 
destabilizing oncogenic mutations in oncoproteins such as BCR-ABL, FLT3, and JAK2 (Ho et al., 
2012) increasing the dependence of tumor cells on Hsp90. Among breast cancer patients, the high 
Hsp90 expression has been associated with decreased survival (Pick et al., 2007).  Such evidence 
strengthened the idea for targeting the Hsp90 complex in tumors.  
Several Hsp90 inhibitors have been tested in the preclinical and clinical settings. The first 
Hsp90 inhibitor identified was the benzoquinone ansamycin geldanamycin (GM) (Whitesell et al., 
1994); however, it displayed low solubility and bioavailability (Supko et al., 1995). A derivative 
of GM, 17-allylamino- 17 demethoxygeldanamycin (17-AAG) entered clinical trials for several 
malignancies, but showed limited success due to poor pharmacokinetics and susceptibility to rapid 
drug resistance mechanisms (Neckers and Workman, 2012). Two more GM analogs, alvespimycin 
and retaspimycin have been pursued as clinical candidates for cancer therapeutics (Butler et al., 
2015). Additional Hsp90 inhibitors that are currently in clinical trials include luminespib, 
onalespib, ganestespib (Butler et al., 2015).   
1.4.3. Autophagy 
Autophagy is an evolutionarily conserved lysosomal mediated catabolic process that 
degrades cytoplasmic components. Autophagy is responsible for the degradation of proteins, 
protein aggregates, and damaged organelles. It is primarily an adaptive mechanism allowing cells 
to mitigate external stresses such as nutrient deprivation, and internal stresses such as increased 
proteotoxic stress. Many studies have focused on targeting autophagy for cancer therapeutics. 
Because the mammalian target of rapamycin (mTOR) pathway regulates autophagy, 
pharmacologic agents that modulate the mTOR pathway have been pursued to affect autophagy 




1.4.3.1. Mechanistic target of rapamycin (mTOR)   
mTOR is a serine/threonine protein kinase that plays a major role in eukaryotic signaling 
pathways by sensing external environmental conditions. mTOR belongs to the phosphoinositide 
3-kinase (PI3K) family of protein kinases comprising of two protein complexes: mTOR complex 
1 (mTORC1) and mTOR complex 2 (mTORC2) (Zarogoulidis et al., 2014). mTORC1, consisting 
of mTOR, Raptor, and mLST8, regulates critical cellular anabolic and catabolic functions based 
on several environmental stimuli (Dunlop and Tee, 2009). Major cellular functions associated with 
mTORC1 are ribosomal biosynthesis, protein synthesis, and metabolism of lipids, nucleotide and 
glucose (Saxton and Sabatini, 2017). Similarly, inhibition of mTORC1 can induce autophagy 
(Saxton and Sabatini, 2017). mTORC2, consisting of mTOR, mLST8, and Rictor, has been 
primarily shown to function as an effector of insulin/PI3K-AKT pathway (Sarbassov et al., 2005). 
Both mTORC1 and mTORC2 have been implicated in tumorigenesis. mTORC1 lies downstream 
of highly mutated oncogenic pathways (PI3K/AKT as well as MAPK pathways), leading to 
hyperactive mTORC1 in cancers, while mTORC2 helps to activate AKT resulting in increased 
proliferation (Saxton and Sabatini, 2017). Therefore, targeting both mTOR complexes has been 
proposed as a plausible idea in cancer therapeutics.    
mTOR was identified as a direct target of a compound called rapamycin, which showed 
remarkable antifungal, immunosuppressive and anti-cancer effect. Rapalogs (rapamycin 
derivatives) temsirolimus and everolimus have been approved for the treatment of breast and renal 
cell carcinomas (Meng and Zheng, 2015). Although, these rapalogs were effective in the pre-
clinical models, barring few extraordinary responders the clinical effects of rapalogs have been 
largely underwhelming (Saxton and Sabatini, 2017). Such lack of effect may be due to the 




tumor-promoting PI3K/Akt pathway upon rapalog treatment could be responsible for the poor 
clinical outcome (Mackenzie and Elliott, 2014). Additionally, rapalog treatment can activate 
autophagy by inhibiting mTORC1 partially mitigating the cytotoxic effects of these compounds.  
Recently, second-generation mTOR inhibitors that target mTOR by inhibiting the ATP-
competitive catalytic activity have been shown to be effective in multiple cancer types and are in 
clinical trials (Zhou and Huang, 2012).  
1.4.4. Ubiquitin proteasome system 
The ubiquitin proteasome system is the principal cellular protein degradation pathway 
responsible for degrading 80-90% of the entire proteome (Lilienbaum, 2013). The ubiquitin 
proteasome system consists of three ubiquitin proteins, E1, E2, and E3, which orchestrate the 
attachment of polyubiquitin (primarily through ubiquitin poly-lysine 48 linkages) to protein 
substrates degraded by the proteasome (Figure 1.7). In the subsequent subsections, I will discuss 
three prominent cancer therapeutic targets in the ubiquitin proteasome system that have emerged 





Figure 1.7. Schematic representation of the ubiquitin proteasome system. Ubiquitin (Ub) is 
activated by ubiquitin activating protein (E1) and subsequently conjugated to the ubiquitin 
conjugating enzyme (E2). Ubiquitin is then tagged to the substrate protein directly or indirectly by 




1.4.4.1. Proteasome  
There are two types of proteasome, constitutive proteasome (Cp) and immunoproteasome 
(Ip). Cp, commonly referred to as proteasome, is a large protein complex consisting of two 
subcomplexes:  one 20S catalytic core and one or two 19S regulatory particle(s). The 20S catalytic 
core consists of seven α subunits (α1- α7) and seven β subunits (β1- β7). In the Cp, β1, β2, and β5 
subunits in the 20S core are responsible for peptide cleavage. The second form of proteasome, 
referred to as Ip, is predominately expressed in cells of hematopoietic origins, where β1, β2, and 




The 19S regulatory particle can be further subdivided into two groups: a regulatory particle of 
non-ATPase (Rpn) subunits and a regulatory particle of triple-ATPase (Rpt) subunits. 
Polyubiquitinated substrate protein docks at the ubiquitin receptor proteins Rpn10 and Rpn13, 
which allow for the attachment of substrate proteins to the 19S regulatory particle. Deubiquitin 
enzymes,  Rpn11, Uch37 and Usp14,  then detach the polyubiquitin from the substrate (Lee et al., 
2011), allowing the substrate to enter the 20S core. Specific ATPases Rpt1-6 further drive the 
substrate inside the 20S core that is responsible for substrate cleavage (Deshaies, 2014).  
Bortezomib (Velcade), a β5 subunit inhibitor of the 20S proteasome, was the first 
proteasome inhibitor to be granted FDA approval for use in multiple myeloma (Kane et al., 2003) 
and later in mantle cell lymphoma (Raedler, 2015). In vitro treatment with bortezomib has been 
shown to cause cell death via two separate mechanisms (Drexler et al., 2000; Lopes et al., 1997). 
Firstly, bortezomib treatment inhibits the degradation of inhibitor of nuclear factor kappa B kinase 
subunit beta (IKKβ), which then inhibits nuclear factor kappa beta (NFкB). Activation of NFкB is 
a pro-survival response, therefore inhibition of NFкB by IKKβ results in cell death (Hideshima et 
al., 2002). Secondly, treatment with proteasome inhibitors attenuates the degradation of misfolded 
and unfolded proteins inducing the unfolded protein response-mediated cell death (Fribley and 
Wang, 2006). Carfilzomib, another FDA-approved proteasome inhibitor, has been shown to 
display a similar mode of action with efficacy in patients with relapsed or refractory multiple 
myeloma (Dimopoulos et al., 2016). Although these two proteasome inhibitors show excellent 
efficacy in hematological malignancies, the studies performed on solid tumors so far have been 
underwhelming (Aghajanian et al., 2009; Aghajanian et al., 2005; Ramirez et al., 2008).  
Several explanations have been provided for the lack of efficacy in solid tumors, most of 




Hematological cancers such as multiple myeloma have elevated levels of nuclear factor kappa B 
(NFкB), therefore stabilization of inhibitor of nuclear factor kappa B kinase subunit beta (IKKβ) 
upon the treatment of proteasome inhibitors show significant effects in these cancers compared to 
solid tumors. Likewise, another explanation for this peculiarity is based on the cellular physiology 
of both multiple myeloma and mantle cell lymphoma. These cancers originate from antibody-
producing cells which make them highly reliant on the endoplasmic reticulum and ubiquitin 
proteasome system for survival. Therefore, inhibition of proteasome and subsequent induction of 
unfolded protein response make them more vulnerable than other cancer types. Lastly, the lack of 
efficacy with proteasome inhibition could be due to drug pharmacology. Several in vitro studies 
have shown effective cytotoxicity by proteasome inhibitors in several solid cancer cell lines 
including ovarian cancer (Caravita et al., 2006; Miyamoto et al., 2013); however, numerous 
clinical trials have failed to show efficacy in patients (Huang et al., 2014). This could be due to 
inefficient drug penetration as well as fast clearance of proteasome inhibitors in patients. 
Intravenous administration of bortezomib has been shown to have a mean half-life of 8.68-14.8 
hours in plasma (Papandreou et al., 2004). Other pharmacological agents targeting proteasome as 
well as other targets within the ubiquitin proteasome system could be effective in solid tumors 
(Anderson et al., 2015; Deshaies, 2014; Du and Mei, 2013; Gentile et al., 2015; Soucy et al., 2009). 
1.4.4.2. NEDD8-activating enzyme E1 (NAE1) 
Following the discovery of the ubiquitin pathway, similar pathways called ubiquitin-like 
protein pathways were identified. NEDD8 is a ubiquitin-like protein, which is activated by the 
NEDD8 activating enzyme (Ubiquitin E1 like protein). NEDD8 is then transferred to the ubiquitin-
conjugating enzyme E2 M (UBE2M) and subsequently to its respective substrates. Culin-ring 




NEDD8, where NEDD8 binding is required for the activity of several culin-ring ligases. MLN4924 
(Pevonedistat) has been identified as a potent and selective inhibitor of NEDD8 activating enzyme 
E1. Treatment with MLN4924 reduced NEDD8 attachment to its substrates, blocked 
approximately 20% of ubiquitin proteasome system-mediated protein degradation and caused cell 
cycle arrest, ultimately resulting in programmed cell death. Anti-tumor activity of MLN4924 has 
been observed in different solid tumor mouse xenograft models (Soucy et al., 2009). Such results 
have prompted multiple clinical trials of MLN4924 as a single agent or in combination with 
existing chemotherapies in mesothelioma, acute myeloid leukemia, chronic myelomonocytic 
leukemia and acute myelogenous leukemia.  
1.4.4.3. Valosin-containing protein (VCP) 
Valosin-containing protein (VCP), also known as p97, is a member of ATPases Associated 
with diverse cellular Activities- ATPase (AAA-ATPase) family of proteins that are involved in 
diverse cellular functions including the endoplasmic reticulum-associated degradation (ERAD), 
the ubiquitin proteasome system, mitochondria-associated degradation, handling aggregates, 
autophagy and chromatin-associated degradation (Meyer et al., 2012), making it a prominent 
regulator of protein quality control. VCP forms a homo-hexameric structure, each monomer 
consisting of an N-terminal domain, a D1 and a D2-ATPase domain and a short C-terminal domain 
(Figure 1.8) (Banerjee et al., 2016; Zhang et al., 2000). As a ubiquitin-segregase, VCP binds to its 
substrates facilitating the extraction of these substrates from the endoplasmic reticulum 
(DeLaBarre et al., 2006; Ye et al., 2001), mitochondria (Kim et al., 2013) and from protein 
complexes (Beskow et al., 2009) to target the substrates for degradation via proteasomes. 
Similarly, increasing evidence have now shown that VCP regulates the clearance of stress granules 




VCP interacts with specific cofactors allowing for such diverse functions in the cell. The family 
of cofactors and their interactions with VCP are extensively discussed in these reviews 
(Hänzelmann and Schindelin, 2017; van den Boom and Meyer, 2017). Because of its prominent 
role in protein quality control and the clinical evidence showing an association between elevated 
VCP expression and poor prognosis in cancer (Tsujimoto et al., 2004a; Valle et al., 2011) and 
tumor recurrence (Yamamoto et al., 2003), several groups have developed inhibitors against this 




Figure 1.8. Diagram of the valosin-containing protein (VCP/p97). Monomeric VCP comprises 
of an N-terminal domain (aa: 2-187), D1 ATPase domain (aa: 209-462), D2 ATPase domain (aa: 
481-763) domain, and a short C-terminal extension (aa 764-800). N-terminal domain interacts with 
substrates and cofactors while D1 and D2 ATPase domains hydrolyze ATP.   
 
Eayarestatin 1 (Eer1) was first identified as a potent inhibitor of the ERAD that negatively 
affected VCP-mediated deubiquitination (Wang et al., 2008). Eer1 was shown to directly interact 
with VCP causing a conformational change resulting in a dysfunctional protein (Wang et al., 
2010b). Subsequently, the Deshaies laboratory set out to identify specific and potent VCP 
inhibitors using luciferase-based high-throughput screening (HTS) assay. The screening identified 




later structural-activity relationship (SAR) studies identified ML240 and ML241 as potent D2 
ATPase-specific VCP inhibitors (Chou et al., 2013). Although these compounds displayed 
increased specificity towards VCP, they lacked proper pharmacological properties for in vivo use. 
Cleave Biosciences later developed an orally bioavailable VCP inhibitor CB-5083 using ML240 
as the starting compound. An oral dose of CB-5083 (100mg/kg) inhibited tumor growth in nude 
mice bearing different cancer xenografts (Anderson et al., 2015).  
Additionally, Magnaghi et al. (2013) screened one million compounds using an NADH-
coupled assay to measure the ATPase activity. This resulted in the identification of NMS-859 as a 
covalent inhibitor and NMS-873 as a non-ATP-competitive allosteric inhibitor of VCP (Magnaghi 
et al., 2013). UPCDC-30245 was identified as yet another VCP inhibitor related to previously 
identified allosteric phenyl indole-based VCP inhibitors (Alverez et al., 2015; Banerjee et al., 
2016) (Figure 1.9). Sorafenib (Yi et al., 2012), rheoemodin (Kang et al., 2014) and Syk inhibitors 
III (Chou and Deshaies, 2011) were also identified as VCP inhibitors. Recently, the alcohol-abuse 
drug disulfiram was shown to inhibit VCP segregase function through the inhibition of VCP 
cofactor NPL4 (Skrott et al., 2017). With a prominent role in the protein quality control, targeting 
VCP clinically could be efficacious against multiple cancer types as well as other disorders such 
as inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia, where 















Figure 1.9. Commonly used valosin-containing protein inhibitors (VCP inhibitors). Chemical 
















1.5. Central hypothesis and aims 
Identifying and targeting non-oncogenic pathways has been actively pursued in several 
tumor types including ovarian cancer (Nagel et al., 2016). In support of this concept, several 
genome-wide genetic screens with short hairpin RNAs (shRNAs) identified components of protein 
quality control as targets of vulnerability in ovarian cancer (Cheung et al., 2011; Marcotte et al., 
2012; Nijhawan et al., 2012). In particular, VCP was identified as one of the lineage-specific 
essential genes in ovarian cancer cell lines compared to non-ovarian cancer cell lines (Cheung et 
al., 2011).  Moreover, VCP was also identified as an essential gene in cyclin E1-overexpressed 
ovarian cancer cells (Etemadmoghadam et al., 2013). Recently, several groups have shown that 
VCP inhibitors are effective in pan-cancer cell lines with clinical candidate CB-5083 showing 
efficacy in multiple mouse xenograft models (Anderson et al., 2015). Based on these studies, I 
proposed the central hypothesis that VCP represents a vulnerable target in ovarian cancer and 
can be targeted by a single agent or a combination with other agents that inhibit protein 
quality control pathways. To address this central hypothesis, I proposed the following three 
Specific Aims: 
1.5.1 Specific Aim 1: To investigate the therapeutic effects of VCP inhibitors in 
ovarian cancer cells. 
VCP plays a prominent role in various cellular processes including endoplasmic reticulum-
associated degradation (ERAD), DNA damage repair, cell cycle regulation and autophagy 
(Yamanaka et al., 2012). Furthermore, VCP inhibitors have emerged in recent years as a potential 
therapeutic option in different malignancies (Anderson et al., 2015). Through my study, I will 
investigate the potential therapeutic efficacy of VCP inhibitors, with a special focus on the clinical 
lead CB-5083 in ovarian cancer. I will characterize the mode of cell death, cell cycle regulation 




1.5.2 Specific Aim 2: To identify compounds that induce synergistic cytotoxicity 
with VCP inhibitors. 
VCP inhibitors induce cytotoxicity in different cancer lines in vitro and in vivo (Anderson 
et al., 2015; Chou et al., 2011; Chou et al., 2014). However, the effects of these compounds in 
combination with other agents that modulate the unfolded protein response in ovarian cancer cells 
have not been characterized. I will determine the potential synergistic cytotoxicity between VCP 
inhibitors and compounds known to modulate the unfolded protein response and define the 
molecular mechanisms that contribute to synergistic drug interactions between VCP inhibitors and 
other agents that modulate the unfolded protein response and cell death pathways.  
1.5.3 Specific Aim 3: To define the mechanism of resistance towards VCP 
inhibitors.   
Development of drug-resistant cell lines through prolonged drug treatment in vitro allows 
modeling the molecular mechanism of resistance that could be seen in the clinics. Similarly, 
studying the molecular mechanisms contributing to cellular resistance to VCP inhibitors helps to 
define the on-target and off-target effects of the drugs. CB-5083 is an oral VCP inhibitor 
currently in Phase I clinical trials. The compound shows favorable pharmacodynamic effects in 
several in vitro and in vivo studies. Although missense mutations in the VCP coding region have 
been reported to contribute to CB-5083 resistance, the mechanism of resistance in ovarian cancer 
is not yet defined. Therefore, I will identify and characterize potential mechanisms of resistance 
towards the oral VCP inhibitor CB-5083 by employing an intermittent and a continuous dosing 
scheme to establish CB-5083 resistant ovarian cancer cells and investigate molecular 
mechanisms contributing to CB-5083 resistance. Finally, I will investigate new strategies that 









Chapter 2: Materials and methods 
Portions of this chapter are reproduced from the following publications with permission where 
required. 
 
 Bastola P,  Neums L, Schoenen FJ, Chien J (2016) VCP inhibitors induce endoplasmic 
reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and 
synergistically kill ovarian cancer cells in combination with salubrinal. Molecular 
Oncology 10, 1559-1574. PMID: 27729194 
 
 Bastola P, Wang F, Schaich M, Gan T, Freudenthal B, Chou TF, Chien J (2017) Specific 
mutations in D1-D2 linker region of VCP/p97 enhance ATPase activity and confer 













 DBeQ, ML240, and ML241 were provided by Dr. Frank Schoenen at the University of 
Kansas (Chou et al., 2013). Salubrinal (CML0951), mifepristone (M8046), UPCDC30245 
(SML1674) and tunicamycin (11089-65-9) were purchased from Sigma-Aldrich. CB-5083 
(S8101), STF-083010 (S7771), bortezomib (S1013) and NMS-873 (S7285) were purchased from 
Selleckchem. DBeQ, ML240, ML241, NMS-873, UPCDC30245, STF-083010, bortezomib and 
CB-5083 were dissolved in dimethyl sulfoxide (DMSO) at the concentration of 50 mM. Salubrinal 
was dissolved at the concentration of 20 mM in DMSO, and tunicamycin was dissolved at the 
concentration of 10 mM in DMSO. Dissolved compounds were aliquoted and stored at -80°C. 
Stocks were thawed at room temperature and dissolved in appropriate media at selected 
concentrations immediately before use.   
2.2. Cell lines and cell culture 
Ovarian cancer cell lines OVCAR10, SKOV3, OVCAR5, and RMG1 were cultured in 1:1 
mixture of MCDB 105 (Sigma-Aldrich, M6395) and Medium 199 (Sigma-Aldrich, M5017), 5% 
fetal bovine serum (Sigma-Aldrich, F0926), and 1% streptomycin/penicillin (Sigma-Aldrich, 
P0781). OVCAR8, OVSAHO parental and OVSAHO resistant cells were maintained in RPMI 
(Sigma-Aldrich, R8758), 10% fetal bovine serum and 1% streptomycin/penicillin. PERK-MEF-/- 
(ATCC, CRL-2976) and GCN2-MEF-/- (ATCC, CRL-2978) were cultured in DMEM, 0.1 mM 
non-essential amino acids (Fisher, MT25025CL), 0.05 nM 2-mercaptoethanol (Sigma-Aldrich, 
M3148), 10% fetal bovine serum, and 1% streptomycin/penicillin. HEK-293T cells were cultured 
in RPMI, 10% fetal bovine serum, and 1% streptomycin/penicillin. All cell lines were kept in a 
humidified incubator at 37°C with 5% CO2.  All cell lines were subjected to cell line identity 




2.3. Sulforhodamine B (SRB) assays and drug synergy studies  
Sulforhodamine B assays were performed as previously described (Vichai and Kirtikara, 
2006) with the following modifications. Briefly, two different density of cells (3000/well and 
5000/well) were seeded in 96-well plates and cultured in 200 μl/well of appropriate growth media. 
The next day, cells were treated with different concentrations of compounds for 72 hours unless 
otherwise specified. After treatment, cells were fixed with 10% trichloroacetic acid (Sigma-
Aldrich, T6399) at 4°C overnight. Fixed cells were then washed with running water and stained 
with 0.057% (weight/volume) sulforhodamine B (Sigma-Aldrich-230162) stain prepared in 1% 
acetic acid solution (Sigma-Aldrich, BP2401) at room temperature for 45 minutes. Excess stain 
was discarded, and cells were washed with 1% acetic acid solution. Stained cells were dissolved 
in 10 mM tris-buffered saline (TBS, pH 10), and fluorescence measurements were taken at 
Excitation 488 nm and Emission 585 nm using a fluorescence plate reader. Dose-response curves 
were fitted, and half-growth inhibition (GI50) values were determined with GraphPad Prism (ver. 
6) using four parameters setting. All dose-response curves were constrained to 100% at the top 
and greater than 0% at the bottom.  
Synergy was determined by calculating the combination indexes (CIs) obtained from the 
fluorescence measurements. Combination indexes were calculated by dividing the expected effect 
by the observed effect. The expected values assume additive effects between two drugs. N 
represents the total number of combination indexes (CIs) determined from 16 different drug 
combinations in duplicates that produced 20-80% effect from three independent experiments. An 






Combination index was calculated using the formula: 
CI = (D1 + (D2 * (1-D1)))/ Dobserved  
where, CI= Combination index 
D1 = average fraction affected by Drug 1, 
            D2 = average fraction affected by Drug 2, and 
            Dobserved = average fraction affected by Drug 1 + Drug 2  
 
 
Figure 2.1. An example of combination index (CI) calculation. 
2.4. Clonogenic Assay 
500-1000 cells/well were seeded in 6-well plates using the appropriate media. The next 
day, the culture media was replaced with media containing appropriate compounds, and cells were 
treated for 48 hours. Following the treatment, media was gently aspirated, and the wells were 
gently washed twice with phosphate-buffered saline (PBS, pH 7.0) and replaced with regular 
growth media. Cells were then allowed to grow in the incubator for 6-10 additional days while 
replacing media every 48 hours. Once the colonies were visible, media was aspirated, and 1 ml of 




was added to each well. The cells were stained with crystal violet solution for 30 minutes and then 
washed with water. In some experiments, crystal violet staining was substituted with 
sulforhodamine B staining as described in the Methods for sulforhodamine B assay. 
Sulforhodamine B staining allows dual quantitation of surviving cells by counting stained colonies 
and by measuring the fluorescence of extracted sulforhodamine B. The plates were then air-dried 
and pictures were taken using the Bio-Rad Imager System. Colonies were counted using BioRad 
Quantity One version 4.6.9 software. Clonogenic survival was determined relative to vehicle-
treated cells and shown in bar graphs using GraphPad Prism (ver. 6).  
2.5. Puromycin Incorporation Assay 
Puromycin incorporation assay was performed as previously described (Schmidt et al., 
2009), with the following modification. 0.5 x 106 cells per well were seeded in 6-well plates and 
cultured in 2 mL of appropriate growth media. The next day, growth media were substituted with 
media containing different concentrations of vehicle or compounds. The plates were placed in a 
humidified incubator at 37°C with 5% CO2 for 5.5 hours, after which 2 μL of 1 mM puromycin 
solution (Goldbio, P-600) was added to each well and incubated for additional 30 minutes. Cells 
were collected, lysed and equal volumes were subjected to Western blotting according to the 
established protocol (please refer to section 2.12). Blots were incubated with antibodies against 
puromycin (Millipore, MABE343) and β-actin (Sigma-Aldrich, A1978). 
2.6. Cellular Thermal Shift Assay (CETSA) 
Cellular Thermal Shift Assay (CETSA) was performed as previously described (Jafari et 
al., 2014), with the following modifications. Briefly, 1 x 106 cells were seeded in 10 cm cell culture 
plates with appropriate growth media. The next day, regular growth media was replaced with 




trypsinized, and cell pellets were collected following centrifugation. Cell pellets were dissolved in 
100 μl phosphate-buffered saline (PBS) pH 7.0 and subjected to heat treatment at 57°C. Following 
heat treatment, proteins were precipitated using freeze-thaw in liquid nitrogen. Cells were then 
subjected to centrifugation at 20,000xg at 40C, and soluble fractions were analyzed by Western 
blot. Blots were incubated with antibodies against the valosin-containing protein (Santa Cruz, 
20799) and β-actin (Sigma-Aldrich, A1978).  
2.7. Transient small interfering RNA (siRNA) knockdown 
0.5 x 106 cells per well were seeded in 6-well plates using appropriate growth media 
without antibiotics. The next day, small interfering RNAs (siRNAs) were transfected using 
Oligofectamine reagent (Life Technologies, 12252-011) according to the manufacturer’s protocol. 
Non-targeting scrambled small interfering RNA was transfected in parallel as a negative control. 
Predesigned siRNAs for the valosin-containing protein (VCP), heme-regulated inhibitor (HRI), 
protein kinase R (PKR) and scrambled siRNAs were purchased from Integrated DNA Technology 
(IDT). Growth arrest and DNA damage-inducible protein 34 (GADD34) siRNA were purchased 
from Santa Cruz Biotechnology (sc-37414). Cells were collected at 48 hours after transfection, 
and whole cell lysates were subjected to Western blotting according to the established protocol 
(please refer to section 2.12). Targeting efficiency of each siRNA was evaluated based on the 
relative reduction in the expression of targeted protein after transfection compared to negative 
control using densitometry analysis. β-actin was used as the loading control.  
2.8. Caspase 3 activity assay 
0.5 X 106 cells/well were seeded in 6-well plates using the appropriate culture media. The 
next day, cells were treated with appropriate compounds in culture media. Cells were scrapped 




20 mM PIPES, 100 mM NaCl, 1 mM EDTA, 0.1%(w/v) CHAPS, 10% sucrose, 10 mM DTT pH 
7.2.  Protein concentration was determined using BCA Assay. 20 μg protein was combined with 2 
μL of 2 mM DEVD-Afc (kindly provided by Dr. Wen-Xing Ding’s laboratory at the University of 
Kansas Medical Center) in 96-well flat-bottom plate (Falcon, 3296). Appropriate volumes of 
caspase buffer were added to make 200 μl/well. The plate was covered and incubated at 37°C. 
After 2 hours, fluorescence measurements were taken using a plate reader at Excitation 400 nm 
(nanometer) and Emission 510 nm (nanometer). Cleavage of the dye-quenched peptide by active 
caspase 3 releases the quencher and produces fluorescence. Fluorescence measurements were 
analyzed using GraphPad Prism (version 6).   
2.9. Analysis of VCP expression from RNA sequencing datasets 
RNA sequencing datasets (RNAseqV2 level3) from high-grade serous ovarian cancer were 
downloaded from the cancer genome atlas (TCGA) Research Network Data Portal 
(http://tcga_data.nci.nih.gov/tcga). The clinical data associated with these samples were 
downloaded from cBioPortal (http://www.cbioportal.org/data_sets.jsp). The sensitive samples (55 
samples) were defined as being disease free for over 24 months while the resistant samples (95 
samples) were defined as being disease-free for less than 12 months. From the data, normalized 
expression was extracted for the gene VCP and plotted in R with the R package ‘caroline’ using 
the plot function ‘violins’ (version 0.7.6. https://CRAN.Rproject.org/package.org/package-
=caroline). A bin-width of h=1650 for the kernel density estimation was used for the plots. Welch’s 
Two Sample t-test was used to calculate the p-value.  
2.10. Cell Cycle Analysis 
1 X 106 cells per plate were seeded in 10 cm cell culture plates with the appropriate culture 




compounds for 18 hours. Cells were then trypsinized and cell pellets were collected in a 15 mL 
centrifuge tubes. Pellets were washed twice with ice-cold phosphate-buffered saline (pH 7.0). Cells 
were then fixed in 2ml of ice-cold phosphate-buffered saline and 95% ice-cold ethanol (Fisher, 
BP2818500) mixed at 1:1 ratio for 1 hour. Fixed cells were twice washed with cold phosphate-
buffered saline. Finally, the pellets were resuspended in 0.1% sodium citrate solution containing 
RNase A (Invitrogen, AM2269) and propidium iodide solution (Sigma-Aldrich, P4170) for 30 
minutes at 370C. Cell cycle profile for each treatment condition was then analyzed using flow 
cytometer based on previously established protocols at the University of Kansas Medical Center 
Flow Cytometry Core.  
2.11. Annexin V apoptotic assay 
0.3 X 106 cells per well were seeded in 6-well plates using the appropriate culture media 
and were allowed to incubate overnight. Cells were then treated with culture media containing 
vehicle or the compounds of interest for the indicated time. After treatment, cells were trypsinized 
and centrifuged at 1500 rpm for 5 minutes. Cell pellets were resuspended in Annexin V Binding 
Buffer containing propidium iodide (BioLegend, 640914). Annexin V and propidium iodide 
staining was determined by flow cytometry according to the manufacturer’s protocol.  
2.12. Western blot and antibodies 
Cells were scrapped and collected at the end of each experiment for western blotting. 
Proteins were extracted in 2X Laemmli Buffer (Bio-Rad, 161-0737) containing protease inhibitor 
(Roche, 05892970001) and phosphatase inhibitor (Fisher, 78440). Equal volumes of samples were 
loaded (unless otherwise specified) in SDS-PAGE and electroblotted onto polyvinylidene 
difluoride PVDF membranes. Blotted membranes were incubated in 5% nonfat dry milk prepared 




were incubated with appropriate primary antibodies prepared in 3% bovine serum albumin in TBS-
T solution overnight at 4°C. Membranes were then washed with TBS-T solution and incubated 
with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies prepared in 3% 
bovine serum albumin in TBS-T solution for 1 hour at room temperature. Immunocomplexes on 
the blots were visualized by the Super Signal West Femto (Pierce, 34096) and recorded by Bio-
Rad imager (ChemiDocTM MP Imaging System).  
Primary antibodies used for Western blotting included IRE1α (cst-3294S), phospho-IRE1α 
(Novus, nb100-2323), CHOP (cst,5554S), ATF4 (cst,11815S), phospho-eIF2α (Abcam, ab32157), 
VCP (sc,20799), PARP (cst,9542), Caspase 3 (cst,9665P), Cleaved Caspase 3 (cst,9661S), 
Caspase 9 (cst,9508P), Caspase 8 (sc,81656), puromycin (EMD Millipore, MABE343), β-actin 
(Sigma-Aldrich, A1978), GADD34 (sc,8327), VCP (sc, 20799) Bip/Grp78 (cst,3177S), p21 
(sc,397), p27(cst,3686S), Cyclin D1 (sc,20044), and Cyclin E (sc,247), PERK (cst,3192S), ATF6 
(cst, 65880), DYKDDDDK (cst,2368), XBP-1s (cst, 12782) . Secondary antibodies included HPR-
linked anti-rabbit IgG (cst-7074) and HPR-linked anti-mouse IgG (cst-7076). Densitometry 
analyses were performed using ImageJ, and graphs were plotted using GraphPad Prism (ver. 6). 
2.13. Genomic DNA extraction, PCR and Sanger sequencing                          
1x106 cells were collected from parental and resistant cell lines. Genomic DNA was 
extracted from each sample using Qiagen DNA purification kit (Qiagen, 69506). Following the 
genomic DNA extraction, segments of the VCP gene (exon 11-16) were amplified by polymerase 
chain reaction (PCR) using Q5 High-Fidelity DNA polymerase (M0491S) with specific primers. 
A complete list of all genomic DNA primers used for this study is provided in Table 2.1. Following 




For Sanger sequencing, all PCR products were first purified using Qiagen PCR purification 
kit (Qiagen, 28104). For each sample, 5 μl of 5 μM sequencing primer (one of the PCR primers 
used for amplification) were mixed with 10 μl of PCR-purified product. The resulting mixtures 
were sent for Sanger sequencing at Genewiz. All Sanger sequencing results were analyzed using 
Sequencher (version 5.0, Gene Codes). 
Primers Forward primer 5'-3' Reverse primer 5'-3' Amplicon 
Ex-11&12 TGGGTCTTTGAGGCAGCATA TGACTCACCCTGGACCAAGT 449 
Ex-13 TAATGGAGGGGATGCTTCTG GCCCTCAGGCAAATCAATAC 339 
Ex-14 CATGCTGGTTTCGGATTTCT GCCTGAGGACTCATGCAAGT 498 
Ex-15 GGGTTGGTCTAAAGGGAAGG TCTCCATGATTGGCACATCT 375 
Ex-16 TTTCCAGAGTGCATTGACAAGT TTTGGTGTAGGTCCCCAAAG 399 
 
Table 2.1. List of sequencing primers for exons 11-16 (VCP-gene). 
2.14. RNA extraction, quantitative RT-PCR and cDNA sequencing             
1x106 cells from each experimental conditions were harvested by centrifugation after 
washing with phosphate-buffered saline. RNA extraction was performed using Trizol reagent 
(Invitrogen, 15596-028) according to the manufacturer’s protocol. One microgram of total RNA 
was reverse transcribed using a random primer (5 µM) and MMLV reverse transcriptase 




Complementary DNA was subjected to polymerase chain reaction (PCR) with specific 
primer pairs spanning exon 7  to 3’ untranslated region (UTR) of VCP (Table 2.2) and the resulting 
amplicon was purified using PCR purification kit (Qiagen, 28104). Purified amplicons were 
sequenced by Sanger sequencing at Genewiz as described in Section 2.13. The results analyzed 
using Sequencher (ver 5.0, Gene Codes). 
Primers Forward primer 5-3 Reverse primer 5-3 Amplicon 
VCP cDNA CAATTGGTGTGAAGCCTCCT AGAAACCCCCTGTCCAGAGT 1886 
 
Table 2.2. Primers used to sequence complementary DNA (VCP-gene). 
For quantitative reverse transcription-polymerase chain reaction (qRT-PCR), 0.5% of the 
complementary DNA (cDNA) was mixed with Qiagen RT2 SYBR Green Fluor qPCR Mastermix 
(Qiagen, 330513). qRT-PCR was performed based on the manufacturer’s protocol.  The list of 
primers used for qRT-PCR is provided in Table 2.3. 
 
Primers Forward primer 5-3 Reverse primer 5-3 Amplicon 
VCP ATGCCATCGCTCCCAAAAGA TGTCAAAGCGACCAAATCGC 174 
18S GCCCGAAGCGTTTACTTTGA TCCATTATTCCTAGCTGCGGTATC 81 
  






2.15. Kaplan-Meier plots 
Kaplan-Meier plotter was used to analyze the clinical association between VCP expression 
and outcome of patients with ovarian cancer (Gyorffy et al., 2012). The Affymetrix Probe ID 
208648_at corresponding to VCP was used in the analysis. The latest version of the dataset (2015 
version) includes progression-free survival and overall survival data from 1306 patients and 1582 
patients, respectively. For the progression-free survival, a total of 1306 patients were included in 
the analysis. The median cutoff value for VCP expression is 778 (expression values range from 9 
to 4128). For the overall survival, a total of 1582 patients were included in the analysis. The median 
cutoff value for VCP expression is 823 (expression values range from 9 to 6440). The dataset 
includes 1144 patients with serous histologic subtype and 36 patients with endometrioid subtype 
of epithelial ovarian cancer.  The remaining cases are not annotated.   
2.16. Determining IC50 values of VCP inhibitors in ATPase assays 
ATPase activity assays were performed as previously described (Chou et al., 2014). 
Inhibition of human valosin-containing protein (25 nM monomer) was carried out in assay buffer 
(50 mM Tris pH 7.4, 20 mM MgCl2, 1 mM EDTA, 0.5 mM TCEP) containing 0.01% Triton X-
100 and 200 μM ATP. 8-dose titration was used to determine half inhibitory concentration (IC50) 
of each compound in inhibiting the ATPase activity, which was determined by the addition of 
Biomol Green Reagent (Enzo Life Sciences, BML-AK111).  
2.17. Molecular Docking  
All molecular docking experiments were carried out with AutoDock Vina (Trott and Olson, 
2010). The structure of valosin-containing protein (VCP ) was acquired from the protein data bank 
(PDB code 5FTK), and modified by removing the bound ADP and solvent molecules, and 




873 (Banerjee et al., 2016). Auto-DockTools 4.2 was utilized to add polar hydrogens and Gasteiger 
charges and to position a 30 x 30 x 30 Å3 search box that included both E470 and the active site 
(Morris et al., 2009). Structure coordinates of compounds of interest were built using Phenix and 
then converted to a .pdbqt format with Auto-DockTools 4.2, allowing full ligand flexibility 
(Adams et al., 2010). Default Autodock Vina settings were utilized for the analysis of binding 
modes, except that exhaustiveness was raised to 100. Measurements and figures were made in 
PyMol (Schrodinger, 2015).   
2.18. Analysis of somatic mutations in tumor samples from the Cancer Genome 
Atlas (TCGA) database 
The database was assessed through the cbioportal website (Gao et al., 2013). All 
sequencing studies (53 published and unpublished studies) from the cancer genome atlas (TCGA) 
were selected. The search for VCP gene indicates a total of 139 mutations (111 missense and 28 
truncating mutations) in 79 samples. Thirteen samples have two mutations per sample, and the 
majority of these mutations have differences in variant allele frequencies, suggestive of 
independent or separate mutations. 
2.19. RNA-sequencing analysis 
 OVSAHO parental and resistant cells were seeded in 6-well plates (0.5 X 106 cells/well). 
The next day, cells were either treated with vehicle (DMSO) or 5 μM CB-5083 for 6 hours. Each 
treatment condition was performed in triplicate. Cells were scraped and collected by 
centrifugation. Cells were then washed twice with phosphate-buffered saline (pH 7.0), and 1 ml 
Trizol reagent (Invitrogen, 15596-028) was added to each sample. Total RNA was extracted using 
the Trizol reagent according to the manufacturer's protocol. One microgram of total RNA was used 




manufacturer’s protocol. RNA sequencing was performed using Illumina HiSeq 4000 by the 
Genome Sequencing Core at Mayo Clinic, Rochester, Minnesota. 
 Sequences produced by Illumina sequencing in the FASTQ format were imported in 
CLCBio Genomics WorkBench (ver. 9) and mapped to the human reference genome (hg19). Reads 
mapping to annotated genes were counted and differentially expressed genes between two groups 
were determined by DESeq2. False discovery rate (FDR) cutoff value of 0.001 and absolute fold 
change of ≥1.5 were used to identify differentially expressed genes with high levels of statistical 
significance between two groups. To identify genes induced or suppressed by CB-5083, a separate 
analysis was performed in parental cells and CB-5083 resistant cells. For pathway analysis, 
differentially upregulated or downregulated genes were analyzed using Metascape webtool.   
2.20. Transient plasmid transfection 
0.5 X 106 cells/well were seeded in 6-well plates in RPMI media with 10% fetal bovine 
serum without penicillin & streptomycin. Cells were then allowed to incubate overnight in 37°C 
humidified incubator containing 5% CO2. The following day, p3XFlag-ATF6 plasmid was 
transfected using Oligofectamine reagent (Life Technologies, 122520-011) based on the provided 
manufacturer’s protocol. Twenty-four hours later, media was aspirated and indicated compounds 
were added for the indicated time. p3XFLAG-ATF6 was a gift from Ron Prywes (Addgene, 
plasmid#11975) (Chen et al., 2002). DYKDDDDK (cst,2368) antibody was used to detect Flag 














Chapter 3: Understanding and enhancing the cytotoxicity of VCP 
inhibitors in ovarian cancer 
Portions of this chapter are reproduced from the following publication with permission where 
required. 
 
 Bastola P,  Neums L, Schoenen FJ, Chien J (2016) VCP inhibitors induce endoplasmic 
reticulum stress, cause cell cycle arrest, trigger caspase-mediated cell death and 
synergistically kill ovarian cancer cells in combination with salubrinal. Molecular 

















Ovarian cancer affected 239,000 women worldwide in 2012 (Ferlay et al., 2015) and it is 
the leading cause of death from gynecologic cancer in the United States. Current standard-of-care 
for advanced-stage ovarian cancer includes debulking surgery followed by adjuvant combination 
chemotherapy consisting of a platinum agent and a taxane agent (Chien et al., 2013). Although the 
combination therapy is effective and the initial response rate is over 70%, the majority of patients 
with advanced disease experience recurrence (Chien et al., 2013).  With subsequent re-challenge 
with platinum-based chemotherapy, most will acquire resistance to chemotherapy and succumb to 
the disease. 
Therefore, it is imperative that novel therapeutic agents be developed to treat ovarian 
cancer and to extend the effectiveness of platinum-based chemotherapy.  Recent advances in 
cancer therapeutics indicate that genetic defects in cancer can be exploited by synthetic lethality 
with chemical inhibitors. Synthetic lethality is a concept first reported in Drosophila genetics to 
describe the lethality of flies arising from a combination of mutations in two or more genes 
(Nijman, 2011). This concept was extended as an approach to target cancer-specific mutations to 
cause lethality in cancer cells and not in normal cells.  For example, mutations in BRCA1 and 
BRCA2 homology recombination (HR) repair genes are common in ovarian and breast 
carcinomas, and cancer cells harboring these mutations are extremely sensitive to PARP1 
inhibition as a result of synthetic lethality (Bryant et al., 2005; Farmer et al., 2005). Accordingly, 
cancer cells harboring mutations in HR repair genes can be selectively killed by PARP1 inhibitors 
which cause reduced toxicity to normal cells (Underhill et al., 2011).  
Several studies have associated valosin-containing protein (VCP) with various cellular 




reassembly, autophagy and cell division (Deshaies, 2014; Meyer et al., 2002; Seguin et al., 2014). 
VCP is involved in the extraction of unfolded proteins from the endoplasmic reticulum. Upon 
extraction, these proteins undergo proteasome-mediated degradation. Cancer cells harbor a 
plethora of mutations which result in an increased load of unfolded proteins required for 
degradation. Accordingly, VCP and components of the proteasomal degradation pathway are 
essential for cancer cell survival and thus present a target of vulnerability in the cancer cell that 
could be exploited for cancer therapy.  
Several groups have recently developed specific inhibitors against VCP (Alverez et al., 
2015; Alverez et al., 2016; Bursavich et al., 2010; Chou et al., 2011; Chou et al., 2014; Chou et 
al., 2013; Fang et al., 2015; Gui et al., 2016; Magnaghi et al., 2013; Polucci et al., 2013; Wijeratne 
et al., 2016), these efforts were reviewed and summarized elsewhere (Chapman et al., 2015).  
Among these specific inhibitors, DBeQ was initially developed as a reversible inhibitor of 
VCP/p97 that compromises protein homeostasis through impairment of both ubiquitin-proteasome 
system and autophagic protein clearance. DBeQ targets both D1 and D2 ATPase domains of VCP 
(Fang et al., 2015). In contrast, ML240, which was derived from the scaffold of DBeQ, targets the 
D2 ATPase domain (Fang et al., 2015). Another VCP inhibitor NMS-873 is a potent noncovalent, 
non-ATP-competitive, allosteric inhibitor of VCP and activates unfolded protein response, inhibits 
autophagy, and induces cell death (Magnaghi et al., 2013). Finally, a derivative of ML240 was 
further developed by Cleve Biosciences to produce orally bioavailable active compound CB-5083 
that shows promising pre-clinical activities (Anderson et al., 2015).  Consequently, CB-5083 is 
currently in two Phase I clinical trials (NCT02243917 and NCT02223598) sponsored by Cleave 




Since VCP is identified as an essential gene in ovarian cancer cell lineages and also in 
Cyclin E1-overexpressed cisplatin-resistant ovarian cancer cell lines, we tested the potential 
cytotoxic activities of quinazoline-based VCP inhibitors, DBeQ, ML240, and its clinical lead CB-
5083 in ovarian cancer cell lines.  Moreover, we also determine the potential synergistic drug 
interactions between VCP inhibitors and salubrinal, an agent that enhances the expression of 
CHOP (also known as DDIT3, DNA Damage-Inducible Transcript 3). 
3.2. Results 
3.2.1 DBeQ and ML240 are effective in reducing cell viability in ovarian cancer 
cells  
We used Sulforhodamine B (SRB) assay to determine the extent of cytotoxicity induced 
by DBeQ and ML240 in four ovarian cancer cell lines, namely OVCAR10, OVCAR8, SKOV3, 
and OVCAR5. Our results indicate that the half-maximal inhibition (GI50) for DBeQ ranges from 
2.6±0.9 μM – 4.6±2.01 μM; while for ML240, it ranges from 0.97±0.46 μM – 2.01±0.92 μM 
(Figure 3.1A-3.1C) in ovarian cancer cell lines. These results suggest that VCP inhibitors are 
cytotoxic towards ovarian cancer cells. ML240 displays higher levels of cytotoxicity compared to 






Figure 3.1. DBeQ and ML240 show increased cytotoxicity towards ovarian cancer cells. (A&B) 
OVCAR10, SKOV3, OVCAR8 and OVCAR5 cells were treated with vehicle (DMSO) as well as 
different concentrations of DBeQ and ML240 ranging up to 25 µM for 72 hours in 96-well plates. 
Dose-response curves were generated using GraphPad Prism using four parameters nonlinear 
regression (curve fit). Curves were constrained on top (100%) and bottom (less than 10%). (C) 
The GI50 for DBeQ and ML240 were shown as Mean + SEM from 3 biological replicates for all 
ovarian cancer cell lines. Each data point in the dose-response curve was generated from three 









3.2.2 VCP inhibitors effectively interact and inhibit cellular VCP 
Next, we compared the mean GI50 from several ovarian cancer cell lines with their relative 
VCP protein expression. A moderate positive correlation was observed between the mean GI50 and 
relative protein expression with both DBeQ (r=0.59) and ML240 (r=0.45) (Figure 3.3A, 3.3C & 
3.3D). These data are consistent with the previous report indicating a positive correlation between 
VCP expression and GI50 for oral VCP inhibitor- CB-5083 (Anderson et al., 2015). Since VCP 
protein expression showed moderated correlation with GI50 for VCP inhibitors in ovarian cancer 
cell lines, we tested the extent to which VCP knockdown enhances the effect of VCP inhibitors. 
Our results indicate 50% (siVCP-1), 80% (siVCP-2), and 85% (siVCP-1+2) knockdown efficiency 
from three independent transient transfections (Figure 3.2A, 3.2B & 3.3B). Following transient 
knockdown, cells were plated for cell viability studies. Our results show a significant reduction in 
GI50 for DBeQ and ML240 following VCP knockdown (Figure 3.2C-3.2E). Moreover, VCP 
inhibitors display a greater reduction of GI50 with siVCP-2 and siVCP-1+2, consistent with higher 
VCP knockdown efficiencies (Figure 3.2E). These results suggest that VCP is a target of DBeQ 
and ML240. Furthermore, we examined cell growth following transient knockdown of VCP. Our 
results show a significant reduction in cell growth with siVCP-2 and siVCP1+2 (Figure 3.2F). 
These results provided the first functional validation of the previous studies identifying VCP as an 
essential gene in ovarian cancer survival (Cheung et al., 2011; Etemadmoghadam et al., 2013).  
Cellular Thermal Shift Assay (CETSA) has been used as an effective tool to assess the 
binding of compounds to intended cellular targets. The assay analyzes the changes in the in vitro 
thermal stability of candidate cellular proteins by compounds of interest (Jafari et al., 2014). 
Initially, we used different temperatures following the incubation of DBeQ and ML240 for heat 




thermal stability of VCP with different concentrations of DBeQ and ML240 at 57oC. Here, we 
show a shift in the thermal stability of VCP at 57oC following 2-hours incubation of cells with 
DBeQ and ML240 at concentrations ranging between 0.1μM- 5 μM, indicating the target 








 Figure 3.2. DBeQ and ML240 bind to cellular VCP/p97. (A) SKOV3 cells were transfected with 
two different siRNAs targeting VCP (siVCP-1 and siVCP-2), and one non-targeting scrambled 
small interfering RNA. Whole cell lysates following transient transfection were used to visualize 
the knockdown efficiencies by Western blot analysis. (B) Densitometry analysis was performed 
using ImageJ to observe the relative VCP expression following three independent siRNA 
transfections (biological replicates). SKOV3 cells transfected with scramble or VCP siRNAs were 




well format and were allowed to recover under normal media for 6 additional days. Cell viability 
was measured using Sulforhodamine B (SRB) Assay. Dose-response curves were generated using 
GraphPad Prism using four parameters nonlinear regression (curve fit). Curves were constrained 
on top (100%) and bottom (less than 10%). (E) Values represent Mean + SEM GI50 measurements 
following VCP inhibition based on three biological replicates. P-values were calculated based on 
the student’s t-test. (F) Values represent Percent growth ± SEM from three technical replicate 
experiments following transient knockdown of VCP followed by 6 additional days of recovery in 
normal media. (G) SKOV3 cells were treated with DBeQ or ML240 at concentrations between 
0.1-5 µM for 2 hours. Cells were subjected to heat-shock treatment at 57°C. Soluble fractions were 
then subjected to Western blot analyses. (H) Values represent the relative thermal stability of VCP 





























Figure 3.3. VCP protein expression correlates with VCP inhibitor cytotoxicity. (A) Whole cell 
lysates were generated from 12 different ovarian cancer cell lines. 40 μg of total protein from each 
sample was subjected to immunoblotting and probed with antibodies against VCP and β-actin. 
Representative immunoblot from two technical replicates. (B) Representative titration blots from 
Figure 3.2A generated by loading half (5 µL) and twice (20 µl) the volume of total protein loaded 
in Figure 3.2A (10 µL). Graphs represent relative VCP expression following transient knockdown 
of VCP upon loading 5 µL, 10 µL and 20 µL of whole cell lysates. Relative expression was 
measured using ImageJ. Graphs display the correlation between VCP protein expression and mean 











3.2.3 VCP inhibitors cause G1 cell cycle arrest  
Given the well-established role of VCP in the cell cycle (Cao et al., 2003; Zhang et al., 
1999), we performed cell cycle analysis to observe any changes in cell cycle distribution following 
the treatment with VCP inhibitors. We observed an increase in G1 and a decrease in S and G2/M 
phases with 5 μM DBeQ as well as an increase sub G0 phase with 10 μM DBeQ (Figure 3.4A). 
Similarly, we saw a reduction in S phase and an increase in sub G0 phase with ML240 treatment 
(Figure 3.4B). Furthermore, oral VCP inhibitor- CB-5083 treatment increased G1 and reduced S 
phase (Figure 3.4C). These results suggest that VCP inhibitors cause G1 cell cycle arrest followed 
by cell death. Next, we analyzed the expression of several cell cycle regulators that are substrates 
of the ubiquitin proteasome system following the treatment with VCP inhibitors. We observed 
variable accumulation of p21, p27, Cyclin D1, and Cyclin E with DBeQ, ML240, and CB-5083 
treatments (Figure 3.4D). Overall, our results indicate that inhibition of VCP results in increased 





Figure 3.4. Treatment with VCP inhibitors causes G1 arrest. (A-C) Propidium iodide (PI) 
staining was performed on SKOV3 cells treated with DBeQ [5 μM and 10 μM], ML240 [1.25 μM 
and 2.5 μM] and CB-5083 [1.25 μM and 2.5 μM] for 18 hours. Bar graphs represent cells in each 
stage of the cell cycle following VCP inhibitor treatment for 18 hours. (D) SKOV3 cells were 
incubated with DMSO (vehicle), 5 μM DBeQ, 1.25 μM ML240 or 1.25 μM CB-5083 for 10 or 18 
hours. Whole cell lysates were analyzed using Western blot. Representative image from at least 





3.2.4 VCP inhibitors induce cell death via the apoptotic pathway 
Previous studies have shown that DBeQ and ML240 induce the activation of caspases and 
apoptosis in non-ovarian cancer cell lines (Chou et al., 2011; Chou et al., 2013). We, therefore, 
analyzed the extent of apoptosis following the treatment with DBeQ or ML240 in ovarian cancer 
cells using Annexin V staining.  We incubated SKOV3 cells with DBeQ [10 μM] or ML240 [5μM] 
for 6 hours followed by Annexin V and DAPI staining. Our results show a significant increase in 
Annexin V & DAPI positive cells following DBeQ and ML240 treatment (Figure 3.5A). 
Activation of procaspases is one the hallmarks of caspase-mediated apoptotic cell death. Here, we 
used immunoblotting to determine PARP cleavage and activation of initiator caspases as well as 
effector caspases. Our results indicate the PARP cleavage at 6-hour time point with DBeQ [10 
μM] and ML240 [5 μM] treatment, which is consistent with the Annexin V-DAPI staining (Figure 
3.5B). We also observed the cleavage of Caspase 9 and Caspase 8 following the treatment with 
VCP inhibitors. Caspase 9 activation was observed at a much earlier time point (6 hours) while 
caspase 8 activation was observed only at 24 hours following DBeQ and ML240 treatment (Figure 
3.5B). 
The activity of Caspase 3 was determined by the Caspase 3 activity assay. Our result 
indicates a significant increase in Caspase 3 activity with DBeQ [10 μM] and ML240 [5 μM] at 6-
hour time point (Figure 3.5C). We observed a 2.5-fold increase in Caspase 3 activity at 24 hours 
with DBeQ and a 10-fold increase with ML240 (Figure 3.5C). Overall, our results are consistent 
with previous studies indicating caspase-mediated apoptosis by these inhibitors (Chou et al., 2011; 
Chou et al., 2013). Furthermore, we show that ML240 treatment results in a similar mode of cell 








Figure 3.5. Incubation with DBeQ and ML240 induces caspase-mediated apoptosis. (A) 
Annexin-V/DAPI staining was performed following 6 hours of DMSO (vehicle), 10 μM DBeQ or 
5 μM ML240 treatment using SKOV3 cells. (B) OVCAR10 cells were treated with 10 μM DBeQ 
or 5 μM ML240 for 0, 6, 10 and 24 hours. Whole cell lysates were analyzed using Western blot. 
Experiment B was replicated in SKOV3 cell lines. C) OVCAR10 cells were treated with 10 μM 
DBeQ or 5 μM ML240 for 0, 6, 10 and 24 hours. The values indicate fluorescence taken from 
three technical replicates. The caspase activity is represented as fold change of untreated group 









3.2.5 VCP inhibitors trigger the unfolded protein response (UPR) 
Inhibition of VCP can impede the extraction of unfolded proteins from the endoplasmic 
reticulum (ER) and induce the unfolded protein response (UPR) (Sano and Reed, 2013). Unfolded 
protein response is executed via changes in three transmembrane ER proteins: IRE1α, PERK, and 
ATF6α (Oslowski and Urano, 2011). Previous studies have shown activation of the PERK branch 
with DBeQ treatment (Auner et al., 2013; Chou et al., 2011). Recently, CB-5083 treatment has 
been shown to activate all three branches of the unfolded protein response (Anderson et al., 2015). 
We decided to perform a detailed analysis comparing the effects of VCP inhibitors in the unfolded 
protein response pathway. SKOV3 cells were treated with DBeQ [10 μM], ML240 [5 μM] and 
CB-5083 [2.5 μM] up to 48 hours. Tunicamycin [2 μM], an inhibitor of N-acetylglucosamine 
transferase, was used as a positive control to observe the activation of the unfolded protein 
response. Our results indicate an increase in phospho-IRE1α by 3 hours with VCP inhibitors 
marking the activation of the IRE1α branch (Figure 3.6A-3.6C).  We also observed an increase in 
the expression of CHOP and ATF4 between 3-12 hours marking the activation of the PERK branch 
(Figure 3.6A & 3.6C). We were unable to determine the status of the ATF6α. This lack of 
immunoreactivity may be due to the low basal expression of ATF6α in SKOV3 cells. Tunicamycin 
treatment showed a similar increase in the expression of phospho-IRE1α, CHOP, and ATF4 
(Figure 3.6D). Phosphorylation of PERK upon ER stress results in the phosphorylation of eIF2α 
at serine 51, which has been shown to decrease cap-dependent protein translation (Harding et al., 
1999). The decrease in cap-dependent protein translation reduces the protein load and allow cells 
to resolve ER stress (Rutkowski and Kaufman, 2004). To observe changes in cap-dependent 
protein translation, we treated SKOV3 cells with different concentrations of DBeQ and ML240 up 
to 10 μM for 5.5 hours and pulsed the cells with 1 μM puromycin for 30 minutes. Incorporated 




in puromycin incorporation following the treatment with VCP inhibitors (Figure 3.6E). 
Collectively, these results suggest that VCP inhibitors trigger the unfolded protein response 
through IRE1α and PERK. Similarly, increased PERK phosphorylation and poly-ubiquitination of 
proteins following CB-5083 treatment have been reported (Anderson et al., 2015). In line with 
CB-5083, treatment with DBeQ and ML240 showed enhanced accumulation of poly-ubiquitinated 





Figure 3.6. Incubation with VCP inhibitors results in the activation of unfolded protein 
response (UPR). SKOV3 cells were incubated with (A) 10 μM DBeQ, (B) 5 μM ML240, (C) 2.5 
μM CB-5083 and (D) 2 μM Tunicamycin (positive control) for 0, 1, 3, 6, 12, 24 and 48 hours. 




response related proteins. (E) SKOV3 cells were treated with different concentrations of DBeQ or 
ML240 for 6 hours and pulsed with puromycin for 30 mins. Whole cell lysates were analyzed for 
incorporated puromycin by Western blot. The results for both DBeQ and ML240 were obtained 
from the same blot that was later spliced together to remove the molecular weight marker. DMSO 
(0 µM) sample served as the control for both drugs. Same results were replicated using OVCAR10 






Figure 3.7. Incubation with VCP inhibitors display increased poly-ubiquitination. OVCAR10 
cells were incubated with (A) DBeQ [10 μM] and (B) ML240 [5 μM] for 0, 6, 10 and 24 hours. 
Whole cell lysates were subjected to Western blot analysis with antibodies against ubiquitin, while 









3.2.6 VCP inhibitors synergize with salubrinal 
Endoplasmic reticulum stress (ER stress) response is an adaptive, pro-survival mechanism; 
however, prolonged ER stress activates pro-apoptotic genes that contribute to cell death (Oslowski 
and Urano, 2011). ER stress induces CHOP expression through PERK-mediated pathway (Harding 
et al., 2000), and CHOP induces the expression of pro-apoptotic gene (PUMA and DR5) and 
decreases the expression of anti-apoptotic gene (BCL2) (Cazanave et al., 2010; Ghosh et al., 2012; 
McCullough et al., 2001; Yamaguchi and Wang, 2004). Therefore, we reasoned that VCP 
inhibitors might act synergistically with compounds that induce CHOP expression. Salubrinal, a 
selective inhibitor of eIF2α dephosphorylation, was first identified as a compound that reduced ER 
stress-induced apoptosis (Boyce et al., 2005). Since then, subsequent studies have shown that 
salubrinal enhances cell death via the induction of CHOP expression (Koizumi et al., 2012; Teng 
et al., 2014). To assess the potential synergistic effect between VCP inhibitors and Salubrinal, we 
investigated four high-grade serous ovarian cancer cell types namely; OVCAR10, OVCAR5, 
OVCAR8 and OVSAHO and two clear cell serous ovarian cancer cell types namely; RMG1 and 
SKOV3. These cells were treated with different concentrations of VCP inhibitors (DBeQ, ML240, 
and CB-5083) and Salubrinal for 72 hours. For this study, we used varying concentrations below 
the GI50 for DBeQ, ML240, and Salubrinal. For CB-5083, we used different concentrations all 
below the pharmacologically achievable dose (Anderson et al., 2015). Our results show synergistic 
effects between DBeQ and Salubrinal as well as CB-5083 and Salubrinal in all the tested ovarian 
cancer cell lines (Figure 3.9A-3.9B). Similar effects were observed with ML240 and Salubrinal 










Figure 3.8. GADD34 inhibition sensitizes ovarian cancer cells towards VCP inhibitors. (A) Two 
high-grade serous cell ovarian cancer cell lines, OVCAR8 and OVSAHO, were incubated with 
different combinations of ML240 and Salubrinal. The error bars display 95% confidence interval 
of the mean combination index (CI) for the combinations resulting in inhibition of growth between 
20-80% from two biological replicate experiments. CI values less than 1 indicate synergy while 
values equal to or more than 1 represent additive and antagonistic effect respectively. (B) 
OVSAHO cells were transfected with siRNA targeting GADD34. Whole cell lysates were 
collected 48 hours post-transfection and subjected to immunoblotting in order to analyze the 
knockdown efficiency of GADD34 siRNA. (C) Scrambled and GADD34 siRNA knockdown 
OVSAHO cells were subjected to 5 μM DBeQ treatment for 48 hours. The values indicate 
fluorescence taken from two technical replicate. The caspase activity is represented in terms of 
fold change and plotted as Mean + SEM.  P-value is calculated based on the student’s t-test. ‘a’ = 
P-value between scrambled and GADD34 knockdown cells in DMSO treatment, ‘b’ = P-value 
between scrambled and GADD34 knockdown cells in 5 μM DBeQ treatment, ‘c’ = P-value 








Next, we analyzed the short-term effect of VCP inhibitors in combination with Salubrinal. 
We treated OVSAHO cells with vehicle (DMSO), DBeQ, CB-5083 as well as combinations 
DBeQ+Salubrinal and CB-5083+Salubrinal. After treatments, cell death was analyzed using 
Annexin V/PI assay. With 8 hours of treatment, we observed a mean cell death of 45.56 % with 
DBeQ and 55.23% with DBeQ+Salubrinal (Figure 3.9C). At the same time point, we only 
observed a modest increase in cell death with CB-5083 as well as the CB-5083+Salubrinal 
treatment (Figure 3.9C). Hence, we decided to evaluate cell death with 8 hours of treatment 
followed by 16 hours in regular media. At 8+16 hours, our results indicate only a slight increase 
in cell death following Salubrinal treatment alone, while DBeQ, CB-5083 as well as their 
combinations with Salubrinal all resulted in a significant increase in cell death (Figure 3.9D). 
Together, our results indicate increased cytotoxicity with long-term (72 hours) as well as short-
term (8 hours and 8+16 hours) treatment following the combination of VCP inhibitors and 
Salubrinal.  
To further validate the results from the synergistic and cell death studies, we performed 
clonogenic assays in two high-grade serous ovarian cancer cell lines: OVCAR10 and OVSAHO. 
Clonogenic assays show a significant reduction in colony formation with the combination of DBeQ 
and Salubrinal as well as CB-5083 and Salubrinal further strengthening the combinational effect 
achieved with VCP inhibitors and Salubrinal (Figure 3.10A-3.10D). Furthermore, siRNA-
mediated knockdown of GADD34 in OVSAHO cells resulted in enhanced caspase-3 activation. 
We observed a significant increase in caspase 3 activity only in GADD34 knockdown cells 
following DBeQ treatment (Figure 3.8B-3.8C). Overall, our results provide an in vitro proof-of-
principle that inhibiting GADD34 in ovarian cancer could be one of the therapeutic strategies when 





Figure 3.9. VCP inhibitors synergize with Salubrinal. Several high-grade serous ovarian cancer 
cell types namely; OVCAR10, OVCAR5, OVSAHO, and OVCAR8 as well as clear cell ovarian 
cancer cell types; SKOV3 and RMG1 were treated with different combinations of (A) DBeQ plus 
salubrinal and (B) CB-5083 plus salubrinal for 72 hours in 96 well format. The error bars in the 
figures represent 95% confidence interval of the mean combination index (CI) from 3 biological 
replicates with several combinations of drugs that resulted in growth inhibition between 20-80%. 
N represents the total number of CIs determined from 16 drug combinations in duplicates that 
produced 20-80% effect from three independent experiments. CI values less than 1 indicate 
synergy while values equal to or more than 1 represent additive and antagonistic effect 
respectively. OVSAHO cells were incubated with DBeQ [15 μM], CB-5083 [5 μM], salubrinal 
[20 μM] and combinations for (C) 8 hours and (D) 8 hours with drug followed by 16 hours in 
regular media. Cells were then subjected to Annexin V/PI staining and percent cell death was 
calculated by adding the cells in Q1, Q2 and Q4 quadrants following flow cytometry. Mean percent 
death ± SEM were plotted using GraphPad Prism from three biological replicate experiments and 
p-values were calculated using the student’s t-test. Symbols ‘*’ and ‘**’ signify p-values less than 








Figure 3.10. VCP inhibitors and salubrinal combination diminishes clonogenic survival. 
Representative clonogenic assay performed in OVCAR10 and OVSAHO cell lines with (A) 
vehicle (DMSO), DBeQ, salubrinal, a combination of DBeQ plus salubrinal and (C) vehicle 
(DMSO), CB-5083, salubrinal, a combination of CB-5083 plus salubrinal treated for 48 hours in 
6-well plates. (B&D) Percent survival based on the number of colonies formed from 3 biological 
replicates. Combination Indexes (CIs) were calculated using the mean number of colonies formed 
from three biological replicates. P-values were calculated using the student’s t-test. 
 
3.2.7 The combination of VCP inhibitors and salubrinal results in enhanced 
unfolded protein response 
To further dissect the mechanism behind the synergistic effect observed with DBeQ and 
Salubrinal, we treated OVCAR10 cells with a sub-lethal dose of DBeQ [3 μM], a sub-lethal dose 
of Salubrinal [20 μM] and the combination of DBeQ and Salubrinal up to 48 hours. Increased 
expression of ATF4 and CHOP was observed within 3-6 hours in all three treatment conditions 
(Figure 3.11A-3.11C). We observed decreased Grp78 expression by 24 hours with DBeQ and 
Salubrinal alone which indicate a decrease in the endoplasmic reticulum stress response (Figure 
3.11A-3.11B). However, an enhanced expression of Grp78 was observed with the combination at 
24 hours indicating an increase in the endoplasmic reticulum stress response (Figure 3.11C). We 
also observed activation of caspase 3 (cleaved form) at 48 hours with DBeQ and Salubrinal 
combination suggesting that increased endoplasmic reticulum stress response triggered apoptosis 
(Figure 3.11C). Similarly, when lysates from different treatment conditions were analyzed, we saw 
enhanced CHOP expression with DBeQ and Salubrinal combination (Figure 3.11D). Taken 
together, these data suggest that GADD34 inhibition enhances the endoplasmic reticulum stress 
response induced by VCP inhibitors resulting in enhanced CHOP expression that triggers 









Figure 3.11. Enhanced unfolded protein response following DBeQ and Salubrinal combination 
results in caspase-mediated apoptosis. OVCAR10 cells were incubated with (A) sub-lethal dose 
of DBeQ [3 μM], (B) sub-lethal dose of salubrinal [20 μM], (C) Combination of DBeQ [3 μM] 
and salubrinal [20 μM] for 1, 3, 6, 12, 24, and 48 hours. Whole cell lysates were subjected to 
Western blot analysis and probed with the above antibodies, (D) OVCAR10 cells were treated 
with DBeQ [3 μM], Salubrinal [20 μM] and combination for 6 hours and 24 hours. Whole cell 
lysates were then subjected to immunoblotting and probed with antibodies against CHOP. β-Actin 










3.2.8 Lower VCP expression in ovarian cancer is associated with poor outcome 
in patients with ovarian cancer  
Since elevated expression of VCP is associated with poor prognosis in various cancer types 
(Tsujimoto et al., 2004b; Yamamoto et al., 2004; Yamamoto et al., 2003), we determined the 
association between VCP expression and clinical outcome in patients with ovarian cancer.  
Surprisingly, Kaplan-Meier analyses of 1648 ovarian tumor samples, provided by the online 
Kaplan-Meier (KM) plotter (Gyorffy et al., 2012), indicate that lower expression of VCP is 
associated with shorter progression-free survival (PFS) and overall survival (OS) in ovarian cancer 
(Figure 3.12A and 3.12B). To further understand this puzzling clinical outcome association, we 
analyzed the ovarian carcinoma RNA-sequencing datasets from the cancer genome atlas (Cancer 
Genome Atlas Research Network, 2011).  We compared VCP gene expression in tumor samples 
collected from high-grade serous ovarian cancer patients that were either sensitive or resistant to 
the platinum-based chemotherapy. Our results show a significant reduction of VCP expression in 
tumor samples that were collected from patients with resistance to chemotherapy (p-value 
=0.01532) (Figure 3.12C). Taken together, these results indicate that ovarian carcinomas with 
lower expression of VCP are associated with poor response to platinum-based chemotherapy, poor 
progression-free survival, and poor overall survival. Although these results are in contrast to 
previously reported studies in other cancer types, the result is highly relevant to ovarian cancer 
because our results point to the clinical potential of using VCP inhibitors in the setting of platinum 
resistance given that these tumors have lower levels of VCP expression and are likely more 





Figure 3.12. Association between VCP expression and clinical outcome. (A) Lower expression 
of VCP in ovarian carcinomas is associated with early disease recurrence (progression-free 
survival). (B) Lower expression of VCP in ovarian carcinomas is associated with poor overall 
survival. (C) RNA sequencing dataset representing high-grade serous ovarian cancer patient 
samples that are sensitive (n=55) and resistant (n=95) to established chemotherapy was 
downloaded from the TCGA Research Network Data Portal. VCP gene expression between the 
two datasets was compared using violin plot. p-value = 0.01532, Welch’s two-sample t-test. 
 
3.3. Discussion 
In this chapter, we provided evidence that ovarian cancer cells are sensitive to VCP 
inhibitors. In particular, cells with lower levels of cellular VCP are more sensitive to the inhibitors. 
These results are consistent with prior studies indicating a strong inverse correlation between VCP 
expression and sensitivity to VCP inhibitors (Anderson et al., 2015).  In addition, we provided 
evidence that VCP inhibitors interact with VCP and confer thermal stability to VCP. Collectively, 
these results demonstrate drug-target interactions and further support the view that lower levels of 
cellular VCP require a lower amount of compounds to inhibit the activity, and that on-target 
inhibition of VCP by these agents contributes to cytotoxicity. These results are potentially 
significant given that VCP expression is significantly lower in high-grade serous carcinomas 




To define the molecular mechanisms associated with cytotoxicity induced by VCP 
inhibitors, we determined the proportion of cells in different phases of cell cycle following drug 
treatment.  We observed that VCP inhibitors induced G1 arrest, as evident by a decrease in S-
phase proportion following 18 hours of drug treatment.  Subsequent to G1 arrest, we observed an 
increase in sub-G0 population and a concomitant decrease in G1 population, suggesting that these 
compounds induce cell death in the G1 population. VCP has been shown to be involved in 
ubiquitin-mediated degradation of cell cycle regulator Cyclin E (Dai and Li, 2001). We showed 
that treatment with VCP inhibitors resulted in the accumulation of Cyclin E, Cyclin D1, p21, and 
p27. Since we used a p53 null cell line, the accumulation of p21 was independent of p53. We 
observed activation of caspase-8 and caspase-9, and increased the activity of caspase-3, indicating 
that both extrinsic and intrinsic apoptotic pathways are activated by VCP inhibitors.  These results 
are consistent with a recent report indicating that VCP inhibitor, CB-5083, induces cell death via 
DR5- and CHOP-dependent pathway (Anderson et al., 2015). 
ML240 has been shown to bind selectively to the D2 domain and inhibit the D2-ATPase 
activity of VCP; while DBeQ inhibits the activity in both D1 and D2 domains (Chou et al., 2014). 
Similarly, CB-5083 which was derived from the scaffold of ML240 is a specific inhibitor of the 
D2 domain of VCP (Zhou et al., 2015). Our results indicate that inhibition of D2-ATPase is 
sufficient to cause the cytotoxic effect in ovarian cancer cells. In addition, specific inhibition of 
D2-ATPase domain of VCP with ML240 may be attributed to the lower GI50 values across all the 
tested cell lines. 
In addition, we provided evidence that VCP inhibitors can be combined with agents that 
modify endoplasmic reticulum stress (ER stress) to enhance cytotoxic activities of VCP inhibitors 




that cytotoxicity of VCP inhibitors can be enhanced by Salubrinal, a GADD34 inhibitor that 
prolongs the phosphorylation of eIF2α.  Although the transient phosphorylation of eIF2α is a 
critical adaptive response to endoplasmic reticulum stress (ER stress), resulting in a decrease in 
cap-dependent translation to lower protein load, sustained phosphorylation of eIF2α, in the 
presence of upstream ER stress, could induce CHOP and CHOP-dependent apoptosis (Marciniak 
et al., 2004). Consistent with this hypothesis, we observed drug synergies between VCP inhibitors 
and salubrinal. It is important to note that recent studies by Parzych et al. reported that Guanabenz, 
a GADD34 inhibitor, decreases cell death induced by DBeQ (Parzych et al., 2015). In our studies, 
we found that salubrinal, another GADD34 inhibitor, enhances the effect of DBeQ and CB-5083 
in several ovarian cancer cell lines. Unlike Parzych et al. studies which determined the cytotoxic 
effect at 8 hours of treatment with one combined dose, our studies determined both the short-term 
and the long-term effect of the several combined doses for VCP inhibitors and Salubrinal. We 
observed synergistic activities of the combined drugs across several concentrations in both short-
term and long-term assays in several ovarian cancer cell lines. Therefore, the differences in the 
outcome of these two studies may be attributable to the differences in cell models, the exposure 












Figure 3.13. Proposed mechanism of action with the combination of VCP inhibitors and 
Salubrinal.  DBeQ, ML240, and CB-5083 induce ER stress and activate PERK pathway.  In the 
presence of upstream ER stress, activated by VCP inhibitors, PERK phosphorylates eIF2α and 
attenuates cap-dependent translation, which lower protein load to restore protein homeostasis. 
However, the presence of sustained ER stress (either by continuous exposure to ER stress 
activating agents) or unresolved ER stress (due to inhibition of GADD34 by salubrinal) can 






Prolonged endoplasmic reticulum stress (ER stress) and subsequent cell death is an 
important mechanism of action of drugs that target the ubiquitin-proteasome system. Bortezomib 
was the first compound successful in targeting the ubiquitin proteasome system in clinical settings; 
however, it has not been very effective against solid tumors (Huang et al., 2014). The failure to 
elicit similar effect has been attributed to the lack of prolonged suppression of proteasome in vivo 
in solid tumor (Deshaies, 2014). VCP inhibitors provide an exciting avenue for the development 
of novel chemotherapy in all tumors with enhanced unfolded protein load. In addition, identifying 
compounds that prolong the ER stress and enhance the cytotoxic effect of VCP inhibitors may be 
useful as a combination treatment strategy in solid tumors. Our results provide a proof-of-principle 
that VCP inhibitors and the ER stress pathways could be targeted in combination with the ER 
stress-prolonging agent Salubrinal for enhanced cytotoxicity. 
Recently, several groups have identified the pathway involved in protein homeostasis as a 
target of vulnerability in ovarian cancer. For example, Cheung et al. used 102 cancer cell lines and 
performed genome-scale synthetic lethal screen with short hairpin RNAs (shRNAs) (Cheung et 
al., 2011). In this study, VCP was identified as one of the 22 putative essential genes in ovarian 
cancer cells. In addition, in their follow-up studies, Hahn and Bowtell groups identified VCP as 
one of the essential genes in Cyclin E1-overexpressing, cisplatin-resistant ovarian cancer cells 
(Etemadmoghadam et al., 2013).  Finally, Marcotte & Brown et al. identified several components 
of protein homeostasis, such as SNRPD-1, PSMD1, PSMA1, PSMB2, RPS17, and EIF3B, as 
essential genes in several cancer cell lines (Marcotte et al., 2012).  Therefore, results from our 
study indicating that VCP/p97, a component of protein homeostasis, can be targeted by DBeQ, 
ML240, and CB-5083 and that these agents induce ER stress and apoptosis in ovarian cancer cells 




Given that pharmacodynamics and pharmacokinetics of CB-5083, which is orally 
bioavailable, are already demonstrated, and that CB-5083 is well-tolerated in mice, it would be 
important to further develop this agent for additional preclinical and clinical studies.  In addition, 
since VCP inhibitors induce ER stress, attenuate protein translation, increase ubiquitylation of 
proteins, it would be important to determine the similarity and differences in the mechanism of 
cell death induced by these agents compared to proteasome inhibitors, such as bortezomib.  In 
particular, bortezomib and heat-shock protein 90 (Hsp90) inhibitors also cause proteotoxic stress, 
and their mechanisms of action include lowering BRCA1 expression and enhancing sensitivity to 
PARP inhibitors and cisplatin (Johnson et al., 2013; Neri et al., 2011; Stecklein et al., 2012). 
Therefore, it would be important to determine the extent to which VCP inhibitors enhances 



















Chapter 4: Atypical activation of the unfolded protein response by 





















Ovarian Cancer is the most lethal gynecological malignancy accounting for approximately 
14,080 deaths in 2017. Currently, the standard treatment regimen includes surgical debulking 
followed by a taxane and platinum combination chemotherapy.  The combination treatment 
regimen shows 70%-80% initial response rate (Berkenblit and Cannistra, 2005). However, upon 
completion of chemotherapy, half of the patients with advanced disease will experience relapse 
within 18-22 months of remission (Armstrong, 2002). Only a small fraction of patients with 
advanced disease (10-15%) achieved long-term remission with the standard chemotherapy 
(Armstrong, 2002). The primary cause of relapse and eventual treatment failure is the preexisting 
intratumor heterogeneity and cellular phenotypic plasticity driven by genetic and epigenetic 
alterations (Lambrechts et al., 2016). The preexisting tumor heterogeneity and plasticity at the time 
of treatment afford some cancer cells with proper adaptive response to chemotherapy to persist 
during the treatment, and these cells contribute to disease recurrence. In fact, the majority of 
patients who achieved a complete clinical response to the first-line chemotherapy will show 
residual disease on second-look laparotomy or will eventually relapse due to persistent disease 
(Armstrong, 2002).  
 After multiple rounds of chemotherapy, persistent tumor clones will expand and acquire 
additional genetic alterations that contribute to the acquired resistance. Therefore, it is critical to 
identify novel therapeutic targets and agents to treat this disease. Recently, several targeted 
therapies gained FDA approval in ovarian cancer. An open-labeled Phase III trial (AURELIA) 
evaluated the efficacy of adding bevacizumab (anti-vascular endothelial growth factor antibody) 
to chemotherapy in platinum-resistant ovarian cancer patients. The trial reported a significant 




with chemotherapy plus bevacizumab) and a non-significant increase in overall survival (13.3 
months with chemotherapy versus 16.6 months with chemotherapy plus bevacizumab) (Husain et 
al., 2016; Pujade-Lauraine et al., 2014). Similarly, a randomized Phase III clinical trial (SOLO2), 
performed on platinum-sensitive relapsed patients with Breast Cancer 1, Early Onset (BRCA1) or 
Breast Cancer 2, Early Onset (BRCA2) mutation, analyzed the efficacy of single-agent olaparib 
(PARP inhibitor) versus placebo. The study reported median progression-free survival of 5.5 
months for placebo versus 19.1 months for olaparib treatment in these women (Ledermann et al., 
2014). These trials including other clinical trials (Ledermann, 2016; Mirza et al., 2016) paved the 
way for the FDA approval of bevacizumab and three PARP inhibitors, namely olaparib, rucaparib, 
and niraparib for the treatment of ovarian cancer. The clinical successes of these targeted therapies 
outline the relevance of developing novel therapeutic approaches in ovarian cancer.  
Several studies have attempted to identify novel therapeutic targets and pathways in 
ovarian cancer. Marcotte et al. (2012) performed a genome-wide synthetic lethal screen with short 
hairpin RNAs (shRNAs) in 72 cancer cell lines, including 15 ovarian cancer cell lines. The study 
identified genes targeting the ubiquitin proteasome system- proteasome subunit alpha 1 (PSMA1) 
and proteasome subunit beta 2 (PSMB2) to be synthetically lethal (Marcotte et al., 2012). 
Similarly, Cheung et al. (2011) performed a separate genome-wide short hairpin RNA screening 
in 102 cell lines, including 25 ovarian cancer cell lines that identified valosin-containing protein 
(VCP/p97), an important component of protein quality control, as one of the 22 putative genes 
essential in ovarian cancer cells (Cheung et al., 2011).  Another study identified VCP to be 
essential in lineage-specific cyclin E1 (CCNE1) amplified ovarian cancer (Etemadmoghadam et 




Protein quality control includes adaptive pathways such as the unfolded protein response 
(UPR) and the chaperone activity of heat shock proteins (HSPs) that aid in the folding of misfolded 
and unfolded proteins. Additionally, protein quality control incorporates degradative pathways 
such as the ubiquitin proteasome system and autophagy that degrade unwanted or misfolded 
proteins into small peptides or individual amino acids. Oncogenic insults such as increased 
mutational burden, copy number alterations, chromosomal duplications/deletions and oncogene-
induced oxidative stress manifest a higher burden in protein quality control, making cancer cells 
more reliant on these mechanisms for survival and proliferation, a phenomenon known as non-
oncogenic addiction. Because cancer cells are addicted to or highly reliant on the protein quality 
control pathways, it is therefore imperative that targeting components of the protein quality control 
would be beneficial in cancer therapeutics. This idea led to the development of agents that target 
elements of the protein quality control mechanism for cancer therapy such as bortezomib and 
carfilzomib (Chen et al., 2011; Kuhn et al., 2007). Targeting protein quality control mechanisms 
can be extended further in designing effective drug combinations. Restorative and destructive 
components of the protein quality control pathway could be selectively modulated to elevate the 
cytotoxic effect mediated by a single agent. An example of targeting the restorative component of 
the protein quality control pathway includes heat-shock protein 90 (Hsp90) inhibitors. 
Interestingly, Hsp90 serves as a capacitor of phenotypic variations and morphologic evolution, 
determines the adaptive properties of genetic variations, and therefore affect the evolution of 
genomes (Queitsch et al., 2002; Rutherford and Lindquist, 1998). Similarly, Hsp90 expression in 
cancer cells is expected to modify the adaptive properties of somatic genetic variations and 
facilitates the evolution of cancer genomes. Therefore, targeting components of protein quality 




evolution of cancer genomes. In this chapter, I set out to explore the possibility of targeting 
multiple components of protein quality control with clinical drug candidates.    
In Chapter 3, we have shown that quinazoline-based VCP inhibitors, such as DBeQ and 
ML240, produce dose-dependent cytotoxicity (Figure 3.1A-3.1C). Although these compounds are 
specific and potent VCP inhibitors, they lacked proper pharmacological properties. Using the 
pharmacophore from ML240, Anderson et al. (2015) identified an oral VCP inhibitor, CB-5083. 
The study reported enhanced biochemical inhibition towards VCP, increased in vitro cytotoxicity 
in several cancer types as well as pronounced in vivo efficacy in multiple mouse tumor xenograft 
models with CB-5083 (Anderson et al., 2015). The results prompted the initiation of two first-in-
class Phase I clinical trials of CB-5083 in hematological cancers and solid tumors. In our current 
study, we investigated the in vitro efficacy of CB-5083 in ovarian cancer and identified new 
strategies to enhance the cytotoxic effect of VCP inhibitors.    
To enhance the cytotoxic effect of VCP inhibitors, we decided to focus on compounds that 
modulate the unfolded protein response. Several inhibitors have been identified over the years that 
regulate specific branches of the unfolded protein response (discussed in Section 1.3.1) (Atkins et 
al., 2013; Papandreou et al., 2011; Ri et al., 2012). However, none of these compounds has gained 
FDA approval. Mifepristone (RU-486) is an FDA-approved oral progesterone receptor antagonist, 
and it has been used in the clinic for ending early term pregnancy. Over the years, several 
additionally targets for mifepristone have been identified including the glucocorticoid receptor 
(Baulieu, 1989) and the nuclear receptor subfamily 1 (Kretschmer and Baldwin, 2005). Multiple 
studies have focused on the anti-cancer effect of mifepristone in meningioma (Grunberg et al., 
2006), triple negative breast cancer (Liu et al., 2016) and ovarian cancer (Goyeneche et al., 2007). 




induces the unfolded protein response (Dioufa et al., 2010; Goyeneche et al., 2007; Zhang et al., 
2016). However, the mechanism resulting in the induction of the unfolded protein response is 
unknown. Here, we show that a clinically achievable dose of mifepristone is synergistic with VCP 
inhibition in ovarian cancer cells. Furthermore, we report that mifepristone treatment inhibits the 
activating transcription factor 6 (ATF6) branch of the unfolded protein response and activates the 
activating transcription factor 4 (ATF4) through activation of the heme-regulated inhibitor (HRI) 
kinase pathway. Our results identify a plausible mechanism of the unfolded protein response with 
mifepristone and establish a clinically relevant drug combination based on targeting protein quality 
control. 
4.2. Results  
4.2.1 CB-5083 treatment induces cytotoxicity in ovarian cancer cells  
We previously observed the dose-dependent cytotoxic effect of VCP inhibitors DBeQ and 
ML240 in a panel of ovarian cancer cell lines (Figure 3.1A-3.1C). However, the cytotoxic effect 
of the oral VCP inhibitor CB-5083 in these cells was unknown. Therefore, we performed the 
sulforhodamine B (SRB) assay to analyze cell viability following the treatment with incremental 
doses of CB-5083 up to 25 μM for 72 hours in high-grade serous ovarian cancer cell lines 
OVCAR10, OVCAR8, OVSAHO, and OVCAR5 as well as in clear cell ovarian cancer cell lines 
RMG1 and SKOV3. Consistent with other compounds in its class, CB-5083 treatment showed a 
dose-dependent cytotoxicity (Figure 4.1A- 4.1F) with half-maximal growth inhibition (GI50) 
ranging from 0.46±0.07 μM to 0.94±0.23 μM (Figure 4.1G). These GI50 values are comparable to 
previously reported half-maximal growth inhibition values in the lung carcinoma cell line A459 
and the colon carcinoma cell line HCT116 (Anderson et al., 2015). Our results suggest that CB-








Figure 4.1. CB-5083 treatment is cytotoxic in ovarian cancer cell lines. (A-F) Ovarian cancer 
cells lines, namely, OVCAR5, OVSAHO, OVCAR10, OVCAR8, SKOV3, and RMG1 were 
treated with increasing doses of CB-5083 ranging from 0.1 µM to 25 µM for 72 hours. Dose-
response curves were generated using GraphPad Prism based on the four parameters nonlinear 
regression. The curves were constrained at the top (100%) and the bottom (>0%). Every point in 
the dose-response curve represents Mean ± SEM taken from three technical replicates for all cell 
lines. (G) The bar graph represents Mean GI50 + SEM taken from four biological replicates in all 





4.2.2 VCP inhibitors show synergistic cytotoxicity with clinically achievable 
doses of mifepristone  
Treatment with VCP inhibitors results in the induction of the unfolded protein response-
mediated apoptosis (Anderson et al., 2015). Hence, we attempted to identify compounds that could 
produce synergistic cytotoxic effects with VCP inhibitors so that these compounds could be 
considered as potential clinical candidates for combination therapy with VCP inhibitors. In 
Chapter 3, we reported that inhibition of Growth Arrest and DNA Damage-inducible 34 
(GADD34) by salubrinal results in synergistic cytotoxicity with VCP inhibitors, including CB-
5083, in several ovarian cancer cell lines. Although the demonstration of synergy between VCP 
inhibitors and salubrinal provided proof-of-concept that multiple agents inhibiting the protein 
quality control pathway can be combined to achieve synergy, the clinical relevance is not 
prominent because salubrinal is not a clinical candidate. Several studies have now indicated that 
treatment with mifepristone (RU-486), an anti-progesterone receptor inhibitor, results in the 
induction of the unfolded protein response (Dioufa et al., 2010; Zhang et al., 2016); however, the 
molecular mechanism contributing to the unfolded protein response by mifepristone is not well 
characterized. Given that mifepristone is an FDA-approved drug, we decided to test the potential 
synergistic cytotoxicity between CB-5083 and mifepristone and to investigate the molecular 
mechanisms contributing to a potential synergy.  
We performed sulforhodamine B (SRB) assays in the panel of ovarian cancer cell lines 
tested in Figure 4.1 with clinically achievable concentrations of CB-5083 (0.1 μM - 1 μM) and 
mifepristone (5 μM - 20 μM). Our results indicate that most cell lines show a synergistic effect 
between these two compounds (Figure 4.2A). The synergistic effects were also observed when 
CB-5083 was substituted with other VCP inhibitors DBeQ and NMS-873 suggesting that 




4.2C). RMG1 cells showed the strongest synergistic effects among the cell lines we tested, hence 
we used this cell line for subsequent studies to investigate the molecular mechanisms contributing 




Figure 4.2. Mifepristone produces synergistic cytotoxicity with VCP inhibitors. A) High-grade 
serous ovarian cancer cell lines OVCAR10, OVCAR5, OVCAR8, and OVSAHO as well as clear 
cell ovarian cancer cell lines RMG1 and SKOV3 were treated with different combinations of 




were calculated at all such combinations that yielded an effect between 20-80%. Each data point 
is shown as the mean CI of all calculated combinations and 95% confidence interval. “n” represents 
a total number of CIs calculated from the combinations that produced the combined effect of 20-
80% from three biological replicates. Mean combination index (CI) less than 1 indicates synergy. 
B) Same as A, but treated with different combinations of mifepristone (between 5-20 µM) and 
DBeQ (between 1-7.5 µM). C) Same as A, but treated with different combinations of mifepristone 
(between 5-20 µM) and NMS-873 (between 1-2.5 µM). (D) For the colony formation assay, 
RMG1 cells were treated with the indicated concentrations of CB-5083 and mifepristone for 48 
hours followed by 6-8 days of recovery in regular media. Mean percent survival ± SEM was 
calculated based on a number of colonies from three biological replicates. (E) Similarly, OVSAHO 
cells treated with indicated concentrations of DBeQ and mifepristone for 48 hours followed by 6-
8 days of recovery in regular media. Percent survival was calculated based on the number of 
colonies from three biological replicates. P values were calculated using the two-tailed student’s 
t-test.  
 
To further corroborate our synergistic studies, we performed colony formation assays in 
RMG1 cells treated with vehicle (DMSO), CB-5083, mifepristone, or the combination of CB-5083 
and mifepristone. Our results indicate that single-agent treatment with 0.5 μM CB-5083 or 20 μM 
mifepristone only shows a modest reduction in colony formation, while the combined treatment 
significantly suppresses colony formation (Figure 4.2D). Similar results were observed with 0.75 
μM CB-5083 and 20 μM mifepristone (Figure 4.2D) as well as with the combination of DBeQ and 
mifepristone (Figure 4.2E). To understand the potential mechanism of cell death with CB-5083 
and mifepristone, we treated RMG1 with vehicle (DMSO), single agents CB-5083 or mifepristone, 
or the combination of CB-5083 and mifepristone for 12 hours or 24 hours. We observed a reduction 
in full-length PARP and total caspase 3 starting at 12 hours as well as a robust induction of cleaved 
caspase 3 at 24 hours (Figure 4.3A). Similarly, caspase activity assays showed a threefold increase 
in activity at 18 hours with the combination of CB-5083 and mifepristone (Figure 4.3C). These 
results indicate that the combination is significantly more effective in inducing caspase-mediated 




Given that both CB-5083 and mifepristone have been shown to induce the unfolded protein 
response, we decided to check two prominent unfolded protein response markers, namely glucose-
regulated protein 78 (Grp78) and C/EBP homologous protein (CHOP) and a marker of proteasome 
inhibition poly-ubiquitinated proteins. We expected the combination to show an increase of both 
unfolded protein response markers and poly-ubiquitin. We observed a robust induction of both 
Grp78 and CHOP in cells treated with the combination or CB-5083 alone but not in cells treated 
with mifepristone alone (Figure 4.3A-4.3B). Moreover, we observed cleaved caspase 3 in cells 
treated with the combination but not in cells treated with a single agent. Consistent with previous 
studies, we observed the increase in poly-ubiquitinated proteins following CB-5083 treatment 
(Anderson et al., 2015). At the tested concentration, mifepristone by itself did not affect the levels 
of poly-ubiquitinated proteins but attenuated the levels of poly-ubiquitinated proteins induced by 
CB-5083. Therefore, we concluded that mifepristone modulates the unfolded protein response, but 















Figure 4.3. CB-5083 and mifepristone combination results in apoptosis. (A) RMG1 cells were 
incubated with vehicle (DMSO), CB-5083 (1 µM), mifepristone (20 µM) and combination (CB-
5083 and mifepristone). Cells were harvested at 12 and 24 hours. Whole cell lysates were subjected 
to immunoblots and probed with the indicated antibodies. (B) Whole cell lysates were collected 
after 18 hours of treatment, subjected to immunoblot, and probed with the indicated antibodies. 
(C) 20 μg of total protein from each sample was subjected to caspase activity assay. The bar graph 
represents relative activity at each condition relative to vehicle (DMSO) treatment from two 
biological replicates. P values were calculated using the two-tailed student t-test. Similar results 





4.2.3 Mifepristone treatment shows atypical modulation of the unfolded protein 
response  
To investigate the effect of mifepristone on the unfolded protein response, we first 
incubated RMG1 cells with a clinically achievable dose of mifepristone (20 μM) and harvested 
cells at different time-points between 1-24 hours. Similarly, we harvested samples incubated with 
different doses of mifepristone (5-80 μM) for 18 hours. Subsequently, whole cell lysates were 
tested with antibodies against all three branches of the unfolded protein response. 20 μM 
mifepristone treatment did not show any difference in full-length ATF6 (ATF6-FL) (Figure 4.4A-
4.4B). High doses of mifepristone (40 μM - 80 μM) do seem to decrease the expression of full-
length ATF6; however, this may be due to cell death observed at these high doses when treated for 
18 hours (Figure 4.4B). Hence, we performed cell viability assays in RMG1 to calculate half-
maximal growth inhibition (GI50) upon mifepristone treatment. GI50 values for mifepristone were 
26.4 μM and 27.9 μM (Figure 4.4C).  
Next, with 20 μM mifepristone treatment, we observed an induction of ATF4 at 24 hours 
and slight inhibition of p-IRE1α starting at 1 hour (Figure 4.4A). In Figure 4.4B, induction of 
ATF4 was observed starting at 20 μM followed by CHOP induction at 40 μM. We observed a 
robust inhibition of p-IRE1α and induction of total IRE1α with increasing dose of mifepristone 
(Figure 4.4B). In both these experiments, we were unable to detect the induction of Grp78 by 





Figure 4.4. Mifepristone shows atypical modulation of the unfolded protein response. A) RMG1 
cells were incubated with vehicle (DMSO) or 20 μM of mifepristone and samples were harvested 
at 1, 3, 6, 10 and 24 hours. Whole cell lysates were subjected to immunoblotting and probed with 
the antibodies for several proteins in the unfolded protein response pathway. 2.5 μM of CB-5083 
and 2 µM of TN (Tunicamycin) treated for 24 hours were analyzed as positive controls. β-Actin 
was used a loading control. B) RMG1 cells were incubated with media (0), DMS0 (D), different 
doses of mifepristone (between 5 μM - 80 μM), 2.5 μM of CB-5083 and 2 μM of tunicamycin 
(TN). All samples were incubated for 18 hours, and protein lysates were immunoblotted with 
several antibodies for proteins in the unfolded protein response pathway. β-Actin was used a 
loading control. Both A&B experiments were reproduced at least in two biological replicate 
experiments. C) RMG1 cells were treated with incremental doses of mifepristone up to 100 µM 
for 72 hours. Dose-response curves were generated with the GraphPad Prism using four parameters 
nonlinear regression and the curves were constrained at top (100%) and bottom (>0%). Every point 







Expression of Grp78, an ER chaperone protein, increases upon the induction of unfolded 
proteins via the activity in IRE1 branch and ATF6 branch of the unfolded protein response. The 
induction of Grp78 serves as an adaptive response to aid in the folding of misfolded and unfolded 
protein in the endoplasmic reticulum allowing cells to resolve the unfolded protein response. 
Therefore, we reasoned that mifepristone may be exerting an inhibitory effect on IRE1 or ATF6 
branch (or both), which would inhibit the expression of Grp78 and attenuate the adaptive response 
when it is combined with VCP inhibitors, thereby resulting in enhanced cytotoxicity. To test the 
potential inhibitory effect of mifepristone on IRE1α, we treated RMG1 cells with increasing dose 
of mifepristone combined with 2 μM tunicamycin, an N-linked glycosylation inhibitor, to robustly 
induce all three branches of the unfolded protein response. As our control, we performed a similar 
experiment with STF-083010 (IRE1α inhibitor).  Our results indicate that both mifepristone and 
STF-83010 caused a dose-dependent attenuation of Grp78 (Figure 4.5A-4.5B). Although 
increasing doses of STF-083010 caused a dose-dependent attenuation of spliced XBP1 (XBP1s), 
the expression of spliced XBP1 did not change with mifepristone treatment (Figure 4.5A-4.5B).  
Next, we treated RMG1 cells with increasing doses of CB-5083 (between 1 - 2.5 μM) for 6 hours. 
We observed an increased in spliced XBP1 (s-XBP1) expression starting at 2.5 μM of CB-5083 
(Figure 4.5C). Once again, we did not observe the attenuation of spliced XBP1 (s-XBP1) with the 
addition of 20 μM mifepristone (Figure 4.5C). These results indicate that mifepristone does not 













Figure 4.5. Mifepristone treatment does not inhibit IRE1α endonuclease activity. A) RMG1 cells 
were incubated with increasing doses of mifepristone (5 µM – 80 µM) with 2 μM of tunicamycin 
for 10 hours. Cells were harvested and proteins were subjected to immunoblotting to analyze the 
indicated proteins. B) RMG1 cells were incubated with increasing doses of IRE1α inhibitor- STF-
083010 (5 µM – 80 µM) with 2 μM of tunicamycin for 10 hours. C) RMG1 cells were incubated 
with increasing doses of CB-5083 (1 µM – 5 µM) with or without mifepristone (20 µM) for 6 
hours. Cells were harvested and proteins were subjected to immunoblotting to analyze the 
indicated proteins. β-Actin was used a loading control. All experiments were performed in three 







Mifepristone (RU-486) was developed as an anti-progesterone inhibitor and later it was 
shown to be a potent inhibitor of glucocorticoid receptor. To investigate the potential role of 
progesterone and glucocorticoid receptors, we used two different cell lines, one lacking 
progesterone receptor (MDA-MB-468) (Subik et al., 2010) and another lacking glucocorticoid 
receptor (IGROV1) (Stringer-Reasor et al., 2015). We treated MDA-MB-468 cells with 10-40 µM 
mifepristone, or CB-5083 (1 µM), or a combination of CB-5083 (1 µM) and mifepristone (20 µM). 
We observed induction of ATF4 and CHOP by mifepristone, indicating that it induces unfolded 
protein response (Figure 4.6A). Moreover, we observed synergistic cytotoxicity between 
mifepristone and CB-5083 in these cells (Figure 4.6B). Similarly, glucocorticoid receptor-negative 
IGROV1 ovarian cancer cells displayed enhanced cytotoxicity to DBeQ and mifepristone (Figure 
4.6C). These results indicate that the unfolded protein response mediated through mifepristone is 







Figure 4.6. Mifepristone activates the unfolded protein response independent of glucocorticoid, 
estrogen and progesterone receptor inhibition. A) Triple-negative breast cancer cell line (MDA-
MB-468) were incubated with indicated compounds for 6 hours. Whole cell lysates were then 
subjected to immublotting with antibodies for indicated proteins. β-Actin was used a loading 
control. B) MDA-MB-468 cells were treated with different concentrations of CB-5083 up to 0.75 
μM and different concentration of mifepristone (20 μM and 30 μM) for 72 hours. Cell viability 
was measured using the SRB assay and dose-response curves were plotted with GraphPad Prism. 
CI stands for combination index. C) IGROV1 cells were treated with indicated concentrations of 
DBeQ and mifepristone for 72 hours. Cell viability was measured using SRB assay and dose 
response curves were generated using GraphPad Prism. All experiments were performed in three 





In addition to IRE1 branch, ATF6 branch also induces Grp78 expression through the 
binding of nuclear ATF6 (ATF6-N) to endoplasmic reticulum stress-responsive element (ERSE) 
(Baumeister et al., 2005). To investigate the potential effect of mifepristone on ATF6 branch, we 
incubated the lysates generated from previous studies (see Fig 4.5C) with ATF6 antibody. We saw 
cleavage of full-length ATF6 (ATF6-FL) with 2.5 μM and 5 μM of CB-5083, however this 
cleavage was blocked with the addition of 20 μM mifepristone (Figure 4.7A).  
 
Figure 4.7. Mifepristone treatment inhibit full length ATF6 cleavage. A) RMG1 cells were 
incubated with increasing doses of CB-5083 (1 µM-5 µM) with or without mifepristone (20 μM) 
for 6 hours. Cells were harvested and proteins were subjected to immunoblotting to analyze the 
indicated proteins. β-Actin was used a loading control. Representative blots from three biological 
replicate experiments.  
 
ATF6, an ER transmembrane protein, undergoes N-linked glycosylation to be functional.  
Induction of the unfolded protein response results in the translocation of full-length ATF6 (ATF6-
FL) to the Golgi. In Golgi, ATF6 is cleaved first by Site-1 Protease (S1P) to intermediate ATF6 
(ATF6-I) and subsequently by Site-2 Protease (S2P) to produce nuclear ATF6 (ATF6-N). To 
further confirm the inhibition of ATF6 cleavage by mifepristone, we expressed 3XFlag-ATF6 




cells with 20 μM mifepristone for 1, 3, 6, 10 and 24 hours. As positive controls for this experiment, 
we treated the cells with 2 μM tunicamycin and 2.5 μM CB-5083 for 3 and 10 hours. The untreated 
sample (D) was collected after 10 hours of vehicle treatment (DMSO). It is important to note that 
full length ATF6 (ATF6-FL) is detected as two bands representing glycosylated and 
unglycosylated AFT6 (Figure 4.8). The unglycosylated ATF6 provides a sensing mechanism that 
regulates unfolded protein response whereby underglycosylation of ATF6 triggers the unfolded 
protein response (Hong et al., 2004). Consistent with the literature, treatment with tunicamycin for 
three hours produces relatively more abundant unglycosylated ATF6-FL (Figure 4.8) and induces 
the active form of cleaved ATF6 (ATF6-N) (Figure 4.8, long exposure). In CB-5083-treated cells 
at three hours, glycosylated ATF6-FL is more prominent than unglycosylated ATF6-FL. Yet, CB-
5083 also induces the active form of cleaved ATF6, suggesting that CB-5083 activates this 
pathway through a mechanism that is distinct from ATF6 underglycosylation. Interestingly, 
mifepristone treatment causes higher levels of glycosylated than unglycosylated ATF6. This effect 
is expected to prevent ATF6 sensing mechanism that is dependent on underglycosylated ATF6 














Figure 4.8. Mifepristone treatment promotes glycosylated ATF6. HEK293T cells were 
transiently transfected with a 3XFlag-ATF6 plasmid for 24 hours and subsequently treated with 
20 µM mifepristone for 1,3,6,10 and 24 hours, while D sample was incubated in DMSO for 10 
hours. 3XFlag-ATF6 expressing HEK293T cells were treated with 2.5 μM CB-5083 and 2 μM TN 
(tunicamycin) for 3 hours and 10 hours. Mock indicates the addition of transfection reagents 
without plasmid. ATF6 FL, ATF6-I and ATF6-N stands for full-length ATF6, intermediate ATF6, 
and nuclear ATF6 respectively. All lysates were subjected to immunoblotting with Anti-flag 







4.2.4 Mifepristone treatment activates heme-regulated inhibitor (HRI) pathway 
to induce activating transcription factor 4 (ATF4) 
  Activating transcription factor 4 (ATF4) gets activated upon phosphorylation of eukaryotic 
initiation factor 2 alpha (eIF2α), which can be phosphorylated by four upstream kinases PERK, 
GCN2, HRI, and PKR (please see the list of abbreviations for full forms). To investigate the 
potential involvement of PERK and GCN2 towards ATF4 activation, we incubated mouse 
embryonic fibroblast generated from PERK knockout mice (PERK-MEF-/-) and mouse embryonic 
fibroblast generated from GCN2 knockout mice (GCN2-MEF-/-) with 20 μM of mifepristone and 
harvested whole cell lysates at 6 and 12 hours. Similarly, we treated both mouse embryonic 
fibroblasts (MEFs) with 2 μM tunicamycin for 10 hours, which acted as positive controls for the 
experiment. As expected, 2 μM tunicamycin was unable to induce the expression of ATF4 in 
PERK-MEF-/-; however, in both conditions ATF4 expression was induced with 20 μM 
mifepristone (Figure 4.9A). These results indicate that mifepristone activated ATF4 independent 
of PERK or GCN kinases. Next, we analyzed the effect of kinases HRI and PKR towards the 
activation of ATF4. We transiently transfected small interfering RNAs (siRNAs) targeting HRI 
and PKR for 48 hours and followed with 20 μM mifepristone treatment for 6 and 10 hours. Our 
results indicate that siRNA targeting HRI was able to attenuate ATF4 expression (Figure 4.9B). 
Taken together, these results suggest that ATF4 activation upon mifepristone treatment is mediated 









Figure 4.9. Mifepristone activates HRI kinase pathway. A) Mouse embryonic fibroblast 
generated from PERK knockout mice (PERK-KO-DR) and mouse embryonic fibroblast generated 
from GCN2 knockout mice (GCN2-KO-DR) were incubated with 20 µM of mifepristone for 6 and 
12 hours. Vehicle (V) and TN (2 μM-Tunicamycin) treatments were performed for 12 hours and 
lysates were probed with indicated antibodies. β-Actin was used a loading control. Representative 
blots from three replicate experiments. B) RMG1 cells were transiently transfected with scrambled 
(Scr) and small interfering RNAs (siRNAs) targeting HRI (siHRI) and PKR (siPKR) for 48 hours 
followed by treatment of 20 µM of mifepristone for 6 and 10 hours. Protein lysates were then 
subjected to immunoblotting with indicated antibodies. β-Actin was used a loading control. Small 
interfering RNAs transfections were replicated in OVSAHO ovarian cancer cell line.  
 
4.3. Discussion 
Endoplasmic reticulum (ER) consists of interconnected tubules and flattened sacs that 
extend the entire cytoplasm. The primary functions of endoplasmic reticulum include post-
translational modifications of nascent proteins, folding of secretory proteins, synthesis of lipids 
and storage of calcium. Several physiological insults such as calcium dysregulation, glucose or 
nutrient deprivation, increased reactive oxygen species and increased burden of misfolded and 
unfolded proteins in the endoplasmic reticulum can trigger the unfolded protein response. The 
unfolded protein response is primarily an adaptive response that is manifested through 
phosphorylation of two transmembrane endoplasmic reticulum kinase IRE1 and PERK and 
cleavage of endoplasmic reticulum transmembrane protein ATF6. Over the years, several studies 




including cancer. In Chapter 3, we showed that the unfolded protein response pathway can be 
induced in ovarian cancer by inhibiting VCP. VCP inhibitors induces unrestrained unfolded 
protein response that eventually initiates caspases-mediated cell death. Furthermore, we showed 
that VCP inhibitors can be combined with salubrinal potentiating the effect of VCP inhibitors. In 
this chapter, our primary objective was to identify a clinically relevant agent that could enhance 
the cytotoxic effect of VCP inhibitors by modulating the unfolded protein response in ovarian 
cancer cells. Several compounds that modulate several branches of the unfolded protein response 
have been identified over the year; however, none has been FDA-approved. Through this study, 
we identified strong synergistic cytotoxicity between mifepristone and several classes of VCP 
inhibitors at a clinically achievable dose of mifepristone.  
Recently, a clinical case report showed that single-agent 200 mg mifepristone (oral/day) 
resulted in long-term high-quality survival of an 80-year-old female with metastatic lung cancer 
and a 58-year-old male with metastatic bilateral renal cell carcinoma. The 80-year-old female was 
reported to have no tumors 5 years after the initial treatment, while the male was reported to have 
stable disease for 10 years with no new lesion. Neither patients reported any side effect from the 
long-term treatment of mifepristone (Check et al., 2016). These evidences indicate that 
mifepristone could be used in cancer therapy even as long-term maintenance therapy. Since oral 
VCP inhibitors display a pan-cancer cytotoxicity, our results have broad implications in terms of 
designing future combination clinical trials with VCP inhibitors.  
Mifepristone was initially approved as an anti-progesterone receptor inhibitor (Naoki et al., 
1988); however, subsequent studies have identified other targets of mifepristone including several 
reports suggesting that mifepristone treatment display atypical unfolded protein response (Dioufa 




upon mifepristone treatment. Mifepristone treatment resulted in the inhibition of Grp78 expression 
(endoplasmic reticulum chaperone) as well as induction of ATF4. Although we observed a 
decrease in phospho-IRE1α and an increase in total IRE1α expression with mifepristone treatment, 
the endoribonuclease activity of IRE1α was not affected by mifepristone. Next, we analyzed the 
changes in the ATF6 branch. Our results indicate that unlike tunicamycin and CB-5083, 
mifepristone inhibits the cleavage of full length ATF6 (ATF6-FL) (Figure 4.10). We also observed 
an increase in glycosylated ATF6 in mifepristone-treated cells. Given that unglycosylated ATF6 
serves as a sensor to induce the unfolded protein response, we speculate that the enhanced 
glycosylation of ATF6 may prevent full engagement of this branch during the induction of the 
unfolded protein response by CB-5083. Moreover, previous studies have shown that glycosylation-
deficient ATF6 (T645I mutation) results in higher rate of Golgi translocation where S1P and S2P 
process ATF6 to produce active ATF6 (Hong et al., 2004). In fact, ATF6 translocation to the Golgi 
is first step in the activation of ATF6 branch in the unfolded protein response. Therefore, increased 
glycosylation of ATF6 that promoted by mifepristone may hinder the translocation of ATF6 to the 
Golgi during the unfolded protein response and attenuate the process of ATF6. Consistent with 
this assertion, our results show that mifepristone prevents the decrease in full length ATF6 that is 
induced by CB-5083. Collectively, our results suggest that mifepristone promotes glycoslylation 
of ATF6 and attenuate the activation of ATF6 branch during the induction of the unfolded protein 










Figure 4.10. Putative mechanism for synergistic cytotoxicity between CB-5083 and 
mifepristone. Treatment with VCP inhibitor- CB-5083 activates activating transcription factor 6 
(ATF6) branch and protein kinase R-like endoplasmic reticulum kinase (PERK) branch. 
Activation of ATF6 can result in the induction of glucose-regulated protein 78 (Grp78). Induction 
of Grp78 is considered a pro-survival response. Similarly, PERK activation can ultimately induce 
CCAAT/Enhancer-binding protein homologous protein (CHOP). Enhanced expression of CHOP 
can be a pro-apoptotic response. Mifepristone treatment inhibits ATF6 branch and enhances CHOP 
expression through the activation of heme-regulated inhibitor (HRI) kinase pathway. The 









Recently, Gallagher et al. used endoplasmic reticulum stress-responsive element (ERSE) 
to screen compounds that could inhibit ATF6 and showed that Ceapsins could selective inhibit 
ATF6α. The study showed that Ceapsin-A7 (ATF6α inhibitor) enhanced the cytotoxicity of 
thapsigargin (unfolded protein response inducer) (Gallagher et al., 2016). Results from our synergy 
studies between VCP inhibitors (unfolded protein response inducer) and mifepristone (ATF6 
branch inhibitor) are therefore in agreement with their observation. However, further studies need 
to done to confirm that the synergistic effect between mifepristone and VCP inhibitors is mediated 
via this mechanism.  
Through this study, we found that mifepristone treatment activates heme-regulated 
inhibitor (HRI) pathway resulting in ATF4 activation. Induction of ATF4 increases the expression 
of CHOP and enhanced CHOP expression has been shown to induce the unfolded protein response 
mediated cell death (Figure 4.10). This underlines a parallel mechanism of action that could result 
in potential synergy between mifepristone and VCP inhibitors. It is possible that both the activation 
of HRI pathway and inhibition of ATF6 branch confers the final synergistic cytotoxicity in our 
experiments. Subsequent studies need to be done to analyze the effect of each of these targets to 
conclusively identify the mechanism of cytotoxicity mediated through mifepristone. Similarly, we 
observed synergistic effect between CB-5083 and mifepristone in IGROV1 (shown to have low 
GR expression) and triple negative breast cancer (TNBC) cell line-MDA-MB-468. These results 
suggest that the atypical unfolded protein response via mifepristone is independent of 
glucocorticoid receptor, estrogen receptor and progesterone receptor inhibition; however, we are 
unable to rule out a potential role of mifepristone through unknown steroids or growth factors 
inhibition. In this chapter, we identified exciting and clinically relevant candidates that can be used 




mechanism of mifepristone in modulating the unfolded protein response. Mifepristone has been 
shown to be a safe compound even when given over a long interval. We envision mifepristone to 
be used as a maintenance therapy together with other modulators of the protein quality control 
pathways such as VCP inhibitors, heat-shock protein 90 (Hsp90) inhibitors, and autophagy 



























Chapter 5: Understanding the mechanism of resistance to VCP 
inhibitors 
Portions of this chapter are reproduced from the following publication with permission where 
required. 
 
 Bastola P, Wang F, Schaich M, Gan T, Freudenthal B, Chou TF, Chien J (2017) Specific 
mutations in D1-D2 linker region of VCP/p97 enhance ATPase activity and confer 


















Valosin-containing protein (VCP), also known as p97 or Cdc48 in yeast, belongs to AAA 
(ATPase Associated with diverse cellular Activities) family of ATPase. The protein has an N 
terminal domain, two ATPase domains (D1 and D2), followed by a short C terminal extension 
(Banerjee et al., 2016; DeLaBarre and Brunger, 2003; Meyer et al., 2012; Zhang et al., 2000). 
These domains are linked via two linker regions between N and D1 as well as D1 and D2 (Please 
see Figure 1.8) (Banerjee et al., 2016). While the N-terminal domain mostly interacts with 
substrates and co-factors, both D1 and D2 domains bind and hydrolyze adenosine triphosphate 
(ATP) (DeLaBarre and Brunger, 2005; Meyer et al., 2012). Mutations in the D2 domain that 
prevent binding of ATP or abolish ATP hydrolysis result in a dominant-negative phenotype 
suggesting that D2 domain is responsible for driving most functions associated with VCP, while 
the ATPase activity in D1 domain provides a supportive function (Song et al., 2003). Recently 
solved high-resolution cryoelectron microscopy structure of VCP depicted a two-step ATP-driven 
conformational changes associated with VCP activity (Banerjee et al., 2016). The structure 
revealed that binding of ATP to the D2 domain brings about a conformational change to D2 and 
subsequently to D1-D2 linker region. The conformational change at the D1-D2 linker region 
allows ATP binding at the D1 domain facilitating substrates to bind to the N-terminal region. The 
structure uncovered the significance of the D1-D2 linker region and demonstrated that D1-D2 
inhibitors caused a steric clash, which abolished the function of VCP (Banerjee et al., 2016). 
VCP has been linked with various cellular processes including ubiquitin-mediated 
degradation (Beskow et al., 2009; Bodnar and Rapoport, 2017), endoplasmic reticulum associated 
degradation (ERAD) (DeLaBarre et al., 2006; Ye et al., 2001), chromatin associated degradation 




(Bug and Meyer, 2012), mitochondria-associated degradation (Kim et al., 2013), and autophagy 
(Ju et al., 2009). Although VCP has been implicated in a multitude of cellular processes, its 
function in the ATP-mediated extraction of unfolded proteins from the endoplasmic reticulum 
(ER) for degradation via proteasome has been extensively studied (Jarosch et al., 2002; Wójcik et 
al., 2006). Similarly, the role of VCP-mediated ATP hydrolysis in the unfolding of ubiquitinated 
client proteins that are targeted for degradation by the proteasome is also well established (Dai and 
Li, 2001). These functions make VCP an essential component in protein quality control (PQC). 
Protein quality control has emerged as an essential factor in tumor development, and components 
of protein quality control have been proven to be valid targets for cancer therapeutics. Recent 
genome-wide short hairpin RNA (shRNA) screens identified various components of protein 
quality control, such as proteasomal subunits and VCP, as essential genes in cancer cells (Cheung 
et al., 2011; Marcotte et al., 2012). Therefore, VCP inhibitors may serve as novel cancer 
therapeutics that exploit unique vulnerabilities or dependencies of cancer cells. 
Several studies reported the development of VCP inhibitors and showed that these 
compounds induce endoplasmic reticulum stress and apoptosis in cancer cells (Anderson et al., 
2015; Chou et al., 2011; Magnaghi et al., 2013). High-throughput screening (HTS) of compound 
libraries from Maybridge Hitfinder Collection and National Institute of Health (NIH) Molecular 
Libraries Small Molecule Repository yielded in the identification of DBeQ (N2,N4-dibenzyl 
quinazoline-2,4-diamine) as a selective, reversible, ATP-competitive inhibitor of VCP (Chou et 
al., 2011). Subsequently, a structure-activity relationship (SAR) study was performed using DBeQ 
and N-benzyl-2-(2-fluorophenyl) quinazoline-4-amine 1 as a starting point. The study resulted in 
the identification of ML240, which displayed improved potency and inhibited the D2-ATPase 




which displayed better specificity towards VCP and more importantly showed efficacy in several 
tumor xenograft models when administered orally  (Anderson et al., 2015; Zhou et al., 2015). Such 
promising results allowed for the start of two Phase I clinical trials.  
Prompted by the potential application of VCP inhibitors in cancer, several studies have 
focused on understanding the mechanism of resistance towards VCP inhibitors. Cells resistant to 
CB-5083 have been shown to harbor mutations in VCP, yet details regarding the mechanism of 
resistance are unknown (Anderson et al., 2015). Similarly, prolonged treatment with an allosteric 
VCP inhibitor, NMS-873, resulted in a heterozygous A530T mutation in VCP. However, these 
resistant cell lines did not show any cross-resistance towards CB-5083 or other VCP inhibitors 
(Her et al., 2016). These results suggest that target alterations may represent a molecular 
mechanism of resistance to VCP inhibitors.  
Given that CB-5083 has entered the realm of clinical trials, we set out to understand the 
mechanism of resistance towards this compound. Here, we established and characterized the in 
vitro mechanism of resistance to CB-5083. Our study indicates target alterations as a potential 
mechanism of resistance to CB-5083 in vitro, thereby providing a critical potentially theranostic 
marker that should be considered in clinical trial settings. Finally, our studies highlight the 
relevance for the further development of novel VCP inhibitors that can overcome resistance to 
existing VCP inhibitors.  
5.2 Result 
5.2.1 Development of CB-5083 resistant cell lines 
With oral VCP inhibitor CB-5083 in two Phase I clinical trials, we set out to understand 
the potential mechanism of resistance towards CB-5083. Since one of Phase I clinical trials for 




line OVSAHO for our studies. To understand the mechanism of resistance towards CB-5083, we 
established CB-5083-resistant cell lines as outlined in Figure 5.1A and 5.1C. We incubated 
OVSAHO cells with 2.5 μM of CB-5083 for 24 hours, which resulted in significant cell death. 
Cells were allowed to recover in the drug-free medium for 5-10 days. Three more rounds of 
treatment and recovery were performed with the incremental increase of 0.5 μM CB-5083 per 
round (Figure 5.1A).  
After four rounds of incremental exposures to CB-5083, we observed a small increase in 
resistance to CB-5083 in the recovered cells (OVSAHO-R) compared to the parental cells (Figure 
5.1B). Next, we treated 500 OVSAHO-R cells with either 2 μM CB-5083 or 3 μM CB-5083 
continuously for 15 days (Figure 5.1C). Surviving cells were allowed to form colonies and 
expanded separately to get two separate populations of resistant cells (O-CB-R1 & O-CB-R2). 
Both O-CB-R1 and O-CB-R2 displayed an elongated cell structure in contrast to rounded cell 
morphology of the parental OVSAHO cells (Figure 5.1F). More importantly, O-CB-R1 and O-
CB-R2 cell lines showed 5.3 and 5.7-fold increase in resistance towards CB-5083, respectively 













Figure 5.1. Development of CB-5083-resistant cells. A) Experimental setup used to generate the 
initial OVSAHO resistant cells. B) Colony formation assay was performed on parental OVSAHO 
cells and OVSAHO-R (resistant) cells. Cells were treated with different concentrations of CB-
5083 between 0.5 μM-2.5 μM for 48 hours and then allowed to recover under normal media for 8 
additional days. C) Experimental setup used to generate O-CB-R1 and O-CB-R2 from OVSAHO-
R. D) OVSAHO parental, O-CB-R1 and O-CB-R2 were incubated with incremental doses of CB-
5083 (0.1 μM-10 μM) for 72 hours and cell viability was determined using SRB assay. Dose-
response curves were generated via GraphPad Prism using four parameters nonlinear regression 
and the curves were constrained on top (100%) and bottom (>0%). Every point in the dose-
response curve represents Mean± SEM taken from at least two technical replicate samples for all 
cell lines. (E) The bar graph represents Mean GI50 + SEM taken from three biological replicates in 
all cell lines. P-values were calculated using Student’s t-test.  F) Images of OVSAHO parental, O-











5.2.2 Molecular characterization of resistance cell lines 
In Chapter 3, we showed that VCP knockdown cells were more sensitive to VCP inhibitors 
than VCP-proficient cells. In contrast, both O-CB-R1 and O-CB-R2 cells showed around 50% 
reduction in the VCP expression (messenger RNA and protein) compared to the parental cells 
(Figure 5.2A, 5.2B). Furthermore, we examined the cytotoxicity of several VCP inhibitors and the 
proteasome inhibitor- bortezomib. Compared to the parental cell line, only NMS-873 displayed 
cross-resistance in O-CB-R1 and O-CB-R2 (Figure 5.2C). Surprisingly, we were unable to observe 
cross-resistance towards DBeQ and ML240, which share close chemical structure to CB-5083. We 
also did not observe cross-resistance to the recently described allosteric VCP inhibitor UPCDC-
30425 as well as the proteasome inhibitor- bortezomib (Figure 5.2C).  
In Chapter 3, we showed that CB-5083 treatment induced the unfolded protein response 
(UPR); therefore, we evaluated the induction of the unfolded protein response with two VCP 
inhibitors- CB-5083 and DBeQ, a proteasome inhibitor- bortezomib, and an endoplasmic 
reticulum stress inducer- tunicamycin. Based on our cytotoxicity data, we expected CB-5083 
treatment to have a reduced activation of the unfolded protein response in the resistance cells. As 
expected, we observed reduced activation of ATF4 at both 3 hours and 6 hours in the resistant cells 
(Figure 5.2D). We also observed the reduced induction of ATF4 in the resistant cells with DBeQ, 
bortezomib, and tunicamycin treatments (Figure 5.2D). Given that tunicamycin and bortezomib 
were not known to directly affect VCP, the attenuated ATF4 induction in resistant cell lines 
suggests that these cells might have acquired an increase in the adaptive capacity to handle the 






Figure 5.2. Effects on VCP/p97 mRNA and protein expression, cross-resistance and changes in 
the unfolded protein response (UPR) in resistant cell line. A) Quantitative RT-PCR was 
performed to evaluate the mRNA expression of VCP in OVSAHO parental, O-CB-R1 and O-CB-
R2. Bar graph represents the mean relative mRNA expression + SEM normalized to 18S from 
three independent q-RT-PCR experiments. P-values were calculated using Student’s t-test B) 
Whole cell lysates were immunoblotted and probed with the antibody against VCP to evaluate the 
protein expression. β-Actin was used as the loading control. Numbers below the VCP blot indicate 
relative VCP expression normalized to the β-Actin loading control. C) Table displays Mean GI50 
± SEM (µM) with several VCP inhibitors and proteasome inhibitor (Bortezomib) from three 
independent experiments in parental and resistant cells. Numbers in the bracket for CB-5083 and 
NMS-873 treatment represent the drug resistance index (DRI) in resistant cells compared to 
parental cells. D) OVSAHO-parental, O-CB-R1, and O-CB-R2 were treated with CB-5083, 
DBeQ, bortezomib or tunicamycin at indicated concentrations. Cells were collected at 3- and 6-
hour time points and whole cell lysates were subjected to immunoblotting and probed with 
indicated antibodies. Numbers below the ATF4 blots indicate relative ATF4 protein expression 





5.2.3 CB-5083 resistant cells harbor missense mutations in the D1-D2 linker 
region of VCP 
Based on previous studies indicating that CB-5083 resistant cells harbor mutations in VCP 
(Anderson et al., 2015; Zhou et al., 2015), we decided to sequence-specific regions of the VCP 
gene. CB-5083 has been shown to be a D2 specific inhibitor (Anderson et al., 2015; Zhou et al., 
2015); therefore, we sequenced all the exons spanning the D2 domain (exon 13-16). Similarly, 
homozygous point mutations in the D1-D2 linker region were observed in CB-5083-resistant cells  
(Anderson et al., 2015). Hence, we decided to sequence the D1-D2 linker region (exon 11 and 12) 
as well. In O-CB-R2, we identified one heterozygous mutation at codon 470 (E470K, exon 12) 
and one heterozygous mutation at codon 603 (Q603*, exon 14) (Figure 5.4A). In another resistant 
cell line, O-CB-R1, we found two heterozygous mutations at codon 470 (E470K and E470D, exon 
12), one heterozygous mutation at codon 603 (Q603*, exon 14) and one heterozygous frameshift 
deletion (N616M fs, exon 14) (Figure 5.4A). Since both O-CB-R1 and O-CB-R2 contained a 
mixed population of cells and could, therefore, harbor heterogeneous mutations in VCP, we 
isolated several single clones from both the resistant cell populations. We generated three sub-
clones from O-CB-R2, and all three sub-clones harbored a similar heterozygous E470K mutation 
in VCP (data not shown). 
We also generated two sub-clones from O-CB-R1 (O-CB-R1.1 and O-CB-R1.2) and 
observed two separate heterozygous mutations, E470K and E470D, in O-CB-R1.1 and O-CB-R1.2 
respectively (Figure 5.4A). O-CB-R1.1 cells also contained a heterozygous nonsense mutation at 
codon 603 (Q603*, exon 14). In contrast, O-CB-R1.2 cells contained a heterozygous frameshift 
deletion at codon 616 (N616M fs*63, exon 14) (Figure 5.4A). Similar to O-CB-R1, both O-CB-




compared to the parental cell line when treated with CB-5083 (Figure 5.3A). In addition, analysis 
of somatic mutations in VCP in tumor samples from the cancer genome atlas (TCGA) dataset 
indicated that frameshift mutations at codon 616 in VCP are frequently observed in cancer samples, 
while mutations in E470 and Q603 have not been reported (Figure 5.3B-5.3C). Previous studies 
identified several homozygous point mutations along the D1-D2 linker region (codons 472, 473, 
and 474) in CB-5083 resistant cells (Anderson et al., 2015). The clusters of mutations within this 




Figure 5.3. Common mutations observed in the cancer genome atlas (TCGA) dataset. A) The 
bar graph represents Mean GI50 + SEM in OVSAHO parental and two sub-clones from O-CB-R1 
(O-CB-R1.1 and O-CB-R1.2) taken from three biological replicates. P-values were calculated 
using the two-tailed student’s t-test. Known missense mutations (B) and truncation mutations (C) 
associated with cancer. Tentative sites for the E470 missense mutations and Q603 truncation 







To determine if the heterozygous mutations at codons 470 and 603/616 are compound 
mutations present in both alleles or two single mutations present separately in two alleles, we 
decided to sequence the complementary DNA (cDNA). In contrast to genomic DNA sequencing 
results, we detected homozygous mutations at codon 470, while no mutation was detected at codon 
603 or 616 in the cDNA (Figure 5.4B). These results suggest that mutations in codons 470 and 
603/616 are not compound mutations present in the same allele. In fact, these results suggest the 
first set of mutations at codon 470 (E470K or E470D) are present in one VCP allele while another 
set of mutations at codons 603 (Q603*) or 616 (N616Mfs*63) are present in the other VCP allele. 
Although VCP mRNA with E470K or E470D mutations is expressed and can be detected in cDNA 
sequencing as homozygous mutations, the VCP mRNA with either Q603* or N616Mfs* 63 
mutations is not expressed because of nonsense-mediated decay, and therefore they are not 







Figure 5.4. CB-5083-resistant cell lines harbor heterozygous mutations at exon 12 and exon 14. 
A) Chromatograms displaying the region of VCP genomic DNA coding sequence at exon 12 and 
exon 14 in OVSAHO parental, O-CB-R2 and O-CB-R1 as well as two pure sub-clones O-CB-
R1.1 and O-CB-R1.2 generated from O-CB-R1. Blue box marks codons 470, 603 and 616 that 
harbors mutations in the resistant clones. B) Chromatograms displaying the region of VCP c-DNA 
in OVSAHO parental, OVSAHO-CB-R2, OVSAHO-CB-R1.1 and OVSAHO-CB-R1.2. Blue box 





Previous studies have shown that the mechanisms of action pertaining to drugs can be 
inferred from the perturbed transcriptomes induced by the drugs (Lamb et al., 2006). To investigate 
potential molecular mechanisms contributing to CB-5083 resistance, we characterized the 
transcriptomes perturbed by CB-5083 in parental and resistant cells. We performed RNA 
sequencing of parental OVSAHO and CB-5803-resistant O-CB-R1 after treatment with vehicle 
(DMSO) or CB-5083 (5 μM) for 6 hours. We selected 6-hours treatment to limit the perturbation 
of gene expression to the primary response induced by CB-5083, as previous studies (Lamb et al., 
2006). First, we analyzed the mutations in VCP in RNA sequencing data from parental and O-CB-
R1 treated with DMSO. Consistent with our Sanger sequencing results, we detected both E470K 
(CT) and E470D (CA) missense mutations in VCP transcripts from O-CB-R1 but not in 
parental cells (Figure 5.5A). Furthermore, we did not detect nonsense mutations at codon 603 or 
codon 616 in both parental and resistant transcripts (data not shown), which further confirmed that 
transcripts with nonsense mutations at codon 603 and codon 616 were subjected to nonsense-


















Figure 5.5. Nonsynonymous mutations in VCP transcripts. A) OVSAHO parental and OVSAHO 
resistant (O-CB-R1) transcripts spanning codon 470 of VCP. The arrows in O-CB-R1 transcripts 
represent two different nonsynonymous mutations in VCP at codon 470 with either C>T (E470K) 
or C>A (E470D). It should be noted that VCP is transcribed from the negative strand, and codon 
470 is read as GAG (a reverse complement of CTC). C>T transition at the first base of the codon 
in the positive strand is read as AAG, which codes for lysine (K). C>A transversion at the third 








Subsequently, we performed mutational analysis to detect other nonsynonymous mutations 
in the resistant cell line compared to the parental cell line. We identified 71 unique nonsynonymous 
substitutions in O-CB-R1. In Table 5.1, we list top 11 nonsynonymous substitutions in O-CB-R1. 
It should be noted that these mutations are found in the transcripts that are abundant in both 
parental and resistant cells, and they likely represent true mutations that are not found in parental 
cells. Next, we investigated perturbed gene expression induced by CB-5083 in both cell lines. A 
total of 3047 transcripts were differentially expressed in the parental cells after CB-5083 treatment, 
while only 31 transcripts were differentially expressed in O-CB-R1 after CB-5083 treatment, with 
an overlap in 19 transcripts between the two cell lines (Figure 5.6A). In Figure 5.6B, we outline 
the number of transcripts that were differentially expressed (upregulated and downregulated) in 















Top Nonsynonymous substitutions in the resistant cell line 
Gene Reference- Amino Acid Substitution  Zygosity 
VCP E470 K Heterozygous 
VCP E470 D Heterozygous 
FLNA R484 W Heterozygous 
UQCR10 S8 L Heterozygous 
MCM7 A241 S Heterozygous 
APBB2 T131 S Homozygous 
TNKS1BP1 P602 H Heterozygous 
ADAM10 I385 F Heterozygous 
SLC16A3 D260 A Heterozygous 
TRAK1 N857 S Heterozygous 
ATG4B V364 D Heterozygous 
 

















Figure 5.6. The number of differentially expressed transcripts with CB-5083 treatment. A) The 
Venn diagram represents the number of the differentially regulated transcripts in both parental and 
resistant cell lines upon 6 hours of treatment with CB-5083 (5 μM). Differential expression was 
calculated based on the false discovery rate ≤ 0.001 and fold change ≥ 1.5. B) The table indicates 
the number of transcripts that are differentially regulated (upregulated and downregulated) in 










Next, we focused on the 19 shared transcripts that were upregulated with CB-5083 in both 
cell lines. We plotted the upregulated transcripts based on their maximum mean expression values 
(Figure 5.7A) and relative fold change values (Figure 5.7B). Based on the maximum mean 
expression values, DDIT3 (CHOP) was the most highly upregulated transcript in the parental 
group (Figure 5.7A). Likewise, based on the fold change values, ATF3 was the most highly 
upregulated transcript among the parental group (Figure 5.7B). Considering that CHOP and ATF3 
are upregulated upon the induction of the unfolded protein response, our results indicate that oral 
VCP inhibitor- CB-5083 induces the unfolded protein response. Although resistant cells show 
induction of these transcripts, the maximum mean expression values for DDIT3 (CHOP) as well 
as fold change for ATF3 transcript are lower in the resistant cell line (O-CB-R1) than parental 
cells, suggesting that the effect of CB-5083 is consistently attenuated in the resistant cells.  
Similarly, we analyzed the 12 transcripts that were upregulated only in O-CB-R1. These 
included transcripts such as IER3IP1_1, EIF3CL, and TIMM23B (Figure 5.7C-5.7D). 
Upregulation of these transcripts may represent an adaptive response that allows O-CB-R1 to 




   
Figure 5.7. Alterations in transcripts related to the unfolded protein response with CB-5083 
treatment. Plots represent A) maximum mean expression values and (B) relative fold change 
values of the 19 shared transcripts that were upregulated with CB-5083 treatment in OVSAHO 
parental and resistant (O-CB-R1) cells. Each line represents a transcript. C) Plot represents the 
log2 fold change of the 12 transcripts that were significantly upregulated with CB-5083 treatment 
only in the resistant cells (FDR<0.001). It should be noted that negative Log2 fold change values 




212D19.4, shown in green line, was upregulated by CB-5083 in parental cells. However, this 
upregulation was not significant. D) Plot represents the relative fold change values of the 12 
transcripts that were significantly upregulated by CB-5083 only in the resistant cell line. 
 
Furthermore, we performed pathway analysis identified through ontology term enrichment 
based on the list of transcripts that were differentially regulated in both cell lines upon CB-5083 
treatment using fold change > 1 and false discovery rate (FDR) ≥ 0.01. These new parameters 
allowed us to capture more transcripts, which were then used to analyze the affected pathways 
inferred from the ontology terms associated with these genes. In both parental and resistant cells, 
the “response to endoplasmic reticulum stress (GO:0034976)” pathway was the most significantly 
associated GO term for genes upregulated by CB-5083 treatment (Figure 5.8A-5.8B). Similarly, 
when we analyzed the ontology terms associated with the genes downregulated by CB-5083, we 
observed GO terms associated with the “cell division” in the parental line, however, this was not 
observed in the resistant cell line (Figure 5.8C-5.8D). In addition to pathways defined by GO 
terms, other pathways included those defined by the Reactome (R-HSA) database and the Gene 
Set Enrichment Analysis Gene Sets (M), and Kyoto Encyclopedia of Genes and Genomes (KEGG) 
pathway database (hsa). These results further confirm that CB-5083 induces the expression of 












Figure 5.8. Differential regulation of pathways with CB-5083 treatment. A) Inferred pathways 
upregulated by 5 μM of CB-5083 treatment in the OVSAHO parental cells. B) Inferred pathways 
upregulated by 5 μM of CB-5083 treatment the resistant (O-CB-R1) cells. C) Inferred pathways 
associated with genes downregulated by 5 μM of CB-5083 treatment in OVSAHO parental cells. 
D) Inferred pathways associated with genes downregulated by 5μM of CB-5083 treatment in the 
resistant (O-CB-R1) cells. Terms with the prefix “GO” are from the Gene Ontology Consortium, 
the prefix “R-HAS” from the Reactome, the prefix “M” from the Gene Set Enrichment database, 








5.2.4 E470K and E470D mutants show higher ATPase activity and increased 
resistance than wild-type VCP  
To determine the effect of specific missense mutations on VCP ATPase activity, we 
performed site-directed mutagenesis of a bacterial expression construct containing VCP as 
previously described (Chou et al., 2014). The list of plasmids used to purify VCP proteins 
(wildtype and E470 mutants) is shown in Figure 5.10C. Wildtype and two mutant form of VCP 
proteins were purified according to the published procedure (Chou et al., 2014) and Biomol Green 
reagent (a modified Malachite Green assay) was used to determine ATPase activity. Figure 5.9A 
demonstrated that both E470D and E470K have elevated ATPase activity, about 5.8-fold and 3.4-
fold respectively. Next, we determined in vitro half-maximal inhibitory concentration (IC50) of 
CB5083, NMS-873, ML240, ML241, and DBeQ (Figure 5.9B-5.9D, Figure 5.10A-5.10B). Our 
result indicated that CB-5083 was about 3.4 to 3.8 fold less active in inhibiting the E470 mutants 
than the wildtype (WT) VCP and interestingly, ML240 was about 15-fold less active (Figure 5.9B, 
5.9D). The allosteric inhibitor NMS-873 was about 2.6 to 2.9-fold less active toward the E470 
mutants (Figure 5.9C). Increased IC50 in the E470 mutants was also observed with ML241 and 
DBeQ (Figure 5.10A-5.10B). These results show the E470 mutants display increased ATPase 












Figure 5.9. Mutations at codon 470 enhance VCP activity and attenuate CB-5083, NMS-873 
and ML240 function. (A)Time-dependent experiment with wildtype (WT) VCP/p97 and two 
E470 mutants to determine their specific ATPase activities. Specific ATPase activity of VCP 
proteins presented in the figure was measured in nmol/min/nmol.  (B)-(D) Titration curves of 
CB5083, NMS-873, and ML240 for WT, E470K, and E470D VCP proteins. IC50 (µM) was 













Figure 5.10. Mutations at codon 470 attenuates other VCP inhibitors function. Titration curves 
of ML241 (A) and DBeQ (B) for WT, E470K and E470D VCP proteins in inhibiting ATPase 
activity. IC50 (uM) was calculated using Prism with the equation [log(agonist) vs. response -- 
Variable slope (four parameters)]. 
 
 
5.2.5 Mutation at E470 may affect binding to CB-5083 and NMS-873  
To determine the binding site of CB-5083, and therefore possible impacts of E470 
mutations, we utilized the molecular docking program AutoDock Vina with a 2.4 Å hexameric 
structure of VCP (PDB code 5FTK) (Figure 5.11A) (Banerjee et al., 2016; Trott and Olson, 2010). 
A search for binding sites of CB-5083 was performed on a hexameric VCP with a 30 x 30 x 30 Å3 
cubic region oriented near the mutation site while keeping the D2 active site of the enzyme within 
the search box. Two thermodynamically similar binding modes were observed: one was at the D1-
D2 interface with the methyl group from the benzimidazole ring in contact with E470. The carbon 




5.11B, 5.11C). The calculated free energy for ligand binding of that mode was -8.9 kcal/mol. A 
previous docking study observed binding of CB-5083 at the ATP binding site of D2 (Zhou et al., 
2015). However, the search parameters used were centered on the D2 active site of VCP and did 
not include the D1-D2 interface region (Zhou et al., 2015).  
Similar to the previous study, we also observed an additional binding pocket in the active 
site of the D2 domain with similar thermodynamic favorability of binding (-9.5 kcal/mol), 
suggesting CB-5083 can bind at both the D1-D2 linker and the ATP binding site, which may 
account for its previous characterization as a competitive inhibitor. However, based on our cellular 
studies the likely mode of action within our experimental design is through interfacial binding near 
E470, and mutations at E470 would likely alter binding of CB-5083.  We also performed docking 
studies on NMS-873 because our resistant cell lines O-CB-R1 and O-CB-R2 displayed the cross-
resistance (Figure 5.2C). NMS-873 has been previously shown to be an allosteric inhibitor of VCP 
and binds at the interface between the D1 and D2 domains (Magnaghi et al., 2013). Molecular 
docking of this compound into hexameric VCP with the same search parameters outlined for CB-
5083 yielded binding modes at the interface (-9.9 kcal/mol) with direct contacts to E470 (Figure 
5.11D-5.11E). This is consistent with mutations at E470 promoting resistance due to disruption of 












Figure 5.11. Molecular Docking of CB-5083 and NMS-873 into VCP. (A) A structural overview 
of two subunits of the VCP hexamer, with one in shades of blue and one in shades of green. The 
lightest shade represents the N terminal domain, the medium shade represents the D1 ATPase 
domain, and the darkest shade represents the D2 ATPase domain, as labeled. The mutation site 
E470 is labeled and in red. The binding sites near the D1-D2 linker of CB-5083 and NMS-873 are 
labeled (B) The primary binding mode of CB-5083, in the interface between the D1 and D2 
subdomains. (C) A close-up view of the binding site of CB-5083, with distances to E470 marked. 
(D) The primary binding mode of NMS-873, at the interface of two VCP subunits and the D1-D2 
linker, which is also in close proximity to the mutation site E470. (E) A close-up view of the 








We observed acquired mutations in VCP in ovarian cancer cells upon the acquisition of in 
vitro resistance to CB-5083. In particular, we consistently observed mutations at E470 in the 
resistant clones. Our results also indicate that specific substitutions, such as E470K or E470D, 
enhance the in vitro ATPase activity. Consistent with enhanced ATPase activities of these mutants, 
higher concentrations of CB-5083 were required to inhibit the activities of these mutants. Although 
these studies highlight the specificity of VCP inhibition by CB-5083 and the cytotoxic effect 
produced by VCP inhibition, our studies also provide an important cautionary note in the 
development of novel therapeutics targeting VCP. Cancer cells can rapidly acquire activating 
mutations in VCP that could bypass the effect of CB-5083.  
Codon 470 is located in the linker region between D1 and D2 domains of VCP. Utilizing 
Cryo-EM, previous studies solved the structure of VCP bound to another inhibitor UPCDC-30245, 
and the results indicate that UPCDC-30245 binds to the linker region between D1 and D2 domains 
(Banerjee et al., 2016). This interaction interferes with the two-step sequential activation of D2 
and D1 by ATP binding. Docking of CB-5083 to the structure, reported by Banerjee et al. (2016), 
suggests that CB-5083 may also associate with the D1-D2 linker region as well as the active site. 
Therefore, we speculate that the mechanism of inhibition of VCP by CB-5083 may be similar to 
UPCDC-30245, in which binding of a ligand to the interface of the two domains prevents the 
ratcheting motion, between D1 and D2 domains, that is required for the function of a full hexamer 
(Banerjee et al., 2016). Future structural studies investigating the interaction between VCP and 
CB-5083 are needed to confirm this assertion.  
Docking studies suggest that, in addition to binding at the active site of VCP, CB-5083 




could, therefore, disrupt the hydrophobic interaction between CB-5083 and E470 and interfere 
with that binding mode. Although the full effect of the mutation cannot be completely understood 
by docking alone, it is possible that amino acid substitution partially occludes the CB-5083 binding 
site, making CB-5083 binding less thermodynamically favorable. Therefore, we speculate that 
E470 substitutions reduce the affinity to CB-5083 and promote resistance to CB-5083. 
In addition to the potential direct effect of E470 mutations on the ligand and target 
interactions, two other indirect mechanisms of inhibition could also be speculated. First, mutations 
at E470 induce conformation changes that lower binding affinity to VCP inhibitors. Second, 
mutations at E470 increase the enzymatic activity of VCP, and therefore a higher amount of 
inhibitors is needed to inhibit VCP mutants. Results from enzymatic in vitro ATPase assays 
indicate VCP mutants are more active than the wildtype VCP. Therefore, activating mutations may 
contribute to resistance to VCP inhibitors (Figure 5.12). These results are similar to the resistance 
mechanism associated with kinase inhibitors where target proteins or other components of the 
targeted pathway became mutated to create a bypass mechanism that produces resistance to kinase 
inhibitors (Johannessen et al., 2010). 
It is interesting to note that although E470K and E470D VCP mutants are resistant to 
ML240, as indicated by in vitro ATPase assays, cells with VCP mutants are still sensitive to 
ML240. One possible interpretation of the results is that cytotoxicity effect produced by ML240 
is not solely dependent on VCP inhibition. These results suggest additional targets of ML240 
contribute to cytotoxicity. It will be important to identify these additional targets so that ML240 







Figure 5.12. Graphical abstract elucidating the in vitro mechanism of resistance to CB-5083. 
Incremental and prolonged exposure to CB-5083 produced cells that acquired resistance to CB-
5058. These cells harbor activating missense mutations at codon 470 (E470K or E470D) of VCP 
gene in one allele and inactivating nonsense (Q603*) or frameshift stop (N616Mfs*63) 
mutations in another allele. Although heterozygous mutations in DNA are detected at these sites, 
only homozygous mutations at codon 470 are detected in cDNA, suggesting that inactivating 
mutations are subjected to nonsense-mediated decay (NMD). The E470 mutants (E470K/E470D) 
display enhanced ATPase activity and require higher concentrations of VCP inhibitors to achieve 







We also observed that CB-5083-resistant cells harbor two different mutations on separate 
alleles: (1) activating mutations at E470, and (2) an inactivating nonsense mutation at Q603* or a 
frameshift deletion at N616. Complementary DNA sequence analysis of expressed VCP transcripts 
identified the E470 mutant transcripts as the primary transcripts. Transcripts containing Q603* 
and N616Mfs*63 are undetectable in the cDNA sequence analysis although these mutations are 
observed in the DNA sequence analysis. These results support our conclusion that nonsense 
mutations (Q603* and N616Mfs*63) are located in the other VCP allele and that transcripts 
produced from this mutant VCP are subjected to nonsense-mediated decay. Additionally, cells 
with mutant VCP show reduced expression of VCP, further providing a corroborating evidence 
that one allele is not expressed. Collectively, these results suggest a co-selection of activating and 
inactivating mutations in VCP under in vitro CB-5083 selection pressure. 
With the RNA sequencing analysis, we validated our Sanger sequencing results and 
showed that resistant cells harbored two different mutations. Interestingly, we observed 69 other 
nonsynonymous mutations in the resistance cells. These include genes such as UQCR10, MCM7, 
SLC16A3, and ATG4B. Some of these nonsynonymous mutations could be passenger mutations 
that were present in a very small population of cells later acquired fitness-conferring mutations in 
VCP during the multiple rounds of CB-5083 treatment. However, some of these mutations could 
be associated with fitness-conferring traits that work in concert with or independently from the 
VCP mutations. Independent drug selection studies with CB-5083 should help in answering this 
question. Upon pathway analysis of differentially regulated genes, we observed the most 
significant association between genes upregulated by CB-5083 and the response to endoplasmic 
reticulum stress in both parental and resistant cells, while downregulated genes by CB-5083 in 




that the response to endoplasmic reticulum stress was the most significant GO term associated 
with genes upregulated by CB-5083 in resistant cells, our results suggest CB-5083 treatment can 
still target mutant VCP to affect protein quality control pathway, albeit the magnitude of the effect 
may be small compared to parental cells. Our assertion is supported by gene expression analysis 
indicating that only 31 genes were upregulated by CB-5083 by at least 1.5-fold in resistant cells 
whereas 1666 genes were upregulated by CB-5083 by at least 1.5-fold in parental cells.     
Finally, we observed inactivating mutations in VCP in tumor samples reported by the 
Cancer Genome Atlas (TCGA) sequencing studies. In particular, truncating mutations at codon 
616 are the most frequent hotspot mutations in VCP in TCGA database. Given that our in vitro 
selection with CB-5083 resulted in co-selection of activating and inactivating mutations in separate 
VCP alleles, the pre-existence of truncating mutations at codon 616 may portend acquired 
resistance to CB-5083. Therefore, ongoing clinical trials investigating the therapeutic effect of CB-
5083 in cancer should investigate the theranostic potential of these mutations in cancer patients 


















Chapter 6: Overall discussion and future directions 
Portions of this chapter are reproduced from the following publications with permission where 
required. 
 
 Bastola P and Chien J (2018) Co-selected mutations in VCP: a novel mechanism of 














The combination of cisplatin (or carboplatin) and paclitaxel (or docetaxel) are the primary 
standard-of-care chemotherapeutic agents for ovarian cancer. Cisplatin became the mainstay of 
ovarian cancer treatment after a series of studies carried out in the 1970s that showed a response 
rate between 25%-30% in ovarian cancer patients resistant to conventional therapy (Wiltshaw and 
Kroner, 1976; Young et al., 1979).  In 1992, paclitaxel (Taxol) was FDA approved for the 
treatment of ovarian cancer. In the 1990s, two randomized controlled clinical trials investigated 
the efficacy of cisplatin and taxol combination in ovarian cancer patients. Both trials reported 
significant improvement in the progression-free survival and overall survival with the combination 
(McGuire et al., 1996; Piccart et al., 2000). Over the last two decades, however, the treatment 
regimen and the survival rates for ovarian cancer have not changed significantly. Recently, several 
targeted therapies have been granted FDA approval in ovarian cancer. These include the VEGF 
inhibitor bevacizumab and PARP inhibitors olaparib, rucaparib and niraparib.  In 2014, olaparib 
became the first targeted agent to be FDA approved for ovarian cancer treatment. Olaparib was 
approved as maintenance therapy for the treatment of advanced ovarian cancer in patients with 
germline BRCA1 or BRCA2 mutations who have received three or more prior lines of 
chemotherapy. Subsequently, rucaparib was FDA approved in 2016 for treating ovarian cancer 
patients with germline and/or somatic mutations in BRCA1 or BRCA2, while niraparib was FDA 
approved in 2017 as maintenance therapy in patients with recurrent platinum-sensitive ovarian 
cancer. Similarly, the VEGF inhibitor bevacizumab was FDA approved in 2014 for the treatment 
of platinum-resistant epithelial ovarian cancer. The FDA approval of these agents lends support to 




clinically approved molecularly targeted agents against ovarian cancer outlines the significance of 
identifying newer targets or therapeutic agents for this disease.  
For this dissertation, I set out to identify vulnerabilities in high-grade serous ovarian cancer. 
A malignant genome harbors copy number alterations, aneuploidy, and mutations, which can be 
seen as inherent vulnerabilities. These alterations increase the transcriptomic stress and 
subsequently increase the proteotoxic stress. Proteotoxic stress can manifest itself as endoplasmic 
reticulum stress response resulting in the induction of the unfolded protein response. Mild unfolded 
protein response restores protein homeostasis by upregulating endoplasmic reticulum resident 
chaperone and downregulating protein synthesis. However, prolonged induction of the unfolded 
protein response (terminal UPR) can trigger cell death (Figure 6.1). I rationalized that increased 
copy number alterations in high-grade serous ovarian cancer create transcriptomic stress and 
subsequently result in proteotoxic stress in these tumors. Therefore, I decided to identify 









Figure 6.1. Inducing terminal unfolded protein response in cancer cells. Cancer genomes harbor 
numerous alterations that result in the increased transcriptomic stress. This in combination with 
metabolic stress in cancer causes proteotoxic stress. The increase in proteotoxic stress triggers 
endoplasmic reticulum stress resulting in the induction of the unfolded protein response. Mild 
induction of the unfolded protein response helps to mitigate the upstream endoplasmic reticulum 
stress. Such induction of the unfolded protein response is considered to be a homeostatic 
(homeostasis UPR). However, a prolonged induction of the unfolded protein response (terminal 
UPR) can trigger cell death. Adapted from: Oakes and Papa, Annual Review Pathology. 2015 




The protein quality control is a pro-survival response, which consists of (1) chaperones that 
allow the folding of nascent peptides during protein synthesis or refolding of denatured proteins 
induced by cellular stresses, (2) endoplasmic reticulum-associated degradation and the unfolded 
protein response that are involved in the adaptive response to endoplasmic reticulum stress, (3) the 
ubiquitin proteasome system that degrades misfolded, unfolded, unwanted, or damaged proteins 
to maintain proteostasis, and (4) autophagy that can remove unfolded protein aggregates through 
lysosomal degradation pathway. Cells ensure protein homeostasis by maintaining a balance in the 
rate of protein synthesis and degradation. Dysfunction in protein homeostasis can trigger abnormal 
the cellular functions and result in various human disorders. Similarly, cancer cells harbor a host 
of genomic alterations which can result in the dysregulation of protein expression and the aberrant 
expression of dysfunctional proteins. Such proteins must be efficiently recycled/degraded through 
cellular degradation machinery to maintain protein homeostasis. Cancer cells are heavily reliant 
on protein quality control pathways for survival and proliferation, a process known as the non-
oncogenic addiction. Hence, targeting components of the protein quality control pathways has 
been shown to be effective in cancer therapeutics. The FDA approval of proteasome inhibitors 
such as bortezomib and carfilzomib has provided support to the idea that the ubiquitin proteasome 
system, a component of protein homeostasis, could be targeted in cancer (Chen et al., 2011; Kuhn 
et al., 2007). Likewise, the effectiveness of compounds such as Hsp90 inhibitors (Sidera and 
Patsavoudi, 2014), autophagy modulators (Boulay et al., 2004), and HDAC inhibitors (Santo et 
al., 2012) in several cancer types further support this idea. 
Multiple genome-wide short hairpin RNAs (shRNAs)-based loss-of-function screening 
studies identified components of the protein quality control pathway, such as protease subunits in 




Marcotte et al., 2012). Based on these studies, I decided to target VCP in ovarian cancer. Next, I 
identified candidate compounds to inhibit VCP in vitro. Based on their specificity towards 
targeting VCP, I decided to use the quinazoline-based VCP inhibitors DBeQ and ML240. During 
the course of this dissertation, another VCP inhibitor, CB-5083, became the first-in-class VCP 
inhibitor to show favorable pharmacokinetics and pharmacodynamics when administered orally in 
tumor-bearing mice. Based on these results, I decided to include CB-5083 in my studies. Upon 
identifying the therapeutic target and compounds, I started this dissertation project with the 
following questions:  
1) Does inhibiting VCP through genetic or pharmacological agents result in cytotoxicity in 
ovarian cancer cells? 
2) Can VCP inhibitors be combined with other agents that modulate the protein quality control 
pathway? 
3) What are some of the mechanisms of resistance towards VCP inhibitors?   
Through this dissertation, I was able to answer these questions. In the subsequent sections, I 
will summarize our results while outlining future directions.  
6.2. Summary and future directions for Chapter 3 
In Chapter 3, we showed a dose-dependent in vitro cytotoxicity induced by VCP inhibitors 
DBeQ and ML240 in several ovarian cancer cells (Figure 3.1).  Similarly, small interfering RNA 
(siRNA)-mediated knockdown of VCP in ovarian cancer cells attenuated cell growth (Figure 3.2). 
These results provided a proof-of-concept that VCP can be targeted in ovarian cancer. 
Additionally, we characterized cellular responses, such as the cell cycle arrest (Figure 3.4), 




3.7), and the activation of apoptosis (Figure 3.5) upon the treatment of VCP inhibitors. VCP has 
been shown to mediate diverse cellular functions including endoplasmic reticulum-associated 
degradation, the ubiquitin proteasome system, mitochondria-mediated degradation, chromatin-
associated degradation, stress granules formation, and autophagy. So far, our studies have 
primarily been focused on the endoplasmic reticulum-associated degradation and the ubiquitin 
proteasome system. It is likely that VCP inhibitors have effects on other cellular processes, and 
these inhibitors could be used to study their effects on other VCP-mediated functions. 
VCP has been linked to several molecular functions pertaining to protein quality control. 
However, one of the primary questions is how VCP mediates such diverse functions. With scores 
of studies illuminating its function in several biological processes, a pattern has emerged. VCP is 
able to mediate such diverse functions through a set of approximately 30 different cofactor 
proteins. Unique sets of cofactor proteins have been associated with separate VCP functions. Major 
cofactors that regulate VCP function include Ufd1-Npl4, p47, and UBXD1 (van den Boom and 
Meyer, 2017). This presents a new avenue to expand the development of function-specific VCP 
inhibitors, where a particular function pertaining to VCP can be targeted by inhibiting VCP 
interaction with a specific cofactor. In fact, some preliminary studies have identified compounds 
that display increased potency against the VCP-p47 complex (Fang et al., 2015). 
Furthermore, we showed that VCP inhibitors can be combined with the GADD34 inhibitor, 
salubrinal, to induce synergistic cytotoxicity (Figure 3.8-3.10). The rationale for a combination 
therapy is to use drugs that work by different mechanisms and can display increased effects when 
used together. Chemotherapeutic agents are often associated with drug-related toxicities. 
Identifying compounds that are synergistic allows lowering the dose of these agents, which could 




compounds can avoid the development of drug resistance. Our results have implications not just 
for ovarian cancer therapy, but results from our studies are relevant for designing combination 
therapies for other tumors. Since VCP inhibitors display cytotoxicity towards multiple different 
cancer types, the combination of VCP inhibitors and salubrinal should show efficacy in other 
cancer types.  
Similarly, we showed that cytotoxicity mediated through VCP inhibitors can be enhanced by 
modulating the unfolded protein response. With scores of compounds that modulate the unfolded 
protein response in the drug development pipeline, our studies provide a rationale for combining 
the compounds that induce terminal unfolded protein response with the compounds that inhibit 
ubiquitin proteasome system. In future, synergistic cytotoxicity can be assessed between VCP 
inhibitors and compounds that have been shown to modulate the unfolded protein response using 
the sulforhodamine B (SRB) assays and drug synergy studies protocol outlined in Chapter 2.3.  
Finally, we showed that VCP inhibitors can be combined with other compounds to enhance 
the cytotoxic effect. In future, high-throughput drug screening can be performed to identify 
possible FDA approved compounds that display synergistic cytotoxicity with VCP inhibitors. 
Identifying FDA approved drug candidates that enhance the synergistic cytotoxicity with VCP 
inhibitors will allow to enhance the efficacy of VCP inhibitors as well as negate the possible 
occurrence of drug resistance.  
6.3. Summary and future directions for Chapter 4 
In Chapter 4, we showed synergy between mifepristone and VCP inhibitors. In this chapter, 
our primary focus was to identify a clinically relevant drug combination with VCP inhibitors. We 
were able to establish that a clinically achievable dose of mifepristone was synergistic with the 




direct application of this dissertation towards providing greater therapeutic benefits in cancer 
patients. Before pursuing this combination in patients, synergistic cytotoxicity towards VCP 
inhibitors and mifepristone need to be assessed in rodent cancer models. For assessing the effective 
on ovarian tumors, ovarian cancer xenografts will be injected intraperitoneally to immune 
compromised mice. Before performing the combination treatment, effective individual dose will 
be established by treating these mice with different doses of CB-5083 and mifepristone using oral 
gavage. Effectiveness with a single agent will be determined by comparing the decrease in tumor 
burden in drug treated mice to the vehicle treated mice. After establishing effective single dose for 
both drugs, experiments will be performed to analyze the effectiveness of the combination 
compared to the single agents. This will be assessed first by examining the tumor burden, and 
second by performing long term survival studies.  
After the establishment of synergy between VCP inhibitors and mifepristone in vitro, we 
investigated the mechanism that contributed to the drug synergy. Mifepristone has been shown to 
modulate the unfolded protein response, but the mechanism was largely unknown. Our results 
point to the activation of the heme-regulated inhibitor (HRI) kinase pathway, and the inhibition of 
the activation transcription factor 6 (ATF6) pathway as two possible mechanisms for the 
mifepristone-induced unfolded protein response. Although we were able to narrow down to two 
potential mediators of the mifepristone-induced unfolded protein response, further studies are 
needed to confirm whether both proteins are necessary for the synergistic cytotoxicity induced by 
the combination of VCP inhibitors with mifepristone.   
 To further dissect the involvement of the HRI kinase pathway towards the synergistic 
cytotoxicity, it would be necessary to perform the synergy experiment following the knockdown 




between VCP inhibitors and specific HRI activators (Chen et al., 2013). Results from these studies 
will allow us to identify the involvement of HRI kinase pathway in providing the synergy between 
VCP inhibitors and mifepristone.   
Similarly, to verify the role of the ATF6 branch in the synergy between VCP inhibitors and 
mifepristone, it would be important to investigate the effects of ATF6 knockdown or knockout in 
several ovarian cancer cell lines treated with VCP inhibitors. The increased sensitivity towards 
VCP inhibitors upon the ATF6 knockdown or knockout will allow us to further implicate ATF6 
in the drug synergy. More importantly, the rescue experiments with the enforced expression of 
transcriptionally active ATF6 should further define the role of ATF6 in the drug synergy between 
VCP inhibitors and mifepristone.      
Our synergy studies show that compounds targeting various components of the protein quality 
control pathway can be combined to enhance the cytotoxicity. During the course of this study, 
first-in-class selective histone deacetylase 6 (HDAC6) inhibitors ACY-241 and ACY-1215 have 
entered clinical trials for several cancer types. HDAC6, a cytoplasmic deacetylase, has gained a 
significant attention as a therapeutic target due to its role in microtubule association and aggresome 
clearance, making it an important mediator of the protein quality control (Dallavalle et al., 2012). 
Additionally, HDAC6 has been shown to associate with Hsp90 (Kovacs et al., 2005) and VCP 
(Boyault et al., 2006) during aggresome formation. These features make HDAC6 inhibitors ideal 
candidates to perform synergistic studies with VCP inhibitors.   
In this dissertation, I used VCP inhibitors to target the protein quality control in ovarian cancer. 
The protein quality control pathway is important for other essential cellular processes such as cell 
cycle regulation, DNA repair, and cell division. Given that DNA repair genes, such as BRCA1 and 




al., 2012) that are involved in protein homeostasis and given that VCP is directly involved in the 
recruitment of P53BP1 in the initial steps of DNA damaging signaling (Acs et al., 2011; Meerang 
et al., 2011), it is possible that VCP inhibitors may enhance sensitivity to DNA-targeted 
chemotherapies, such as carboplatin, cisplatin, and inhibitors of poly (ADP)-ribosylation 
polymerases (PARP inhibitors).  
6.4. Summary and future directions for Chapter 5    
In Chapter 5, we employed a combination of incremental and continuous dosing scheme 
to establish CB-5083 resistant ovarian cancer cell lines. We identified two heterozygous mutations, 
E470D and E470K, in the D1-D2 linker region (Figure 5.4). This amino acid position is close to 
previously identified point mutations in CB-5083-resistant cell lines (Anderson et al., 2015), which 
further underlines the importance of the D1-D2 linker region in the development of resistance to 
CB-5083. Furthermore, the in vitro VCP ATPase activity assay showed an increase in basal 
ATPase activity and a higher IC50 towards several classes of VCP inhibitors in these VCP-mutant 
cells compared to parental counterparts (Figure 5.9). Additionally, we performed unbiased docking 
to show that E470 is located in a putative CB-5083 binding site (Figure 5.11). Our results in 
combination with mutations observed by Anderson et al., suggest D1-D2 linker region as an 
additional putative binding site for CB-5083.  
Besides the discovery of missense mutations in the D1-D2 linker region, we also found 
heterozygous nonsense mutations at Q603 and N616. Furthermore, these nonsense mutations were 
identified only in genomic DNA sequencing and not in the cDNA sequencing of CB-5083-resistant 
cells. These results suggest nonsense mutations at Q603 and N616 are subjected to nonsense-
mediated decay. Consequently, mutant cell lines showed reduced expression of VCP mRNA and 




N616 is one of the most reported alterations of VCP in several cancer subtypes, making it a relevant 
theranostic marker in selecting patients in clinical trials. Our studies suggest that the co-selection 
of an activating mutation (such as E470K) and an inactivating mutation (such as Q603*) is 
necessary for the development of resistance to CB-5083 (Bastola and Chien, 2018). Therefore, 
tumors with preexisting somatic mutations at N616 are expected to quickly develop resistance to 
CB-5083, and these patients may not benefit from the treatment. 
VCP forms hexameric complexes, and our results suggest that inhibition of a wildtype VCP 
subunit by CB-5083 in a hexameric complex is sufficient for cytotoxicity. Hence, activating 
mutation in one VCP allele that escapes inhibition by CB-5083 is not sufficient to generate 
resistance to CB-5083, and the other VCP allele is also subjected to either activating mutation or 
truncation mutation.  In our studies, we observed that the second VCP allele is lost through 
nonsense mutations (Figure 6.2A). Furthermore, previous studies have shown a correlation 
between gene copy number and mRNA level of VCP with resistance to VCP inhibitors (Anderson 
et al., 2015); however, the correlation values were low. Our results indicate that mutations in VCP 








Figure 6.2. Co-selected mutations in VCP confers resistance to CB-5083. A) Presence of both 
wildtype VCP alleles results in wildtype VCP protein hexamer, which can be inhibited by CB-
5083. Similarly, the presence of one mutant allele (E470K or E470D) results in VCP protein 
hexamers with mixed VCP proteins (wildtype and mutant). However, inhibition of wildtype 
protein in the complex upon CB-5083 treatment is sufficient for cytotoxicity. Loss of wildtype 






Our study identified a unique pattern of co-selected mutations with CB-5083 treatment, 
whereby prolonged treatment allowed for the selection of activating missense mutations at D1-D2 
linker region and inactivating nonsense mutations at the D2 domain. This co-selection could occur 
in one of three scenarios as outlined in Figure 6.2B. Both mutations may appear synchronously or 
asynchronously in a sequential manner. We observed a progressive establishment of resistance 
towards CB-5083 which allows us to favor the asynchronous model of resistance; however, the 
definitive study needs to be done to confirm this model of resistance. Similarly, further studies are 
required to identify exact sequence of asynchronous mutations that lead to resistance (scenario 2 
or scenario 3). Nonetheless, given that truncation mutation at N616 is found in tumor samples, it 
is conceivable to suggest that these tumor cells could acquire asynchronous activating mutations 


















Figure 6.3. Putative scenarios of co-selected mutations. A) Co-selected mutations observed upon 
CB-5083 treatment can occur via three scenarios. Scenario 1 outlines the chance of two different 
mutations occurring simultaneously; whereas scenario 2 and 3 outline the occurrence of serial 
mutations whereby mutations at D1-D2 linker is then followed by mutations at the D2 domain or 






In order to study the progression of VCP resistance, we can take the drug resistance study 
performed in Chapter 5 as a template. In Figure 5.1A & 5.1C, we outline a combination of 
intermittent and continuous dosing scheme to generate CB-5083 resistant cell lines. We could 
apply this dosing scheme while collecting cells after each round of drug treatment. Tumor cells 
should gradually develop resistance towards CB-5083. Sequencing VCP gene and complementary 
DNA at various time points during the selection process should help us track the sequence of 
activating and inactivating mutations in the development of resistance in the tumor cells.  
In Chapter 5, we showed that recombinant E470D and E470K proteins display increased 
ATPase activity and resistance to VCP inhibitors using VCP-ATPase assay; however, we have not 
shown if the introduction of these missense mutations results in resistance to CB-5083 in cell lines. 
Clustered regularly interspaced short palindromic repeats-Cas9 (CRISPR-Cas9) genome editing 
can be used to introduce these mutations in OVSAHO parental cell lines.  
Although in vitro ATPase assay suggests VCP mutant proteins (E470K and E470D) are 
cross-resistant to other VCP inhibitors, such as ML240 and DBeQ, CB-5083-resistant cells 
carrying these mutations retain their sensitivity towards ML240 and DBeQ. These results suggest 
that off-target effects of ML240 and DBeQ contribute to cytotoxicity. It would be important to 
define additional targets of ML240 and DBeQ, as these cellular targets may be important for 
further development of therapeutics to overcome resistance to CB-5083.  
Lastly, our results in Chapter 5 show that target alternation can be a potential route to 
resistance towards VCP inhibitors. Establishment of resistance cell lines and creation of novel 
VCP mutant proteins should aid in the development of novel VCP inhibitors as well as provide 




6.5. Overall conclusion 
In conclusion, our studies provide a proof-of-concept that VCP can be targeted in ovarian 
cancer. Likewise, we identified clinically relevant drug combinations (CB-5083 and mifepristone) 
that should be investigated further. Importantly, we showed that VCP inhibitors can be synergistic 
with other compounds that modulate the unfolded protein response. Lastly, we showed that 
prolonged treatment with VCP inhibitor- CB-5083 can result in the development of resistance 
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